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ABSTRACT 
Chapter 1: Chapter One provides an overview on the Bohlmann-Rahtz pyridine 
synthesis. New procedures, implementing metal based Lewis acids, Brønsted acids and 
metal-free Lewis acid catalysts have been used in this process. Also, new one-pot two- 
and three-component methodologies have been developed for the synthesis of various 
natural products containing the pyridine motif and these have been compared and 
contrasted. 
This chapter also discusses signalling pathways in Werner syndrome cells. The inhibitor 
SB203580 has been shown to prevent the phosphorylation of the p38α kinase in a ATP 
competitive manner and this implicates this mechanism in accelerated ageing and gives 
potential to the prospect of targeting this pathway in a drug discovery programme, if 
better mechanistic understanding can be garnered. 
 
Chapter 2: Chapter Two discusses the Bohlman–Rahtz synthesis of various substituted 
pyridines. The process has been modified to be simple, involves mild conditions and 
provides the heterocyclic targets in high yield. We have shown that substituted 
pyridines could be synthesised efficiently under microwave conditions using a relatively 
short reaction time. The process was also successful for the production of a range of 
fused heterocycles containing the pyridine moiety in high yield, including pyrido[2,3-
d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones. 
 
Chapter 3: Chapter Three describes the efficient synthesis of the p38 MAPK inhibitor 
UR-13756 using a Hantzsch-type three component cyclocondensation. Microwave 
irradiation of a mixture of 3-amino-1-methylpyrazole hydrochloride, 
1-(4-fluorophenyl)-2-(pyridine-4-yl)ethanone and 4-fluorobenzaldhyde for 4 hours in 
ethanol under acidic catalytic conditions provided UR-13756 in high yield (71%) after 
purification by column chromatography. 
 
Chapter 4: Chapter Four shows the synthesis of 4-(3-amino-1-(4-methoxyphenyl)-1H-
pyrazol-4-yl)benzamide in three steps by the use of rigorous experimental procedures 
under microwave conditions. This technique led to faster heating rates and allowed the 
rapid optimization of yields. These advantages were observed in all steps and allow 
formation of products in high yields. Biological study of the inhibitor 4-(3-amino-1-(4-
methoxyphenyl)-1H-pyrazol-4-yl)benzamide showed, by ELISA analysis, that p38 
signalling was inhibited in control dermal cells. Some progress was made towards the 
synthesis of 3-amino-4-[1-(3-1H-pyrazol-4-yl)]benzamide. 
 
Chapter 5: Chapter Five investigates the synthesis of the chemotherapeutic agent 
RO3201195, a highly selective inhibitor of p38α, in seven steps under microwave 
conditions. The procedure provides a relatively high overall yield of the desired product 
and all other intermediates involved in individual steps compared with conventional 
heating methods.  
 
Chapter 6: Chapter Six provides the experimental procedures and various spectroscopic 
data for the synthesized compounds. 
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ABBREVIATIONS 
A    Anisomycin 
app    Apparent  
APcI    Atmospheric pressure chemical ionization  
Ar    Unspecified aromatic aryl substituent  
c    Concentration 
CDCl3    Deuterated chloroform 
Column chromatography Flash column chromatography 
d    Doublet 
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m    meta 
MAOS    Microwave–assisted organic synthesis 
MAP    Mitogen activated protein 
MAPK    Mitogen activated protein kinase  
MAPKAPK–2 (MK2a) MAPK activated protein kinase 2a 
MAPKK   Mitogen activated protein kinase kinase 
MAPKKK   Mitogen activated protein kinase kinase kinase 
Me    Methyl 
MHz    Megahertz 
min    Minute(s) 
MK2a (MAPKAPK2)  MAPK–activated protein kinase 2a 
MKK3    Mitogen activated protein kinase kinase 3 
MKK6    Mitogen activated protein kinase kinase 6  
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mmol    Millimole(s) 
mol    Mole(s) 
mp    Melting point  
MS     Low–resolution mass spectrometry 
MW    Microwave irradiation 
nM    Nanomolar 
vii 
NMR    Nuclear magnetic resonance 
p    para 
p–TsOH   para–toluenesulfonic acid monohydrate 
p38    Protein 38 
p38α MAPK   Protein 38α mitogen activated protein kinase (isoform α) 
p38α∙MK2a   Protein 38α mitogen activated protein kinase activated 
protein kinase  
Ph    Phenyl 
pHSP27   Phosphorylated heat shock protein 27 
pp38    Phosphorylated protein 38 
R    Specified substituent  
Rf    Retention factor  
RT    Room temperature 
s    Singlet  
SAR    Structureactivity relationship 
t    Triplet 
tert    Tertiary  
TFA-d                                     Deuteriotrifluoroacetic acid 
THF    Tetrahydrofuran 
TLC    Thin layer chromatography 
TNFα    Tumor necrosis factor–α 
W    Watt 
WRN    Werner gene (defective) encoding the disease  
WRNp    Werner protein 
WS    Werner Syndrome 
vs    versus 
µM    Micromolar 
viii 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS                                                                                          III 
ABSTRACT                                                                                                                  IV 
ABBREVLATIONS                                                                                              V 
TABLE OF CONTENTS                                                                                       VIII 
 
CHAPTER ONE: INTRODUCTION  
 
1.1 The discovery of pyridine 2 
1.2 The Bohlmann–Rahtz pyridine synthesis 4 
1.2.1 Discovery 4 
1.2.2 Recent improvements in methodology 5 
1.2.2.1 Use of catalysts and solvents 5 
1.2.2.2 Tandem oxidation–heteroannelation Bohlmann–Rahtz reactions 9 
1.2.2.3 Microwave synthesis 11 
1.2.2.4 Continuous flow reactors 13 
1.2.3 Applications 17 
1.2.3.1 Synthesis of pyrido[2,3–d]pyrimidines and uracil derivatives 18 
1.2.3.2 Combinatorial library synthesis 22 
1.2.3.3 Natural product chemistry 25 
1.3 Werner syndrome 36 
1.4 Use of MAPK inhibitors to treat Werner syndrome 38 
ix 
1.5 Conclusion 43 
1.6 Goals of the project 45 
1.7 References 45 
 
CHAPTER TWO: SYNTHESIS OF PYRIDINE DERIVATIVES  
 
2.1 Introduction 54 
2.2 Bohlmann–Rahtz Reaction 54 
2.3 Hantzsch dihydropyridine synthesis 61 
2.4 Synthesis of substituted pyridine derivatives 63 
2.5 Synthesis of substituted pyrido[2,3-d]pyrimidinone derivatives 72 
2.6 Conclusions 77 
2.7 References 78 
 
CHAPTER THREE: SYNTHESIS OF AMINOPYRAZOLES, 
PYRAZOLOPYRIMIDINES, PYRAZOLOPYRIDINES AND THE P38 MAPK 
INHIBITOR UR-13756  
 
3.1 Introduction 82 
3.2 Synthesis of 3-amino-1-methylpyrazole hydrochloride 88 
3.3 Synthesis of UR-13756 92 
3.3.1 Use of p38 MAPK Inhibitors for the treatment of Werner Syndrome 92 
3.3.2 Synthesis of the highly selective p38 MAPK inhibitor UR-13756 94 
3.4 Towards the synthesis of pyrazolopyrimidine 99 
3.5 Towards the synthesis of pyrazolopyridines from aminopyrazoles 107 
3.6 Conclusion 113 
x 
3.7 References 114 
CHAPTER  FOUR: SYNTHESIS OF PYRAZOLE DERIVATIVES AS 
INHIBITORS OF PROTIEN KINASE MK2  
 
4.1 Introduction 119 
4.2 Development of specific MK2 inhibitors for the treatment of inflammatory 
diseases 120 
4.3 Synthesis of 4-[3-amino-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]benzamide 128 
4.4 Biological behaviour of MK2 inhibitor 4.2 on Werner syndrome cells 133 
4.5 Attempted synthesis of 3-amino-4-[1-(3-1H-pyrazol-4-yl)]benzamide 136 
4.5.1 Synthesis of 3-amino-1-(3-bromophenyl)-1H-pyrazole 138 
4.5.2 Synthesis of 3-amino-1-[3-(1H-indol-6-yl)phenyl]-1H-pyrazole 139 
4.5.3 Synthesis 3-amino-1-(3-(1H-indol-6-yl)phenyl)-4-bromo-1H-pyrazole 141 
4.5.4 Alternative attempt at the synthesis of 3-amino-4-[1-(3-1H-pyrazol-4-
yl)]benzamide 141 
4.6 Conclusion 144 
4.7 References 145 
 
CHAPTER FIVE: SYNTHESIS OF THE P38 INHIBITOR OF RO3201195  
 
5.1 Introduction 148 
5.2 Use of p38 inhibitors for treatment of Werner syndrome cells 151 
5.3 Synthesis of the highly selective RO3201195 153 
5.3.1 Synthesis of methyl 3-methoxybenzoate 156 
5.3.2 Synthesis of 3-methoxybenzoylacetonitrile 156 
5.3.3 Synthesis of 2-(3-methoxybenzoyl)-3-phenylaminoacrylonitrile 160 
xi 
5.3.4 Synthesis of 5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl)-3-methoxyphenyl    
ketone 161 
5.3.5 Synthesis of 5-amino-1H-(pyrazol-4-yl)-3-hydroxyphenyl ketone 162 
5.3.6 Synthesis of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-{[(R)-2,2-
dimethyl-1,3–dioxolan-4-yl]methoxy}phenyl ketone 163 
5.3.7 Synthesis of 5-amino-1-(4-fluorophenyl)-4-{3-[2(S),3-
dihydroxypropoxy]benzoyl} pyrazole 164 
5.4 Conclusion 165 
5.5 References 166 
 
CHAPTER SIX: EXPERIMINTAL  
 
6.1 Experimental Techniques 170 
6.2 Synthesis of 2-amino-3-ethoxycarbonylhepta-2,4-dien-6-one 171 
6.3 Synthesis of ethyl 2,6-dimethylpyridine-3-carboxylate 172 
6.4 Synthesis of 2,6-dimethyl-3-pyridinecarbonitrile 174 
6.5 Synthesis of 3–cyano–2-methyl-6–phenylpyridine 175 
6.6 Synthesis of ethyl 2,6-dimethyl-4-phenylpyridine-3-carboxylate 176 
6.7 Synthesis of 2-amino-7-methylpyrido[2,3-d]pyrimidin-4(3H)-one 178 
6.8 Synthesis of 1,3,7-trimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 179 
6.9 Synthesis of 2-amino-7-phenylpyrido[2,3-d]pyrimidin-4(3H)-one 180 
6.10 Synthesis of 1,3-dimethyl-7-phenylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 181 
6.11 Synthesis of 2-amino-5-methyl-7-phenylpyrido[2,3-d]pyrimidin-4(3H)-one 182 
6.12 Synthesis of 3-amino-1-methyl-1H-pyrazole hydrochloride 183 
6.13 Synthesis of 1-(4-fluorophenyl)-2-(4-pyridyl)ethanone 184 
xii 
6.14 Synthesis of 4,6-bis(4-fluorophenyl)-2-methyl-5-(pyridin-4-yl)-2H-
pyrazolo[3,4-b]pyridine (UR-14756) 186 
6.15 Synthesis of 5-amino-4-cyano-1-phenyl-1H-pyrazole 188 
6.16 Synthesis of 5-amino-4-aminocarbonyl-1-phenyl-1H-pyrazole 190 
6.17 Synthesis of 4-hydroxy-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine 191 
6.18 Synthesis of 5-amino-1-methyl-1H-pyrazole 192 
6.19 Synthesis of 5-amino-1-phenyl-1H-pyrazole 193 
6.20 Synthesis of 3-amino-1-phenyl-1H-pyrazole 194 
6.21 Synthesis of 3-amino-1-(4-methoxyphenyl)-1H-pyrazole 195 
6.22 Synthesis of 3-amino-4-bromo-1-(4-methoxyphenyl)-1H-pyrazole 196 
6.23 Synthesis of 3-amino-4-(4-aminocarbonylphenyl)-1-(4-methoxyphenyl)-1H-
pyrazole 198 
6.24 Synthesis of 3-amino-1-(3-bromophenyl)-1H-pyrazole 199 
6.25 Synthesis of 3-amino-4-bromo-1-(3-bromophenyl)-1H-pyrazole 201 
6.26 Synthesis of 3-amino-1-(3-(1H-indol-6-yl)phenyl)-1H-pyrazole 202 
6.27 Synthesis of 3–methoxybenzoic acid methyl ester 204 
6.28 Synthesis of 3–methoxybenzoylacetonitrile 205 
6.29 Synthesis of 2–(3–methoxybenzoyl)–3–phenylaminoacrylonitrile 207 
6.30 Synthesis of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methoxyphenyl 
ketone 208 
6.31 Synthesis of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-hydroxyphenyl 
ketone 210 
6.32 Synthesis of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-{[(S)-2,2-
dimethyl-1,3-dioxolan-4-yl]methoxy}phenyl ketone 211 
xiii 
6.33 Synthesis of 5-amino-1-(4-fluorophenyl)-4-{3-[2(S)-3-
dihydroxypropoxy]benzoyl}pyrazole 212 
6.34 References 214 
 
 
 
 
 
 
 
Chapter One: Introduction 
2 
 
 
 
 
 
 
 
 
 
CHAPTER ONE: INTRODUCTION 
 
 
 
 
Chapter One: Introduction 
2 
 
Chapter One 
Introduction 
1.1 The discovery of pyridine 
In 1846 the first pyridine base, picoline, was isolated from bone oil by Thomas 
Anderson.
1
 The chemistry of pyridine was born when Wilhelm Körner (1869) and 
James Dewar (1871) independently formulated a monoaza analogue of benzene.
2
 
Understanding the structure of pyridine enabled a number synthetic processes to be 
developed. The synthesis of 2-picoline (1.2; Scheme 1.1) albeit in low yield was 
reported by Baeyer
3,4
 from the reaction of acrolein (1.1) with aqueous ammonia 
(Scheme 1.1). 
 
O NH3
N Me
1.1 1.2
 
Scheme 1.1: Synthesis of 2-picoline (1.2) from acrolein (1.1) and ammonia 
 
In 1876 the laboratory synthesis of pyridine (1.3) was discovered by Ramsey.
5
 
Reaction of a mixture of acetylene and hydrogen cyanide in a red-hot tube gave the 
heterocycle 1.3 (Scheme 1.2).
5
 Large quantities of pyridine were obtained from natural 
sources via coal tar distillation. 
N
1.3
HCN
2
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Scheme 1.2: Synthesis of pyridine (1.3) from acetylene and HCN 
In the 1930s Elvehjem and Koehn were able to isolate nicotinamide (1.4) and 
nicotinic acid (1.5) from vitamin B2 (Figure 1.1).
6
 Their discovery provided treatment 
for human pellagra, a vitamin deficiency causing dermatitis and dementia. One could 
chart that from that date, researchers started to pay attention to the synthesis and 
properties of pyridine derivatives. 
N N
O
NH2
O
OH
1.4 1.5
 
Figure 1.1: Structures of nicotinamide (1.4) and nicotinic acid (1.5) 
 
The chemistry of pyridine provided fundamental understanding of the chemistry 
and properties of biological systems, since this heterocycle plays an important role in 
both biological and chemical coordination. The pyridine ring system is one of the most 
common heterocyclic motifs that is found to modulate various enzymes of living 
organisms. For example, nicotinamide adenine dinucleotide phosphate (NADP
+
: 1.6; 
Figure 1.2) is intimately involved in various oxidation–reduction processes.7  
O OH
OH
O
N
P O
O O P
O
O
O
O
OH
OH
N
N
N
N
H2N
CONH2
NADP+ (1.6)
 
Figure 1.2: Structure of nicotinamide adenine dinucleotide phosphate (NADP
+
: 1.6) 
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Also, the pyridine moiety is found in over 7000 pharmaceutical drugs such as 
the anti-tuberculosis drug 1.7, the HIV inhibitor L-754,394 (1.8), agrochemicals 
1.91.11 (Figure 1.2)8 and a large number of natural products.911 
 
N
O NHNH2
Isoniazide 1.7
(antituberculosis)
NO
N
N
OtBuHN
OH
H
N
O
OH
L-754,394 1.8 (potent HIV protease inhibitor)
N
CNNC
Cl Cl N CCl3Cl
Pyridinenitrile 1.9
(Fungicide)
Nitrapyrin 1.10
(Bactericide)
NH2
Cl
Cl
Me
OH
O
Picloram 1.11
(Herbicide)
 
Figure 1.3: Structures of some pyridine pharmaceutical drugs and agrochemicals 
 
1.2 The Bohlmann-Rahtz pyridine synthesis 
1.2.1 Discovery 
Various methods are available for the synthesis of pyridines.
12
 One such method 
is the Bohlmann-Rahtz pyridine synthesis which was first discovered in 1957.
13
 
Substituted pyridines were synthesized in a two–step process by the reaction of 
enamines 1.12 and alkynyl ketones or aldehydes 1.13 (Scheme 1.3). The first step 
involves production of the corresponding aminodiene intermediate 1.14 in high yield. 
The second step involves conversion of intermediates 1.14 to the corresponding 
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trisusbtituted pyridines 1.15 (Scheme 1.3) at high temperature (120–170 °C).13 
Compounds 1.15 were produced in excellent overall yields.  
 
R1
H2N R
2
NR1
R2
R3
R3
O
+
1.12 1.13 1.14
R3
O
R1H2N
R2
50

C, 5 h
120–170 oC
Neat
EtOH
1.15
 
Scheme 1.3: The traditional Bohlmann-Rahtz pyridine synthesis 
 
1.2.2 Recent improvements in methodology 
The Bohlmann-Rahtz pyridine synthesis has been recognised as a valuable 
method for the synthesis of pyridine derivatives. The Bagley research group has 
developed various efficient processes for the synthesis of pyridines under microwave 
conditions for exploration of their biological properties.
1416
  The Bohlmann-Rahtz 
process provides various tri- and tetrasubstituted pyridines with total control of 
regiochemistry. Many attempts have been made to improve the process so that it can be 
carried out under milder conditions. The following sections will highlight current 
developments in the Bohlmann–Rahtz synthesis of substituted pyridines. 
 
1.2.2.1 Use of catalysts and solvents 
The scope and utility of the Bohlmann-Rahtz reaction
17
 has been developed to 
take place in a single step In order to investigate these improvements, aminodienone 
1.14a was synthesised by standard Bohlmann-Rahtz methodology,
17
 from ethyl 
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β-aminocrotonate (1.12a) and but-3-yn-2-one (1.13a) in ethanol (EtOH) at 50 °C to give 
the corresponding cyclodehydration precursor in 98% yield. However, the availability 
and volatility of butynone 1.13a prompted researchers to find alternative approaches for 
the production of 1.14a. Therefore, a mixture of ethyl β-aminocrotonate (1.12a) and 
4-(trimethylsilyl)but-3-yn-2-one (1.13b), which is cheaper, readily available and less 
volatile than 1.13a, was heated to 50 °C in various solvents (Table 1.1).
17
  
 
Table 1.1: Michael addition of 1.12a and 1.13b in various solvent at 50 °C 
 
Solvent Yield of 1.14a (%) Solvent Yield of 1.14a (%) 
Acetone No reaction Diethyl ether No reaction 
Toluene No reaction Neat No reaction 
Dichloromethane No reaction Dimethylsulphoxide 59 
Chloroform No reaction Ethanol 98 
 
In most cases no reactions took place. However, when a mixture of 1.12a and 
butynone 1.13b was heated at 50 °C for 5 hours in EtOH (the solvent originally used by 
Bohlmann and Rahtz) or dimethylsulphoxide (DMSO) the corresponding aminodienone 
1.14a was produced in 98 or 59% yield, respectively (Scheme 1.4). 
 
Me
H2N CO2Et
Me
O
+
1.12a 1.13b 1.14a (98%)
Me
O
MeH2N
EtO2C
TMS
EtOH
50 oC, 5 h
 
Scheme 1.4: Synthesis of aminodiene 1.14a using a modified alkynone 1.13b 
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The Bohlmann-Rahtz synthesis requires the use of a Michael donor (enamine) 
and a Michael acceptor (alkynone), therefore, in principle the use of a Brønsted
18
 (such 
as acetic acid, AcOH) or Lewis acid
19
 could affect the conjugate addition and the double 
bond isomerisation of aminodienone 1.14a, and facilitate spontaneous cyclodehydration 
to pyridine 1.15a. In this regard, the use of an acid catalyst could affect the reaction to 
take place could at lower temperatures than the traditional Bohlmann-Rahtz conditions. 
It was found that heating aminodienone 1.14a at 50 C in a mixture of toluene (PhMe) 
and acetic acid (in 5:1 by volume) gave pyridine 1.15a in excellent yield (Scheme 
1.5).
18,19
  
 
1.14a
Me
O
MeH2N
EtO2C
NMe
EtO2C
Me
1.15a (100%)
50 oC
PhMe, AcOH
 
Scheme 1.5: Synthesis of pyridine 1.15a from aminodienone 1.14a by Brønsted acid 
catalysis 
 
A range of Lewis acids (e.g. BF3·OEt2, FeCl3, ZnBr2, Yb(OTf)3) have been used 
successfully as an alternative to Brønsted acids in this process.
18
  A range of substituted 
pyridines 1.15 were produced in high yields from aminodienone 1.14 under acidic 
conditions in a single step in heating at reflux in dichloromethane (Scheme 1.6).
18
 It was 
found that reactions catalyzed by zinc(II) bromide were faster and more efficient than 
those conducted in the presence of ytterbium(III) triflate.
18
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R1
H2N R
2
NR1
R2
R4
R4
O
+
1.12 1.13 1.15 (32–90%)
Yb(OTf)3 or ZnBr2 (15 mol%)
PhMe, reflux, 5–24 hR
3
R3
 
Scheme 1.6: One-step Lewis acid catalysis synthesis of substituted pyridines 1.15 
 
The conjugate addition/cyclodehydration of enamines 1.12 and alkynones 1.13 
in toluene at 50 °C in the presence of Amberlyst-15 ion exchange resin for 26 hours 
have also been attempted (Scheme 1.7).
18
  This procedure was efficient and substituted 
pyridines 1.15 were produced in high yields (7183%).18  
 
R1
H2N R
2
NR1
R2
Me
Me
O
+
1.12 1.13 1.15 (71–83%)
Amberlyst 15
PhMe, 50 oCR3
R3
 
Scheme 1.7: Synthesis of pyridines 1.15 using Amberlyst-15 ion exchange resin 
 
A three-component condensation of a range of -keto esters 1.16, alkynones 
1.13 and ammonium acetate in excess (Scheme 1.8) provided a much more efficient 
approach towards a number of polysubstituted pyridines 1.15.
20
 The reaction involved 
the use of two mole equivalents of 1.13 to produce the corresponding substituted 
pyridine 1.15 in good to excellent yield (5596%) in a single preparative step with total 
regiocontrol.
20
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R1
O CO2Et
NR1
EtO2C
R3
R3
O
+
1.16 1.13 1.15 (55-96%)
NH4OAc, PhMe
acid cat. 20 hR2
R2
 
Scheme 1.8: Three component condensation reaction for the production of substituted 
pyridines 1.15 under acidic conditions 
 
Clearly the results reported in Scheme 1.8 showed the scope of using cheap and 
commercially available 1,3-dicarbonyl compounds 1.16 with alkynones 1.13 to produce 
various substituted pyridines 1.15 in high yield. 
A mild acid-free three-component condensation reaction for the production of 
substituted pyridines 1.15 has also been developed.
21
 Reaction of 1,3-dicarbonyl 
compounds 1.17 and alkynones 1.13 in ethanol under reflux conditions for 24 hours in 
the presence of  ammonium acetate produced the corresponding substituted pyridines 
1.15 in moderate to excellent yields (3898%) after purification (Scheme 1.9).21   
Me
O COR1
NMe
R1OC
R3
R3
O
+
1.17 1.13 1.15 (38-98%)
NH4OAc, EtOH
R2
R2
reflux, 24 h
 
Scheme 1.9: Mild acid-free three-component condensation reaction for the production 
of substituted pyridines 1.15 
 
1.2.2.2 Tandem oxidation-heteroannelation Bohlmann-Rahtz reaction 
The in-situ tandem oxidation-heteroannelation of propargylic alcohols 1.18 with 
either o-iodoxybenzoic acid (IBX) or manganese dioxide provided a new one-pot 
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tandem route to nitrogen-containing heteroaromatic building blocks. The process 
involved four separate synthetic transformations in a single preparative step.
22
 Various 
heteroannelation reactions provided high yields and with total regiocontrol of the 
pyridine 1.15 from either enamine 1.12 or -keto ester 1.17 precursors. 
The process involved heating an enamine 1.12, generated beforehand from the 
reaction of 1.17 and ammonia, with a one-fold excess of both the propargylic alcohols 
1.18 and o-iodoxybenzoic acid in dimethylsulphoxide-acetic acid (5:1) at 65 °C 
overnight to give the corresponding substituted pyridines 1.15 in 2073% yields after 
purification (Scheme 1.10).
22
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Scheme 1.10: Tandem oxidation-heteroannelation of proparglic alcohols for the 
production of substituted pyridines 1.15 
 
The efficiency of this process was found to be dependent on the nature of the 
propargylic alcohol. Low yields obtained in some cases could be attributed to oxidative 
degradation of 1.12 under the reaction conditions. Indeed, when a range of propargylic 
alcohols 1.18, -keto esters 1.17 and ammonium acetate were heated under reflux 
conditions in a toluene-acetic acid mixture (5:1 by volume) in the presence of 
manganese dioxide in a one-pot pocess, this gave the corresponding substituted 
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pyridines 1.15 (Scheme 1.10), in up to 96% yield and with total regiocontrol. Therefore, 
generating the enamine in-situ from the condensation of the corresponding β-keto ester 
1.17 and ammonia was effective in reducing enamine degradation.
22
 The process 
represented in Scheme 1.10 is a convenient three component cyclocondensation that 
involves four transformations in a single preparative step.
22
 
 
1.2.2.3 Microwave synthesis 
The use of microwave dielectric heating, known as microwave-assisted organic 
synthesis (MAOS), in synthetic chemistry is a valuable and convenient alternative to the 
conventional conductive heating methods.
23
 Microwave-assisted chemistry can provide 
faster heating rates and improve reaction rates by carrying out transformations under 
sealed vessel conditions well above the boiling point of the reaction solvent.  The 
popularity and reproducibility of microwave chemistry has increased dramatically due 
to recent advances in instrumentation that led to development of new synthetic reactions 
and rapid optimisation of existing procedures.
2429
 
The Bohlmann-Rahtz reaction has been investigated under microwave-assisted 
conditions in a self-tuning single-mode CEM Discover™ Focused Synthesizer.30 For 
example, reaction of a mixture of ethyl β-aminocrotonate 1.12a and an excess 
phenylpropynones 1.13 in toluene or dimethylsulphoxide at 170 °C under microwave 
conditions gave the corresponding substituted pyridines 1.15 in 7698% yields (Scheme 
1.11) after 1090 minutes.30 
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Scheme 1.11: One-pot synthesis of substituted pyridines 1.15 via heteroannelation of 
enamine 1.12a with alkynones 1.13 under microwave or thermal conditions 
 
The use of dimethylsulphoxide which is a more polar solvent was found to be 
more efficient under microwave irradiation and resulted in a shorter reaction time (10 
min) compared with the use of toluene (90 min). Reactions conducted in toluene could 
be accelerated in the presence of zinc(II) bromide (15 mol%) as a Lewis acid catalyst.
30
  
However, the optimum conditions involved the use of a solution of tolueneacetic acid 
(5:1 by volume) at 170 °C for 10 minutes. The reaction was also successful in some 
cases when no solvent was used and high yields of the products were obtained.
30
  
Clearly, the microwave-assisted reaction facilitated both Michael addition and 
cyclodehydration in a single synthetic step and afforded substituted pyridines 1.15 as 
single regioisomers. Also, all of the reactions carried out under microwave-assisted 
conditions provided substituted pyridines 1.15 in a higher yield compared with the 
corresponding processes conducted by traditional conductive heating methods, although 
rigorous temperature control was not investigated for a formal comparison of specific, 
non-thermal microwave effects, for which there is no rigorous evidence in this 
transformation. The only exception was the solventless reaction that gave higher yields 
in a Carius tube, possibly because of poor energy transfer when a neat reaction mixture 
was irradiated under microwave conditions.  
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The reaction represented in Scheme 1.11 showed a one-pot microwave-assisted 
Bohlmann-Rahtz reaction. The process is a simple and highly-expedient route for the 
production of tri- and tetra-substituted pyridines which proceeds with total control of 
regiochemistry.
30
 Nonetheless the generality of the microwave-assisted process is only 
viable for substrates that can tolerate the high temperature conditions. 
 
1.2.2.4 Continuous flow reactors 
From the early reactions carried out in domestic ovens to the use of multimodal 
or monomodal instruments designed for organic synthesis, microwave-heating 
technology has been implemented worldwide and continues to be developed.
2429
 
However, although modern monomodal instruments dedicated for MAOS are very 
successful in small scale processes, efforts to process this technology in continuous flow 
(CF) reactors have in the past been frustrated by the physical limitations of microwave 
heating, with a penetration depth of only a few centimetres and the limited dimensions 
of the standing wave cavity. Current technology has attempted to overcome these 
disadvantages with conventional instruments by the use of CF reactors that pump the 
reagents through a small heated coil that winds in and out of the cavity, with external 
temperature monitoring using a fibre optic sensor, although alternative methods, such as 
using a multimode batch or CF reactor, have also been described. 
A new method for carrying out MAOS under CF processing using a 
commercially available monomodal microwave synthesizer has been described by the 
Bagley research group.
31
 A 10 mL flow cell was inserted into the cavity of a self-
tunable monomodal microwave synthesizer, irradiated, and stabilized at the desired 
reaction temperature through moderation of microwave power before the introduction 
of reagents into the reactor (Figure 1.4). Aminodienone 1.14b was dissolved in the 
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reaction solvent and introduced into the microwave cavity through a small tube (~5 mm 
internal diameter) via a HPLC pump. The mixture of solvent and 1.14b was passed 
through a layer of sand (~10 g) to minimize dispersion and create micro-channels within 
the small tube and coupled with the microwave irradiation in the reaction chamber to 
exit at the bottom of the reaction tube.  As a result of the continuous pressure exerted by 
the HPLC pump under the action of a back pressure regulator, the reacting mixture 
passed through the micro-channels in the sand, was forced up the reaction tube and was 
collected in a flask for purification by column chromatography to produce substituted 
pyridine 1.15b. 
 
Figure 1.2: Schematic diagram of the CF microwave reactor 
 
The development of a new microwave-assisted CF process shown above for the 
synthesis of pyridines based upon the Bohlmann-Rahtz reaction was examined in this 
microwave flow cell.
31
 To this end, aminodienone 1.14b was subjected to 
cyclodehydration in a CF process under homogeneous conditions in a mixture of 
tolueneacetic acid (5:1 by volume) over sand. The results were compared with batch 
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experiments that were carried out in a sealed tube under conventional microwave 
synthesis and a homogeneous CF process using a commercially available Teflon heating 
coil (Scheme 1.12).
31
  
 
Ph
O
MeH2N
PhMe-AcOH (5:1)
100 oC, 0.1 M
1.14b
NMe
EtO2C
Ph
1.15b (>98%)
microwave
(A, B or C)
Reagents and conditions:
A: 150 W, sealed tube, 2 min.
B: 300 W, CF in Teflon heating coil, 1 mL/min.
C: 300 W, with simultaneous cooling, CF in a glass tube charged with sand,
1 or 1.5 mL/ min.
EtO2C
 
Scheme 1.12: Microwave assisted Bohlmann-Rahtz synthesis of pyridine 1.15b 
 
Conventional microwave synthesis (method A) using the same reaction tube (10 
mL) as described for the CF process, in the same solvent mixture and 1.14b, that was 
then sealed and irradiated for a fixed time. The product was purified by conventional 
methods. The shortfall with this batch method, as mentioned earlier, is the fact that only 
a small amount of material could be processed at any one time because of the small 
volume (10 mL) of the reaction tube. Further comparisons were also made with the 
commercially available Teflon heating coil system (method B), which benefits from a 
continuous spiralling of the tube in the microwave cavity; this was also an open system 
similar to the one described in Figure 1.4 and is a more direct comparison to the CF 
system described (method C). Under conditions that gave efficient conversion (>98%) 
to pyridine 1.15b, the processing rates of material using the glass tube reactor (method 
C) were considerably higher. 
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Moreover, CF reactions run at the same flow rate used less magnetron energy in 
the glass tube (Method C) than in the Teflon heating coil (Method B), demonstrating 
that a glass tube CF reactor offers (1) improved heating efficiency; (2) the potential for 
operation on a large scale; (3) successful transfer from batch (Method A) to CF 
processing (Method C); and (4) improved performance over commercial Teflon heating 
coils. As a result of these findings based in part upon the Bohlmann-Rahtz synthesis, the 
scene has been set to transfer this processing technology to large-scale operations, 
ultimately leading potentially to an industrial-based process. 
Optimization of residence times were established for efficient reaction by the 
use of a Syrris microreactor platform in which these parameters transferred well to 
microwave-assisted batch, continuous flow regimes and stop-flow in addition to 
continuous flow conductive heating apparatus. Small variations in the required 
residence time could be resulted from the differences in how the temperature of the 
reactor was measured, being either the external or internal temperature of the cell. Of 
Microwave-assisted batch processes in a single-mode cavity were found to be the most 
efficient among the apparatus investigated.
15
  They were successfully transferred to 
continuous stop-flow production in the Voyager system, batch processing in a 
multimode synthesizer on <4 mmol scale and continuous processing in the single-mode 
Discover system. Finally, through small adjustments in residence time and reaction 
dilution, this reaction was successfully transferred to mesoscale production by the use of 
continuous flow multimode microwave reactor.
15
 Clearly, this indicated that present 
technique does have the means to scale-out or scale-up microwave batch experiments 
and the Bohlmann–Rahtz cyclodehydration reaction’s parameters could be reliably 
transferred between different technology platforms for mesoscale production. It is 
premature to say whether these same design rules hold for other reactions and systems 
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of study. In a similar fashion, it could be anticipated that discoveries made in 
microwave batch experiments, especially for homogenous mixtures, will follow similar 
principles.
15
 One would expect the scale up of these methods would be relatively 
straightforward using a single- or multi-mode microwave flow reactor, a stop-flow 
microwave platform, or a multimode batch reactor. However, the scale was not much 
more than a ten-fold increase for a multimode batch reactor. On the other hand, 
continuous flow conductive heating platforms operating on either meso- or micro-scale 
production, would seem to give rise to small but significant differences in the chemical 
efficiency of reaction, which one could attribute to variations in temperature 
measurement or heating profile.
15
 Whether these design rules hold for the scale up of 
heterogeneous processes, such as reactions over a catalyst, is another matter entirely and 
one that will continue to provide significant challenges for the continuous flow 
platforms and microwave-assisted synthesis for some time to come, and the results 
compared with a glass tube microwave flow reactor.
15 
To explore the scale-up of a microwave-assisted procedure in this regard in the 
first instance to mesoscale production using continuous flow technology, the Bohlmann-
Rahtz reaction was investigated using a range of commercial technology platforms. 
 
1.2.3 Applications 
The scope and applications of modified Bohlmann-Rahtz procedures towards the 
synthesis of various substituted pyridine-containing heterocycles has recieved great 
attention from chemists. These heterocycles, including substituted pyridines and fused 
pyridines such as pyrido[2,3-d]pyrimidines, play an important role as building blocks in 
natural product synthesis and so new, efficient and expedient methods are of 
considerable value. 
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1.2.3.1 Synthesis of pyrido[2,3-d]pyrimidines and uracil derivatives 
The synthesis and biological activities of various pyrido[2,3-d]pyrimidines 
(5-deazapteridines) have received relatively little attention in spite of their structural 
relationship to both pyridines and pterins.
3234
 In recent years interest in pyrido[2,3-
d]pyrimidines has increased dramatically as a results of their biological properties and 
the potential for folate antagonists
35,36
 to elicit highly species-specific responses as 
antitumour,
37
 antibacterial,
3842
 anti-inflammatory
43
 and insecticidal agents.
44
 
Following the success of various modified Bohlmann-Rahtz conditions for the 
synthesis of pyridines,
1719
 it was proposed by Bagley’s research group that similar 
Michael addition-cyclodehydration strategies could be used for the production of highly 
functionalised 5-deazapteridines.
45
 The first study of this kind investigated the synthesis 
of pyrido[2,3-d]pyrimidines using ethynyl ketones under Lewis acid catalyzed 
conditions.
45
 For example, the preparation of 2-substituted pyrido[2,3-d]pyrimidines 
1.21 from the corresponding (diaminopyrimidinyl)propenone 1.20 or in one pot from 
the reaction of diaminopyrimidinone 1.19 and alkynones 1.13 was reported (Scheme 
1.13). When a solution of the pyrimidine derived Bohlmann-Rahtz intermediate 1.20a 
or 1.20b and zinc(II) bromide (20 mol%) in dimethylsulphoxide was heated overnight at 
110 °C the heteroannelated product, 1.21a or 1.21b, respectively, was produced in 
quantitative yield (Scheme 1.13).
45
 Furthermore, when a solution of 
diaminopyrimidinone 1.19 and either alkynone 1.13c or 1.13d in dimethylsulphoxide 
was heated at 110 °C for 72 hours in the presence of zinc(II) bromide (20 mol%) the 
pure pyrido[2,3-d]pyrimidine 1.21a,b was isolated in 92 and 89% yield, respectively 
(Scheme 1.13).
45
 When the reaction was catalysed with ytterbium(III) triflate (20 mol%) 
gave a slightly impure product 1.21a,b in 94 and 91% yields, respectively (Scheme 
1.13).
19
 Although these reactions were highly efficient and gave the deazapterin as a 
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single regioisomer, the prolonged reaction times and high temperature conditions were a 
significant drawback to high-throughput operation. 
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Scheme 1.13: Synthesis of pyrido[2,3-d)pyrimidines 1.21a,b using Lewis acid catalysis 
 
The structural identity of pyrido[2,3-d]pyrimidine 1.21a and regiochemistry of 
the reactions conducted in acetic acid and N,N-dimethylformamide were confirmed by 
further experimentation.
45
 (3-Oxobut-1-enyl)pyrimidine 1.20a was heated to 180 °C to 
facilitate Bohlmann-Rahtz cyclodehydration and the product obtained was identical to 
pyrido[2,3-d]pyrimidine 1.21a in every respect.
45
 This is an indication that both the one 
and two-step methods for pyrido[2,3-d]pyrimidine synthesis based upon a Bohlmann-
Rahtz pyridine annelation, proceeded with total regiocontrol (Scheme 1.14) and in 72–
95% yield, depending on the solvent used, by C-alkylation and subsequent 
cyclodehydration of Michael addition product 1.20a.
45
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Scheme 1.14: Summary of conditions to synthesize 1.21a 
 
To explore the scope of the process, the treatment of pyrimidinone 1.19 with 
various 4-substituted alkynones 1.13 in a range of solvents (acetic acid, ethanol, 
N,N-dimethylformamide or dimethylsulphoxide) under four different sets of reaction 
conditions (A–D), at room temperature or with heating to 180 °C to effect 
cyclodehydration, was investigated towards the synthesis of a number of pyrido[2,3-
d]pyrimidines 1.21 (Scheme 1.15).
45
 In many of these cases, isolation of 
pyridopyrimidines 1.21 could be effected simply by precipitation upon the addition of 
water. 
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Scheme 1.15: Synthesis of 1.21 from alkynones 1.13 under different conditions 
 
The course of the reaction was found to be dependent on the choice of alkynone 
and solvent. Terminally substituted alkynones (R
1
 ≠ H) appeared to be slow in reaction, 
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presumably because of increased steric hindrance in the Michael addition, resulting in 
stating materials being recovered even after long reaction times (72 hours) at room 
temperature in DMSO or DMF as a solvent. The purity of pyrido[2,3-d]pyrimidines 
1.21 synthesised by method A or B in DMSO was much higher than similar reactions 
conducted in either ethanol or DMF.
45
 
The Michael addition and subsequent cyclodehydration of pyrimidinone 1.19 
and various alkynones under optimized methods did produce pyrido[2,3-d]pyrimidines 
1.21 in excellent yields (7198%). This process was effective in various solvents, 
although DMSO emerged as the best solvent under these conditions. The experimental 
procedures were facile, required no further purification and provided the heterocyclic 
targets in one or two steps with total regiocontrol.
45
  
These successful Bohlmann-Rahtz conditions were subsequently adopted for the 
synthesis of pyridopyrimidines 1.23a from the 6-aminouracil derivative 1.22a (R
3
 = R
4
 
= H) and 4-(trimethylsilyl)butynone (1.13e) in DMSO at 110 
o
C for 72 hours in the 
presence of either zinc(II) bromide or ytterbium(III) triflate (20 mol%) as a Lewis acid 
catalyst to give the products in 60 or 52% yield, respectively (Scheme 1.16).
46
 The 
reaction was found to be quite general in scope and various 5-deazapterins 1.23 were 
produced in good yield (Scheme 1.16).
45
 When trimethylsilyl-substituted alkynones 
1.13 (R
1
 = SiMe3) were reacted with uracil derivatives 1.22, spontaneous 
protodesilylation accompanied Michael addition-cyclodehydration to produce 
pyridopyrimidines 1.23 (R
1
 = H).
46
 When these reactions were conducted either in the 
absence of a Lewis acid or at room temperature the efficiency of the reaction was 
reduced dramatically. The optimum conditions involved heating aminouracil 1.22 and 
the corresponding alkynone 1.13 at 110 °C in the presence of zinc(II) bromide for 72 h 
to give the products 1.23 in 60–75% yield.46 Replacing zinc(II) bromide with 
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ytterbium(III) triflate caused a small reduction in the efficiency of the 
cyclocondensation process. It was apparent that the Lewis acid catalyzed 
cyclocondensation was appropriate for various alkynones and uracil derivatives 1.22 
and constituted a reliable method for the synthesis of pyridopyrimidines.
46
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Scheme 1.16: Reaction of 6-aminouracil 1.22 and alkynone 1.13 under Lewis acid 
catalyzed conditions 
 
1.2.3.2 Combinatorial library synthesis 
With the development of new Bohlmann-Rahtz methods for the synthesis of 
pyridine and related heterocycles, efforts to apply this reaction technology to the 
combinatorial synthesis of pyridine libraries was carried out. In the first instance, a 
targeted combinatorial pyridine library was generated with varying product ratios and 
high library purity using a simple acid-base extraction workup procedure. For example, 
the reaction of ethyl β-aminocrotonate (1.12a) with various alkynones 1.13 produced a 
small library of pyridines 1.15 (Scheme 1.17) using either Bohlmann-Rahtz conditions 
in ethanol (Method A), in an acetic acid–toluene mixture (Method B) or in the presence 
of a Lewis acid in toluene (method C) and the product ratios and library purities were 
compared.
47
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Scheme 1.17: Combinatorial synthesis of substituted pyridines 1.15 
 
Heating a mixture of 1.12a and 1.13 to 50
 
 °C in ethanol followed by isolation 
and heating the isolated intermediate produced according to the traditional Bohlmann-
Rahtz method to 160 
o
C for 3 h gave the corresponding substituted pyridines 1.15, with 
protodesilylation occurring throughout the course of reaction.
47
 The product ratio (R) 
was large and varied between 1 < R < 25, although the overall yield and product purity 
were good.
47
 Some protodesilylation also took place when the reaction was conducted 
in a mixture of tolueneacetic acid (method B) and although the product ratio (R) 
improved, varying between 1 < R < 8.3, the overall yield was low (30%).
47
 However, 
the Lewis acid-catalyzed conditions (method C) resulted in no protodesilylation and 
gave 1.15 in high purity and yield.
47
 The product ratio (R) was between 1 < R < 2, 
indicating that under these conditions all ethynylketone subset members reacted 
efficiently to give a diverse combinatorial library of products. It was curious to note that 
the product ratios varied between the different heteroannelation procedures, as did the 
identity of the major product, indicating that the alkynones display different reactivity 
profiles according to the method used.
47
 It was concluded that the Lewis acid-catalyzed 
methods appeared to provide the best overall yield, product ratios, and library purity for 
the solution phase combinatorial synthesis of pyridines from ethyl β-aminocrotonate 
(1.12a) in the Bohlmann-Rahtz synthesis. 
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This approach has the potential to produce highly-substituted and heavily 
functionalized pyridines directly from readily available starting materials without the 
need for purification and so should complement other published procedures for the 
solution phase combinatorial synthesis of pyridine libraries.
47
 
Simple low molecular weight heterocycles make ideal scaffolds on which to 
base the high throughput synthesis of libraries of drug-like compounds. Examples 
include the use of 1,2,5-thiadiazolidin-3-one-1,1-dioxide and pyrimidine scaffolds in the 
synthesis of serine proteinase and kinase inhibitors, respectively,
48
 and the use of simple 
pyridine scaffolds to generate libraries of inhibitors of HIV-1 protease and Factor Xa.
49
  
Moody and co-workers developed new heterocyclic scaffolds 1.23 for library synthesis, 
trisubstituted pyridines 1.24–1.26 containing two points of potential diversity via 
Bohlmann-Rahtz methodology (Figure 1.3). 
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Figure 1.3 Pyridine scaffold 1.23 and the corresponding pyridines 1.24–1.26 
 
The conditions used for the synthesis of pyridine 1.26 provided, for example, 
this product in 77% yield by the reaction of enamine 1.27 with butynone 1.13b in 
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ethanol under reflux (Scheme 1.18).
50
 Hydrolysis of ester 1.26 gave acid 1.28 (Scheme 
1.18). Following a design process directed towards drug-like products, acid 1.28 was 
coupled with various amines to provide 14 protected intermediates in 61–87% yield on 
a 100 mmol scale, that were then subjected to further reaction with 148 carboxylic acids 
on Boc-deprotection to generate 2072 amides for biological screening. 
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Scheme 1.18: Drug design library synthesis applying the Bohlmann-Rahtz pyridine 
synthesis 
 
Clearly, the use of modified Bohlmann-Rahtz methodology has been 
demonstrated in an efficient large scale synthesis of the pyridine scaffold 1.28 
containing two points of diversity and applied in library synthesis.
50
 
 
1.2.3.3 Natural product chemistry 
The Bohlmann-Rahtz reactions of bis-acetylenes 1.29 with enamine 1.30 under 
traditional conditions, in ethanol under reflux, has also been investigated and afforded 
the corresponding alkynylpyridines 1.31 in high yield (Scheme 1.19).
51
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Scheme 1.19: Bohlmann-Rahtz reaction for the synthesis of substituted pyridines 1.31 
 
The initial report by Baldwin
51
 inspired the synthesis of analogues of various 
heterocyclic -amino acids such as azatyrosine 1.32, mimosine 1.33 and lathyrine 
1.34.
52
 Such compounds were found to display antibiotic, antitumor, wool growth and 
pollen growth inhibitory activities (Figure 4).
52 
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Figure 1.4: Structures of heterocyclic -amino acids, azatyrosine 1.32, mimosine 
1.33 and lathyrine 1.34 
 
Reaction of alkynone 1.35 and 3-aminobut-2-enoic acid methyl ester 1.30 in 
ethanol under reflux gave the corresponding trisubstituted pyridine, -alanine 1.36 in 
81% yield (Scheme 1.20).
51
 Subsequent deprotection and purification by ion exchange 
chromatography afforded the free amino acid 1.37 as an analogue of the -amino acid 
L-azatyrosine 1.32 (Scheme 1.20).
51
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Scheme 1.20: Bohlmann–Rahtz synthesis of analogue 1.37 of L-azatyrosine 1.32 
 
In a similar manner condensation of alkynone 1.35 and 4-aminopent-3-en-2-one 
(1.38) gave -alanine 1.39 in 91% yield (Scheme 1.21).51 Subsequent deprotection gave 
the corresponding amino acid 1.40 (Scheme 1.21).
51
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Scheme 1.21: Bohlmann-Rahtz synthesis of analogue 1.40 of L-azatyrosine 1.32 
 
The most significant application of the Bohlmann-Rahtz reaction to be reported 
to date is in the synthesis of thiopeptide antibiotics. This class of naturally-occurring 
antimicrobial compounds isolated from bacteria includes, for example, thiostrepton 1.41 
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(Figure 1.5), Sch 40832 1.42 (Figure 1.6), micrococcin P1 1.43 (Figure 1.7) and 
nosiheptide 1.44 (Figure 1.8).
53
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Figure 1.5: Thiopeptide antibiotic 1.41 
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Figure 1.6: Thiopeptide antibiotic 1.42 
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Figure 1.7: Thiopeptide antibiotic 1.43 
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Figure 1.8: Thiopeptide antibiotic 1.44 
 
The sulfomycins are one sub-class members of this family of antibiotics, 
isolated in this instance from Streptomyces viridochromogenes. Acidic hydrolysis of 
sulfomycins 1.45a–c with 6M HCl at 110 °C for 6 hours gave the chemical degradation 
product (±)-sulfomycinine hydrochloride 1.46 (Scheme 1.22).
54
 Furthermore when 
sulfomycin I 1.45a was heated under reflux in methanol in the presence of 
Amberlyst-15 ion-exchange resin for 20 hours, this gave the degradation products 
sulfomycinic amide 1.47, methyl sulfomycinate 1.48 and dimethyl sulfomycinamate 
1.49 (Scheme 1.22), all of which were used collectively to assist the structural 
elucidation of the natural product.
54
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Scheme 1.22: Degradation of the sulfomycins 1.45a–c 
 
Dimethyl sulfomycinamate (1.49; Scheme 1.23) was synthesised from keto 
amide 1.50 using modified Bohlmann-Rahtz methodology (Scheme 1.23).
55
 When the 
ketone 1.50 was heated under reflux overnight in methanol in the presence of 
ammonium acetate, this gave the Bohlmann-Rahtz precursor, enamine 1.51, in 80% 
yield (Scheme 1.23).
55
 Bohlmann-Rahtz reaction of enamine 1.51 with methyl 
oxobutynoate 1.52 in methanol at room temperature gave pyridine 1.53 (Scheme 1.23) 
in 93% yield as a single regioisomer via Michael addition and spontaneous 
cyclodehydration.
55
 This pyridine synthesis was later improved by the Bagley research 
group by the introduction of a one-pot three-component process.
21
 Heating -keto amide 
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1.49, used as a tautomeric mixture, methyl oxobutynoate 1.52, and ammonium acetate 
(10 equiv) under reflux in methanol for 5 hours gave pyridine 1.53 directly in 81% 
yield.
21  
Elaboration of oxazole-pyridine 1.53 was achieved in a further 6 steps resulting 
in the synthesis of dimethyl sulfomycinamate 1.49 with total regiocontrol in 13 steps 
and 8% overall yield, by the Bohlmann-Rahtz heteroannelation of enamine 1.51, or in 
12 steps and 9% overall yield by a three-component cyclocondensation using -keto 
amide 1.49 and ammonia in methanol.
55
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Scheme 1.23: Bohlmann-Rahtz synthesis of dimethyl sulfomycinate (1.49) 
 
Synthetic efforts using modified Bohlmann-Rahtz methodology has also been 
directed towards other members of the thiopeptide antibiotics. Cyclothiazomycin (1.54) 
was isolated from the fermentation broth of Streptomyces sp. NR0516 obtained from a 
soil sample collected at Kanagawa, Japan, and has been shown to be a selective 
inhibitor of human plasma renin at an IC50 of 1.7 M.
56
 Chemical degradation of the 
natural product 1.54 gave heterocyclic amino acid -lactam 1.55 and saramycetic acid I 
1.56 (Scheme 1.24).
57
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Scheme 1.24: Degradation products of cyclothiazomycin 1.54 
 
-Lactam 1.61 was synthesized starting from the corresponding amino acid 1.57 
using the Bohlmann-Rahtz pyridine synthesis (Scheme 1.25).
58
 Reaction of (R)-β-keto 
ester 1.57
59
 with ammonium acetate gave enamine 1.58 in 70% yield and 92% ee when 
the reaction was carried out at room temperature in ethanol (Scheme 1.25). The 
Bohlmann-Rahtz reaction of enamine 1.58 and propynone 1.59 gave pyridine 1.61 as a 
single regioisomer in 73% yield, albeit only in 14% ee.  Changing the cyclodehydrating 
agent from a Brønsted acid to N-iodosuccinimide, at 0 °C, gave pyridine 1.60 in much 
improved enantiomeric purity, 92% ee. 
To improve this process still further, a one-pot process was developed by the 
addition of ammonium acetate to a solution of (R)-β-keto ester 1.57 (>99% ee) in 
ethanol. After 4 hours at room temperature, thiazolylpropynone 1.59 was added and the 
mixture was stirred to complete the Michael addition. The mixture was then cooled to 
0 °C, and N-iodosuccinimide was added (Scheme 1.25) to give C- and N-terminal-
protected amino acid 1.61 in 55% yield and 96% ee from this one-pot reaction. 
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Scheme 1.25: Synthesis of cyclothiaomycin central domain 1.61 
 
Retrosynthetic studies of the thiopeptide amythiamicin A 1.62 provided a further 
application of the Bohlmann-Rahtz reaction by Michael addition-cyclodehydration of 
enamine 1.64 and alkynone 1.65 (Scheme 1.26).
60
 Michael addition of enamine 1.64 
and alkynone 1.65 in ethanol followed by acetic acid-catalyzed cyclodehydration at 70 
°C gave the amythiamicin heterocyclic domain 1.66 with total regiocontrol in 85% yield 
and 93% ee (Scheme 1.26).
60
 Overall, this heterocyclic cluster 1.66, related to 
amythiamicin (1.62), was generated in only 9 steps and 18% overall yield from 1.63.
60
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Scheme 1.26: Retrosynthetic analysis of amythiamycin A (1.62) and the forward 
synthesis of the target domain 1.66 
 
Promothiocin A (1.67) was isolated from Streptomyces sp. SF2741 and its 
structure was proposed in 1994, principally on the basis of NMR spectroscopic 
analysis.
61
 The synthesis of 1.67 reported by Bagley and Moody (Scheme 1.27) 
confirmed the natural product constitution an stereochemistry, based upon a Bohlmann-
Rahtz strategy.
62
 Reaction of enamine 1.69 with alkynone 1.70 in ethanol at 50 °C 
overnight according to traditional Bohlmann-Rahtz conditions, followed by heating to 
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high temperature to effect cyclodehydration, gave the pyridine intermediate 1.68 
(Scheme 1.27) in 83% yield.   
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Scheme 1.27: The structure of promothiocin A (1.67) and a summary of the total 
synthesis incorporating a traditional Bohlmann-Rahtz reaction 
 
1.3 Werner syndrome 
Werner syndrome (WS) is one of the most well characterized premature ageing 
disorders. Patients with WS have several symptoms of ageing that present at a younger 
age than normal. However, not all symptoms of WS resemble the normal ageing 
process, and WS is best described as a segmental progeroid disorder.
63
 There are several 
other premature ageing syndromes such as Cockayne syndrome, Rothmund Thompson 
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and Hutchinson Guilford progerias. Such conditions are very rare in the general 
population.
64
   
The development of premature ageing in Werner syndrome is characterized by a 
number of clinical symptoms, including short stature, premature greying of the hair, 
cataracts, osteoporosis, type II diabetes, high levels of inflammatory diseases and 
accelerated atherosclerosis, accompanied by a high incidence of cancers, and also 
arteriosclerosis.
65
 The clinical picture of WS is more complex than a simple global 
acceleration of age-linked pathology. This disease provides a convincing mimic of the 
normal ageing phenotype: individuals with WS appear to have essentially normal 
immune function and lack notable pathology of the central nervous system. The median 
life expectancy of WS patients is 47 years, with major cause of death being myocardial 
infarction or mesenchymal neoplasm.
66
 
The development of research in this area has focused on defining the cellular 
role of the Werner protein, WRNp, encoded by the gene defective in the disease, WRN. 
WRNp is a nuclear 1432-amino acid protein.
67
 The WRNp interacts with many proteins 
involved in DNA replication, transcription, DNA recombination and DNA repair.
68
 The 
nuclear protein, WRNp, is found predominantly in the nucleoli but relocates to 
replication foci at S phase of the cell cycle, and to sites of DNA damage in response to 
DNA-damaging agents such as 4-nitroquinoline 1-oxide.
69
 Primary WS cells display 
genome instability, manifested by telomere dysfunction, an elevated rate of 
chromosomal translocation and genomic deletions,
70
 and are hypersensitive to a subset 
of DNA damaging agents,
71
 suggesting that the WRNp plays a key role in the cellular 
response to specific types of DNA damage. These features have led to WS being 
classified as a genome instability syndrome.
72
 Cultured cells from normal individuals 
have a finite capacity to divide, after which they enter a state of permanent cell-cycle 
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arrest termed ‘replicative senescence’ or also named ‘cellular senescence’. Senescence 
has been postulated to contribute to normal human ageing and shows acceleration in 
WS.
73
 Primary fibroblasts from WS patients show a very abbreviated in vitro lifespan; 
they divide more slowly than normal cells, exit the cell cycle at a higher rate than 
normal fibroblasts and so senesce more rapidly.
74
 Studies suggest that WRNp 
participates in biological pathways by acting at telomeric ends. WS cells display some 
defects in telomere metabolism, including increased rates of telomere shortening
75
 and 
deficiencies in repair at telomeres.
76
 Both normal and WS fibroblasts use the 
progressive erosion of chromosomal telomeres as a cell division ‘counter’, but recently 
it has been shown that this telomere driven senescence synergizes with an additional 
telomere-independent mechanism in WS.
77
  
The accelerated ageing of mitotic tissue in vivo has been linked with the 
premature senescence of cultured primary fibroblasts in vitro, which show a very 
abbreviated lifespan. Cellular senescence in normal human fibroblasts but also in WS 
fibroblasts appears to be triggered by telomere erosion.
78
 Young WS fibroblasts have 
telomeres of similar length to young normal cells but they senesce with longer mean 
telomere lengths. This might indicate that WS cells are more sensitive to variations in 
telomere length. 
 
1.4. Use of MAPK inhibitors to treat Werner syndrome 
Mitogen activated protein kinases (MAPKs) are intracellular signal transduction 
molecules, a group of protein serine/threonine kinases that are activated in response to a 
variety of extracellular stimuli and mediate signal transduction from the cell surface to 
the nucleus. They regulate various physiological and pathological cellular phenomena, 
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including inflammation, cell cycle, cell differentiation, apoptotic cell death, oncogenic 
transformation, tumor cell invasion, and metastasis. The MAPK superfamily consists of 
at least four broad families, namely extracellular-signal-regulated kinase (ERK), 
Jun-NH2-terminal kinases (JNKs), ERK5 (or big MAPK1, BMK-1) and p38 MAPK. 
MAP kinases, in combination with several other signaling pathways, can differentially 
alter the phosphorylation status of the transcription factors in a pattern unique to a given 
external signal. The mechanism by which this occurs involves the enzymatic transfer of 
phosphate groups from high-energy donor molecules, such as a ATP, to specific target 
molecules (substrate), in a process termed phosphorylation. Specifically p38 MAPK is 
implicated in transducing the stress signal arising from stalled replication forks, leading 
to telomere independent senescence. Classical MAP kinase signaling occurs in 
cascades, involving MAP kinases (MAPK) that are activated by MAPK kinases 
(MAPKK), which are in turn activated by MAPKK kinases (MAPKKK). The activation 
of specific MAPKK kinases through extracellular signals, such as endotoxins, stress, 
inflammatory cytokines TNF- (tumor necrosis factor-) and IL-1 (interleukin-1) 
and growth factors, leads to phosphorylation and activation of downstream MAPK 
kinases that, in turn, phosphorylate and activate their MAP kinase. The activated MAP 
kinases can activate downstream kinases and transcription factors leading to stabilized 
mRNA that encode cytokines and receptors involved in inflammation and immunity, 
regulation of gene expression, translation, cell cycle progression, proliferation, 
differentiation, growth inhibition and apoptosis (Figure 1.9).
79
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Figure 1.9: Mitogen-activated protein kinase signaling cascades
79 
 
It has been established that the p38 MAP kinase pathway is activated in response 
to physical stress signals such as osmotic shock, heat, UV light and in response to such 
pro-inflammatory cytokines as TNF-, IL-1 and growth factors. The p38 kinase is 
widely expressed in many cell types, including immune, inflammatory and endothelial 
cells. There are four p38 isoforms known as , ,  and  and each encoded by a 
separate gene, but the p38 kinase is believed to be the family member primarily 
responsible for regulation of inflammation. The p38 MAPK is activated through 
bis-phosphorylation on a Thr-Gly-Tyr motif located in a region known as the activation 
loop, leading to increased production of pro-inflammatory cytokines such as TNF- and 
IL-1. Activation is achieved by dual-specificity serine/threonine MAPK kinases, 
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MKK3 and MKK6. These kinases serve as upstream MAPK kinases responsible for p38 
activation. The primary substrate of p38 MAPK is MAPK activated protein kinase 2 
(MAPKAPK-2 or MK2) which in turn phosphorylates the small heat shock protein 
HSP27. This protein promotes polymerization of actin filaments and maintains integrity 
of the cytoskeleton (Figure 1.10).
80
 The p38 MAP kinase is a protein serine-threonine 
kinase: it plays a central role in numerous pro-inflammatory responses. An important 
and accepted therapeutic approach for potential drug intervention in inflammatory 
disease is the reduction of pro-inflammatory cytokines.   
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Figure 1.10: The p38 MAPK signalling pathway 
 
The initial discovery in 1994 of p38 as the molecular target for a novel class of 
cytokine suppressive inhibitors has been exemplified by the prototypical inhibitor, 
pyridinylimidazole, SB203580 (1.71) (Figure 1.11).
81
 This is one of a number of 
Chapter One: Introduction 
42 
prototypes originally prepared as inflammatory cytokine synthesis inhibitors that 
subsequently were found to be selective inhibitors of p38 MAP kinase. SB203580 
(1.71) inhibits the catalytic activity of p38 MAP kinase by competitive binding in the 
ATP pocket.   
 
F
N
H
N
N
S
Me
O
1.71
 
Figure 1.11: The prototypical inhibitor SB203580 (1.71) 
 
Studies of p38 MAP kinase show this enzyme possesses a hydrophobic pocket 
not occupied by ATP (1.72). This provides opportunities for the discovery and design of 
selective small molecule ATP competitive inhibitors imitating ATP-adenine and gaining 
selectivity by occupying areas unfilled by ATP (1.72). Crystallographic mutational and 
biochemical studies by researchers at Boehringer Ingelheim demonstrated that 
SB203580 (1.71) and related pyridin-4-yl imidazole derivatives bind in the ATP 
binding site of p38. The pyridine ring nitrogen of the inhibitor forms a hydrogen bond 
to the backbone NH of Met109 in the linker region. This is a common feature observed 
in all crystal structures of p38 in complex with respective pyridin-4-yl imidazole 
derivatives. This H–bond underlines the crucial importance of the pyridine ring for 
biological activity.
82,83
 While the 4-fluorophenyl ring of SB203580 (1.71) binds to a 
hydrophobic region which in p38 is represented by an unusually spacious pocket, a 
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second hydrophobic area below the linker region is left unoccupied by simple pyridin-4-
yl imidazole inhibitors (Figure 1.12). 
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Figure 1.12: SB203580 (1.71) binding modes with p38 
 
1.5 Conclusions 
The Bohlmann-Rahtz pyridine synthesis has re-emerged as a viable route to 
substituted pyridines. New procedures, implementing metal based Lewis acid, Brønsted 
acid and metal free Lewis acid catalysis have been introduced in which various solvents 
including non-protic (toluene) and protic (ethanol and dimethylsulphoxide) were used. 
Also, new one-pot two- and three-component methodologies to produce substituted 
pyridines have been developed. Such procedures have been applied to the synthesis of 
various natural products and pyridine-containing libraries designed specifically for drug 
discovery, natural product mimetics and especially in the synthesis and structure 
elucidation of the thiopeptide antibiotics. The methods have been found to be 
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regiospecific and highly stereoselective, as well as relatively ecologically benign 
through promotion by microwave irradiation. 
 The mutant gene that encodes for the WRN protein has permitted the molecular 
pathology of Werner syndrome and its biological basis to be uncovered. Primary WS 
cells show many of the characteristics of cells growing under ‘replication stress’, 
display genome instability, manifested by telomere dysfunction, an elevated rate of 
chromosomal translocation and genomic deletions, and are hypersensitive to a subset of 
DNA damaging agents. These features suggest that the WRNp plays an important role 
in the cellular response to specific types of DNA damage. The genome instability seen 
in WS, together with the frequent replication fork stalling, provides a plausible trigger 
for replication stress in WS cells and a possible involvement for the p38 signalling 
pathway in inducing a shortened replicative life span. The studies have identified that 
premature senescence could be the result from activation of the ‘stress-associated p38 
mitogen-activated protein kinase’ (MAPK), which is pivotal in orchestrating many 
stages of inflammation. Various heterocyclic inhibitors of the p38 MAPK signaling 
pathway have been investigated in Werner syndrome cells, such as SB203580, a 
cytokine-suppressive anti-inflammatory drug. The results revealed an unexpected 
reversal of the ageing phenotype of drug-treated WS fibroblasts, which show a much 
increased replicative life span and a growth rate and morphology that resembles that of 
young normal cells. The inhibitor SB203580 has been shown to prevent the 
phosphorylation of p38α kinase in a ATP competitive manner and this implicates (but 
does not prove) this mechanism in accelerated ageing and gives potential to the prospect 
of targeting this pathway in a drug discovery programme, if a better mechanistic 
understanding can be garnered.  
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1.6 Goals of the project 
The aim of the work was to develop new, rapid microwave-assisted methods for 
the synthesis of various substituted heterocycles, including pyridine derivatives where 
upon a Hantzsch-type three-component condensation, or related process, is involved. 
Also, new methodology for the synthesis of several biologically active inhibitors will be 
attempted under microwave conditions.  
The research aimed to modify the Bohlmann-Rahtz pyridine synthesis to be 
simple, general, require short reaction times, involve mild conditions and to be high 
yielding. Such improvements could be achieved by carrying out the reactions under 
microwave conditions. 
The project also aimed to synthesise the p38 MAPK inhibitor UR-13756 using a 
Hantzsch-type three component cyclocondensation under microwave irradiation 
conditions. Such procedure if successful should be simple and convenient and could 
build upon advances in Bohlmann-Rahtz pyridine synthesis in the development of 
improved methodology. 
As an alternative inhibitor chemotype, 4-(3-amino-1-(4-methoxyphenyl)-1H-
pyrazol-4-yl)benzamide was aimed to be synthesised in three steps under microwave 
conditions. The biological activities of such inhibitor would be investigated. 
As a final inhibitor chemotype, the project also aimed to prepare the 
chemotherapeutic agent RO3201195, a highly selective inhibitor of P38α using 
improved methods. It was planned to synthesise RO3201195 in seven steps under 
microwave conditions to prepare rapid access to this target for future biological 
evaluation.  
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CHAPTER TWO 
SYNTHESIS OF PYRIDINE DERIVATIVES 
2.1 Introduction 
 The synthesis of pyridine derivatives continues to attract interest from both 
chemists and biologists due to their wide range of biological properties.
1,2
 Various 
methods are available for the synthesis of substituted pyridines. The Bohlmann–Rahtz 
pyridine synthesis is one such method for the synthesis of pyridine derivatives that can 
proceed in a single step.
3
 Condensation of ethynylketones with enamines gave the 
corresponding aminodiene as an intermediate which underwent cyclodehydration to 
give the substituted pyridine derivatives. 
The Bohlmann–Rahtz reaction is related to the well–known Hantzsch 
dihydropyridine synthesis. However, no aromatization oxidation step is required. 
Although the Bohlmann–Rahtz pyridine synthesis is highly versatile, it suffers from 
drawbacks that have limited its synthetic utility such as the requirement of high 
temperature for the cyclodehydration. Some of these drawbacks have been overcome to 
make it a convenient process for the synthesis of pyridines, although its substrate scope 
remains incompletely defined to date. 
 
2.2 Bohlmann–Rahtz Reaction 
 Bohlmann and Rahtz first reported the synthesis of substituted pyridines 2.4 in a 
two step process.
3
 The first step involves reaction of enamines 2.1 and ethynylketones 
or aldehydes 2.2 to produce the corresponding aminodienone intermediates 2.3 (Scheme 
2.1).
3
 Intermediates 2.3 were found to be kinetically stable due to the enone 
E-geometry. The second step involves heating 2.3 at 120–170 °C to promote the C=C 
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E/Z isomerisation followed by spontaneous cyclodehydration to provide the 
corresponding substituted pyridines 2.4 in high yield (72–90%; Scheme 2.1).3 
 
R2
NH2R
1
H
O R3
EtOH
50 °C
NH2R
1
R3
O
R2
2.1 2.2 2.3
120 - 170 °C
Vacuum
N
R2
R1 R3
2.4 (72 - 90 %)R1 = Me, Ph
R2 = CO2Et, COMe, CN
R3 = H, Me, Ph, C7H15
 
Scheme 2.1 Synthesis of 2,3,6–trisubstituted pyridines 2.4 via BohlmannRahtz 
methods
3 
 
 The reaction represented in Scheme 2.1 is related to the Hantzsch 
dihydropyridine synthesis,
4-8 
but the use of ethynylketones provided the pyridine 
directly without the final aromaization step.
9,10
 
 A suggested mechanism for the Bohlmann–Rahtz reaction is represented in 
Scheme 2.2 which involves a Michael addition followed by cyclodehydration to 
produce the pyridine derivative. 
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Scheme 2.2 Suggested mechanism for the two–step Bohlmann–Rahtz synthesis of 
substituted pyridines 2.4 
 
 It was found that the Bohlamm–Rahtz reaction proceeded well in polar solvents 
rather than non–polar solvents and favoured polar protic solvents (e.g. ethanol) over 
polar aprotic solvents (e. g. dimethylsulfoxide).
8
 
 It has been reported that the use of acetic acid promoted the conjugate addition 
and double bond isomerisation of intermediates 2.3 necessary for cyclodehydration to 
produce pyridine derivatives 2.4.
11
 For example, condensation of 2.1a and 2.2a gave 
intermediate 2.3a in 98% yield which underwent cyclodehydration in acid medium to 
provide trisubstituted pyridine 2.4a in quantitative yield (scheme 2.3).
11
 However, the 
reaction failed to provide the product when the ethyl ester (CO2Et) was replaced by a 
cyano group .
11 
 
Chapter Two: Synthesis of Pyridine Derivatives 
57 
NH2Me
SiMe
O Me
EtOH
50 °C, 5 h NH2Me
Me
O
2.1a 2.2a 2.3a
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Scheme 2.3 Synthesis of trisubstituted pyridine 2.4a via Bronsted acid Catalyst 
 
 Lewis acid catalysts have been used successfully for the production of 
substituted pyridines 2.4 in this process.
11,12
 Various Lewis acids such as FeCl3, 
Sc(OTF)3, ZnBr2 and Yb(OTF)3 have been used;
11,12
 however, boron trifluoride etherate 
failed to produce the corresponding pyridine derivative. Zinc(II) bromide and 
ytterbium(III) triflate were found to be the most effective Lewis acids for the production 
of 2.4 in high yield.
11,12
 Generally reactions catalysed by zinc(II) bromide were faster 
and higher yielding than those conducted in the presence of ytterbium(III) triflate with a 
few exceptions. 
 As an alternative, reactions of enamines 2.1 and ethynyl ketones 2.2 in the 
presence of Amberlyst-15 ion-exchange resin for 26 hours at 50 °C in toluene gave the 
corresponding tetrasubstituted pyridines in 71–83% yields.12 
 A new multiple-component condensation reaction has been investigated to 
overcome the poor availability of precursors in this reaction.
13
 Such a process involves a 
three–component condensation of a β-keto ester 2.5 and alkynone 2.2b in the presence 
of ammonium acetate in toluene under reflux condition for 20 hours (Scheme 2.4).
13
 
The enamine 2.1 was generated in-situ and then reacted with 2.2b to produce the 
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corresponding aminodienone intermediate 2.3b. Acid catalysed cyclodehydration of 
2.3b afforded the corresponding substituted pyridines 2.4b (Scheme 2.4) in 67–96% 
yields.
13
 Acetic acid, zinc (II) bromide and Amberlyst 15 were used successfully as acid 
catalysts in this 3-component process.
13 
 
OMe
Et
O Me
2.1b 2.2b
NMe Me
2.4b
O
EtO EtO
O Et
NH4OAc, PhMe
acid catalyst
ref lux, 20 h
 
Scheme 2.4 Three-component condensation reaction for the production of substituted 
pyridine 2.4b 
 
 Further modifications of a multistep three-component condensation process have 
been reported for the synthesis of a series of substituted pyridines 2.4 in 38–98% yield 
using ammonium acetate in ethanol under reflux conditions for 24 h.
14
 
 In a related process, Dechoux reported a method for the cyclization of δ-
dienaminoesters 2.6 to produce pyridinones 2.7 on treatment with NBS under basic 
conditions (Scheme 2.5)
15,16
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Scheme 2.5 Synthesis of pyridinones 2.7 and pyrroles 2.8 
 
 Bagley’s research group have investigated the treatment of various Bohlmann-
Rahtz aminodienones 2.3 with NBS under Dechoux’s conditions and 5-bromopyridines 
2.9 were produced in 83–98% yield (Scheme 2.6).14 
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O
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O
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O
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O
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O
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2.3
2.9 (83-98%)
 
Scheme 2.6 Synthesis of substituted pyridines 2.4 via bromination–cyclodehydration 
2.3 
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 Also, N-iodosuccinimide (NIS) was successfully used to produce a range of 
substituted pyridines 2.4 in 84–98% yields at 0 °C in ethanol (Scheme 2.7).14 In this 
case the iodosuccinimide behaved as a Lewis acid rather than a halogenating agent to 
catalyze the cyclodehydration to the pyridine. 
 
2.4 (84-98%)
NH2R
2
R3
O
RO
O
2.3
N R3R
O
RONIS, EtOH
0 °C
 
Scheme 2.6 Synthesis of substituted pyridines 2.4 via NIS-mediated cyclodehydration 
of aminodienones 2.3 
 
 Traces of iodine could have been responsible in the NIS-mediated reaction to 
give the reported yield of product.
17
 In order to probe this possibility, it was found that 
the use of iodine alone gave a quantitative yield of the corresponding substituted 
pyridine 2.4; the reaction was general for various substrates 2.3 and provided high 
yields (92–98%) of pyridine products 2.4.14 
 A new one–pot tandem oxidation–heteroannelation of propargylic alcohols 2.9 
with either ortho-iodoxybenzoic acid (IBX) or manganese dioxide (MnO2) has been 
found to provide substituted pyridines.
18
 This reaction of β-ketoesters 2.10 with 
propargylic alcohols 2.9 in the presence of ammonium acetate under reflux in a mixture 
of toluene–acetic acid (5:1) gave the corresponding pyridines 2.4 (Scheme 2.8) in high 
yield.
18
 It was postulated that the enamine 2.1 was produced in-situ from condensation 
of the β-ketoester 2.10 with ammonia.19 
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R2 NH2
R4
R6HO
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R6O
N
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R3
R2 R6
2.4
2.10 2.1
2.9 2.2
 
Scheme 2.8 Tandem oxidation–heteroannelation of alcohols 2.9 
 
 Substituted pyridines 2.4 were also synthesised in low to high yields under 
microwave conditions.
19,20
 For example, it was found that reactions of β-aminocrotonate 
2.1a with alkynones 2.2 in DMSO at 170 °C for 20 minutes under microwave 
conditions gave substituted pyridines 2.4 in 24–94% yields (Scheme 2.10).19 However, 
the reaction involved the use of very high temperatures which could be considered as a 
disadvantage. Also, under these conditions, the yield of a number of substituted 
pyridines 2.4 was low in some cases. 
 The Bohlmann–Rahtz reaction has been applied in the synthesis of various fused 
heterocycles containing a pyridine moiety.
2124
 It has also been used for the production 
of more complex target molecules and biologically relevant structures.
2529
 
 
2.3 Hantzsch dihydropyridine synthesis 
 The Hantzsch dihydropyridine synthesis was first reported in 1891.
4
 It is a well-
known multi-component reaction that involves an aldehyde, β-ketoester (two molar 
equivalents) and ammonia or ammonium acetate.
4
 For example, reaction of 
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formaldehyde, ethyl acetate (2.5) and ammonium acetate in aqueous medium under 
reflux conditions gave dihydropyridine 2.11 (Scheme 2.9). Aromatisation of 2.11 with 
FeCl3 gave the corresponding pyridine derivative 2.12 in 93% yield (Scheme 2.9).
4
 
 
EtO
O
Me O
HCHO, NH4OAc
H2O, reflux, 1 h N
H
O
EtO
O
OEt
MeMe
FeCl3
reflux, 2 h N
O
EtO
O
OEt
MeMe
2.5 2.11 2.12
Scheme 2.9 Hantzsch dihydropyridine synthesis 
 
 The reaction proceeded via Knoevenagel condensation product 2.13 (Figure 2.1) 
which is another key intermediate, along with ester enamine 2.14 (Figure 2.1) in this 
reaction. Product 2.13 was produced from reaction of ethyl acetoacetate with 
formaldehyde, whilst intermediate 2.14 was generated by condensation of the second 
equivalent of ethyl acetoacetate (2.5) with ammonia. Evidence of the mechanistic 
course has been provided in studies by Katrizky.
41 
 
EtO
O
Me O H2N
O
OEt
Me
2.13 2.14
 
Figure 2.1 Key intermediates 2.13 and 2.14 in Hantzsch dihydropyridine synthesis 
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 The mechanism for Hantzsch reaction is represented in Scheme 2.10. 
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Scheme 2.10 Suggested mechanism for Hantzsch dihydropyridine synthesis 
 
 The Hantzsch synthesis has been applied in the production of various 
dihydropyridine derivatives where the reaction benefits from use of microwave 
irradiation and various catalysts.
3040 
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2.4 Synthesis of substituted pyridine derivatives 
 The aim of the work reported in this chapter was to develop a new synthetic 
approach for the synthesis of substituted pyridine derivatives that was applicable to the 
pyrazolopyridine core of UR–14756 and other fused pyridine-containing heterocyclic 
motifs. The use of microwave irradiation to facilitate Bohlmann-Rahtz pyridine 
synthesis had met with some success in previous studies, although yields could be 
variable. Furthermore, the use of Lewis acids (15 mol% ZnBr2) or Brønsted acids 
(AcOH) had been found to be compatible with these conditions.
19
 Thus, our initial goal 
was to establish if by combining the action of microwaves and a catalyst would provide 
a reliable and rapid route to Bohlmann-Rahtz pyridines that could then be extended to 
access fused pyridine-containing heterocycles. In particular, since AuCl3 had been 
reported to exhibit high efficiency as a catalyst in glucoside synthesis,
42
 based upon its 
alkynophilicity, its behaviour in the Bohlmann-Rahtz reaction was prioritised as a good 
initial system of study. 
 The first target was the synthesis of ethyl 2,6-dimethylpyridine-3-carboxylate 
(2.4a) under microwave conditions to consolidate the pyridine forming step. Compound 
2.4a was previously synthesised within our research group
11 
from the reaction of ethyl 
β-aminocrotonate (2.1a) and 4-(trimethylsilyl)but-3-yn-2-one (2.2a) to produce 
intermediate 2.3a (Scheme 2.3).
11
 Cyclodehydration of 2.3a under acidic conditions 
provided 2.4a in high yields.
11
 
 The first task was the synthesis of intermediate 2.3a under microwave 
conditions. Various attempts were made to synthesis 2.3a from the reaction of 2.1a and 
2.2a in ethanol under microwave irradiation. The results obtained are recorded in Table 
2.1 along with those obtained in a comparative process under reflux conditions. 
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Table 2.1 Synthesis of intermediate 2.3a under microwave conditions 
 
NH2Me
SiMe
O Me
EtOH
NH2Me
Me
O
2.1a 2.2a 2.3a
O
EtO
EtO
O
 
Entry 
Reaction conditions 
Yield (%) 
Temp (°C) Time (h) 
1 50, reflux 5 98
a 
2 60, MW 1 86
a 
3 60, MW 1 100
b 
 
a
 Yield of pure product 2.3a after purification by column chromatography (silica gel; 
ethyl acetatepetroleum ether in 1:1 by volume). 
b
 Yield of pure product 2.3a after crystallization from a mixture of hexaneacetone, 7:1 
by volume. 
 
 The results reported in Table 2.1 clearly indicated that compound 2.3a could be 
produced in quantitative yield under microwave conditions at 60 °C for 1 hour (Table 
2.1; Entry 3). Also, no column chromatography was needed to purify the product 2.3a. 
This represented the most rapid method reported to date for efficient access to substrates 
for Bohlmann-Rahtz cyclodehydration and as such should facilitate the study of the 
second cyclodehydration step. 
 The structure of 2.3a was confirmed by various spectroscopic data (see Chapter 
6; Section 6.2 for details). The atmospheric pressure chemical ionization mass spectrum 
of 2.3a showed a molecular ion peak at m/z = 197. The HRMS of the molecular ion 
peak confirmed the formula as C10H15NO3. The IR spectrum showed a strong absorption 
bands at 1740 and 1640 cm–1 due to two carbonyl groups. The 
1
H NMR spectrum 
showed two characteristic doublets (J = 15 Hz) at δ 7.45 and 6.38 ppm due to the 
CH=CH protons. It also showed the presence of three methyl groups that resonated at δ 
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2.45 (singlet), 2.10 (singlet) and 1.22 (triplet, J = 7.1 Hz) ppm. 
13
C NMR spectroscopic 
analysis showed the presence of two carbonyl carbons that resonated as singlet signals 
at δ 199.7 (ketone) and 170.5 (ester) ppm and also showed all other carbons that were 
consistent with the given structure. 
 Having successfully synthesised 2.3a in quantitative yield under microwave 
conditions, our attention turned next to the synthesis of substituted pyridine 2.4a under 
various reaction conditions, including the use of a lewis acid catalyst with high 
alkynophilicity (AuCl3). In order to improve and optimize this process, solvent, 
temperature and catalyst were varied and the isolated yield of the pyridine product was 
determined, where appropriate. The results obtained are recorded in Table 2.2. 
 
Table 2.2 Synthesis of ethyl 2,6-dimethylpyridine-3-carboxylate 2.4a under various 
reaction conditions 
 
NH2Me
Me
O
2.3a
NMe Me
2.4a
EtO
O
EtO
O
 
Entry 
Temp 
(°C) 
Time (h) Solvent Acid Catalyst Yield (%) 
1 RT 5 PhMe AcOH _____ 85 
2 RT 5 PhMe AcOH HAuCl4.H2O 99 
3
a 
RT 20 2-propanol _____ CeCl3 _____ 
4 120, MW 1 PhMe AcOH HAuCl4.H2O b 
 
a
 NaI was used. 
b
 An unknown side product was generated but its structure was not established. 
 
 Firstly, it was found that the yield of 2.4a was improved to 99% when 
HAuCl4.H2O was used as a catalyst in toluene as solvent in the presence of acetic acid 
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at room temperature for 5 hours (Table 2.2; Entry 2). This compared favourably with 
the 85% isolated yield when no Au catalyst was used (Table 2; Entry 1) but acetic acid 
was present. However, in comparison when CeCl3 was used as a catalyst in 2-propanol 
the reaction never went to completion even after 20 hours at room temperature (Table 
2.2; Entry 3). The reaction was attempted under microwave conditions (120 °C for 1 
hour) in a mixture of toluene and acetic acid to accelerate the process, but the desired 
product 2.4a was no longer formed (Table 2.2; Entry 4). The NMR spectrum of the 
crude material showed the presence of a new product but its structure could not be 
established. 
 The structure of 2.4a was confirmed by spectral data from NMR, MS and IR. 
The APcI mass spectrum of 2.4a showed the presence of a pseudo molecular ion peak 
(MH) at m/z = 180 and the HRMS confirmed its formula as C10H14NO2. The 
1
H NMR 
spectrum of 2.4a show two characteristic doublets (J = 8 Hz) that resonated at 8.08 and 
7.22 ppm which were attributed to H-4 and H-5 of the pyridine ring, respectively. The 
13C NMR showed a singlet signal at δ = 166.1 ppm due to the carbonyl carbon. Also, it 
showed resonances for all pyridine carbons and the two methyl and ethyl groups. 
 Since microwave conditions were not successful to produce pyridine 2.4a from 
2.3a, our attention next turned to the synthesis of 2.4a directly from 2.1a and 2.2a 
without isolation of the intermediate 2.3a. If successful this would provide a more direct 
route to the target pyridines. The results obtained are recorded in Table 2.3 carried out 
in toluene and in the presence and absence of HAuCl4.H2O as catalyst. 
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Table 2.3 Synthesis of pyridine 2.4a directly from the reaction of enamine 2.1a and 
ethynylketone 2.2a 
 
 
NMe Me
2.4a
EtO
O
NH2Me
SiMe
O Me
2.1a 2.2a
O
EtO
PhMe
HAuCl4.H2O
 
Entry 
Temp 
(°C) Time (h) Solvent 
Catalyst 
Yield (%) 
1 RT 5 PhMe HAuCl4H2O ____ 
2 RT 5 PhMeAcOH HAuCl4H2O a 
3 120, MW 1 PhMeAcOH ____ 62 
4 120, MW 1 PhMeAcOH HCl 74 
5 120, MW 1 PhMeAcOH HAuCl4H2O 96 
 
a
 A new product was produced but its structure was not established. 
 
 Curiously, it was found that reaction of 2.1a and 2.2a under microwave 
conditions at 120 °C for 1 hour in toluene in the presence of acetic acid and 
HAuCl4.H2O produced 2.4a in 96% yield (Table 2.3; Entry 5). This was now in stark 
contrast to the process conducted at room temperature using the Au catalyst for 5 hours 
in the presence or absence of acetic acid, neither of which provided the desired product 
2.4a (Table 2.3; Entries 1 and 2). Product 2.4a (Entry 5) was indistinguishable in all 
respects from the material produced from intermediate 2.3a (Table 2.2). To establish if 
the addition of HAuCl4H2O had facilitated the reaction two further experiments were 
carried out: firstly the Au catalyst was omitted and the reaction repeated (Entry 3) and 
secondly HCl was added to the reaction mixture (Entry 4) to establish if the presence of 
the Brønsted acid had been responsible for any increase in yield. In both of these cases 
pyridine 2.4a was isolated. It was concluded that, in this system of study, AcOH and 
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HCl may well be behaving as Brønsted acid catalysts for the Bohlmann-Rahtz reaction 
but the presence of a Lewis acid catalyst with high alkynophilicity may have 
contributed to the high yield of the process. 
 Having successfully produced 2.4a under microwave conditions in a single step 
and in only 1 h reaction time, our attention next turned to the synthesis of other 
substituted pyridines to test the generality of the process. However, it was found that 
reaction of ethyl 3-aminocrotononitrile (2.15) and 4-(trimethylsilyl)but-3-yn-2-one 
(2.2a) under the Au-catalyzed conditions this time was not successful, whereas 
microwave irradiation in dry ethanol at 150 °C for 1 hour in the absence of HAuCl4 
gave 2,6-dimethyl-3-pyridinecarbonitrile (2.16) in 79% yield after purification by 
column chromatography (Scheme 2.11). 
 
N
NC
Me Me
2.16 (79%)
NH2Me
SiMe
O Me
2.15 2.2a
CN
EtOH, MW
150 °C , 1h
+
 
Scheme 2.11 Synthesis of 2,6-dimethyl-3-pyridinecarbonitrile (2.16) under microwave 
conditions 
 
 The APcI mass spectrum of 2.16 showed a pseudo molecular ion peak at m/z = 
133 (MH) and the EI-mass spectrum showed a molecular ion peak at m/z = 132 (M
•+
). 
The HRMS confirmed the formula of the molecular ion as C8H8N2. The presence of the 
C≡N group was confirmed by both IR and 13C NMR spectroscopy. The IR spectrum 
showed an absorption band at ν = 2190 cm–1 due to the C≡N stretch vibration. The 13C 
NMR spectrum showed a singlet carbon at δ 117.5 ppm due to the nitrile carbon. The 
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1
H NMR spectrum of 2.16 showed the presence of two doublets (J = 8 Hz) at δ = 8.05 
and 7.22 ppm due to H-4 and H-5 of the pyridine ring, respectively and two singlet 
signals at δ 3.32 and 2.61 ppm due to methyl group proton resonances. 
 Given that for nitrile-containing substrates relatively simple conditions were 
successful in pyridine formation, our attention turned to the use of a much less-reactive 
ethynylketone to establish the scope of the process. To that end, the synthesis of 
3-cyano-2-methyl-6-phenylpyridine (2.17) was attempted from reaction of ethyl 
3-aminocrotononitrile (2.15) and 4-phenyl-3-butyn-2-one (2.2c) under microwave 
conditions (Scheme 2.12).  
 
Me NH2
NC
MeO
Ph
EtOH
150 °C, 1h,MW N
Ph
MeMe
NC
2.15 2.2c 2.17 (75%)
+
 
Scheme 2.12 Synthesis of 3-cyano-2-methyl-6-phenyl pyridine (2.17) under microwave 
conditions 
 
 Once again, the use of HAuCl4 gave mixtures of products whereas irradiation in 
a protic solvent gave the desired pyridine. Compound 2.17 was produced in 75% 
isolated yield (Scheme 2.12) after purification by column chromatography when the 
reaction was carried in ethanol under microwave conditions at 150 °C for one hour. It 
was concluded that even terminally-substituted ethynylketones when reacted with 
aminocrotononitrile substrates gave good yields of the Bohlmann-Rahtz pyridines in 
one step under these simple conditions. 
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 The EI–mass spectrum of 2.17 showed a pseudo molecular ion peak at m/z = 207 
and the HRMS of the pseudo molecular ion confirmed its formula as C15H13N (MH). 
The IR spectrum of 2.17 showed an absorption band at ν 2290 cm-1 due to the C≡N 
group. Furthermore, the NMR spectra of 2.17 were in agreement with the assigned 
structure. 
 Given that the crotonate precursors were the substrates that required the 
presence of the Au catalyst for efficient conversion to the pyridine, we investigated one 
further reaction of ethyl 3-aminocrotonate (2.1a) and the terminally-substituted less-
reactive ethynylketone, 4-phenyl-3-butyn-2-one (2.2c), under microwave conditions in 
an attempt to produce ethyl 2,6-dimethyl-4-phenylpyridine-3-carboxylate (2.18; Scheme 
2.13). 
H2N Me MeO
Ph
PhMe-AcOH
N
Ph
MeMe
2.1a 2.2c 2.18 (49%)
O
EtO EtO
O
HAuCl4.H2O
150 °C, 1h, MW
 
Scheme 2.13 Synthesis of 2,6-dimethyl-4-phenylpyridine-3-carboxylate (2.18) under 
microwave conditions 
 
 It was found that reaction of 2.1a and 2.2c in toluene and acetic acid in the 
presence of gold hydrochloride as a catalyst under microwave irradiation at 150 °C for 1 
hour gave 2.18 in 49% yield (Scheme 2.13) after purification by column 
chromatography. This was a considerable improvement over a related AcOH catalyzed 
method (50 °C, 5-6 h) investigated previously which failed to give the desired 
pyridine.
43 
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 The structure of 2.18 was confirmed by IR, NMR and mass spectral data. The IR 
spectrum of 2.18 showed a strong absorption band at ν 1730 cm–1 due to the carboxylate 
group. The APcI mass spectrum showed a very intense (100%) pseudo molecular ion 
peak at m/z = 256 due to MH. The EI mass spectrum of 2.18 showed the presence of a 
molecular ion peak m/z = 255 and the HRMS confirmed the formula of the molecular 
ion as C16H17NO2. The NMR spectral data were in agreement with the predicted one 
collected from Chem Draw. 
 Having successfully synthesised a range of substituted pyridines our attention 
was next turned to the synthesis of fused heterocycles containing the pyridine moiety. 
Given that, for all but the most challenging of substrates, the use of simple conditions in 
the presence of acetic acid under microwave irradiation gave good yields of the 
corresponding pyridines, this method was favoured as the procedure of choice. The 
synthesis of pyrido[2,3-d]pyrimidines from uracil derivatives has been reported in the 
past and serves as a rapid route to the 5-deazapterin motif,
44
  but many of these 
reactions suffer from low yields, use expensive or not readily available precursors and 
suffer from limited substrate tolerance. Uracil derivatives are versatile building blocks 
for the synthesis of a wide range of nitrogen-containing heteroaromatic species.
45 
Pyrazolopyridines,
46
 pyrimidopyrimidines,
47
  pyrazolopyrimidines,
48
 pyridopurines,
49
 
and xanthine derivatives
50
 have all been prepared by the functionalisation of these 
precursors, which provide a ready-assembled 2-aminopyrimidin-4-one motif for 
incorporation into the target heterocycle. On this basis, we sought to develop a facile 
and rapid synthesis of pyrido[2,3-d]pyrimidines representing a 5-deazapterin unit from 
commercially available aminouracil derivatives using a heteroannulation process based 
upon the Bohlmann-Rahtz pyridine synthesis.
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2.5 Synthesis of substituted pyrido[2,3-d]pyrimidinone derivatives 
 Reaction of 2,4-diamino-6-hydroxypyridine (2.19) with equimolar quantities of 
3-butyn-2-one (2.2d) in acetic acid under microwave conditions was attempted in an 
attempt to produce 2-amino-7-methylpyrido[2,3-d]pyrimidin-4(3H)-one (2.20; Scheme 
2.14). The reaction mixture was irradiated at 120 °C for 30 min and submitted for 
aqueous work-up. The crude mixture was examined by TLC analysis, which showed the 
formation of a new product and the consumption of both of the starting materials. 
Product 2.20 was obtained in 90% yield without the need for further purification. 
Compound 2.20 was previously synthesised in similar yield but in ethanol at 50 °C for 
72 h.
12
 The new process clearly showed that the use of microwave conditions provided 
an efficient and simple synthesis of the deazapterin structure 2.20 (See Section 6.7). 
 
HN
N
O
H2N NH2 O Me
AcOH
30 min, 120 °C
HN
N N
O
H2N Me
+
2.19 2.2d 2.20 (90%)
 
Scheme 2.14 Synthesis of 2-amino-7-methylpyrido[2,3-d]pyrimidin-4(3H)-one (2.20) 
 
 The structure of 2.20 was confirmed by spectroscopic and spectrometric data 
obtained from NMR, MS and IR. The IR spectrum showed a strong absorption band at ν 
= 1666 cm
–1
 corresponding to the vibration of the carbonyl group. The APcI spectrum 
showed an intense pseudo molecular ion peak at m/z 177 and the high resolution mass 
spectrum of this ion confirmed its formula as C8H19N4O (MH
+
). The 
1
H NMR spectrum 
of 2.20 showed two characteristic doublets (J = 8.1 Hz) that resonated at  = 9.05 and 
7.62 ppm due to H-5 and H-6, respectively. The 
13
C NMR spectrum showed all the 
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expected signals and was consistent with the suggested structure of 2.20 (See Section 
6.7). 
 In a similar manner, the reaction of aminodimethyluracil 2.21 with equimolar 
quantities of 3-butyn-2-one (2.2d) in acetic acid under microwave conditions gave 
7-amino-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2.22) in 99% isolated 
yield (Scheme 2.15). 
 
N
N
O
O NH2
Me
Me
N
N N
O
O Me
Me
Me
O Me
AcOH
30 min, 120 °C
+
2.21
2.2d
2.22 (99%)
 
Scheme 2.15 Synthesis of 1,3,7-trimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.22) 
 
 The structure of 2.22 was confirmed by the spectroscopic data obtained by IR, 
NMR and MS analysis. The electron impact mass spectrum of 2.22 showed the absence 
of a molecular ion peak but showed a pseudo molecular ion peak at m/z 190 due to 
elimination of a methyl radical from the molecular ion ([M – Me]+). The high resolution 
mass spectrum of this ion confirmed its formula as C9H8N3O2. The 
1
H NMR spectrum 
showed the presence of protons due to the three methyl groups and two characteristics 
doublets (J = 8.1 Hz) that resonated at  = 8.32 and 7.03 ppm due to H-5 and H-6, 
respectively (See Section 6.8). 
 Also, it was found that reaction of 2,4-diamino-6-hydroxypyridine (2.19) with 
an equimolar quantity of 1-phenyl-2-propyn-1-one (2.23) in acetic acid under 
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microwave conditions gave 2-amino-7-phenylpyrido[2,3-d]pyrimidin-4(3H)-one (2.24) 
in 96% yield (Scheme 2.16). 
 
HN
N
O
H2N NH2 O
AcOH
30 min, 120 °C
HN
N N
O
H2N
+
2.19 2.23 2.24 (96%)
 
Scheme 2.16 Synthesis of 2-amino-7-phenylpyrido[2,3-d]pyrimidin-4(3H)-one (2.24) 
 
 The structure of 2.24 was confirmed by the spectroscopic and spectrometric data 
obtained from NMR and MS. The EI–mass spectrum of 2.24 showed a molecular ion 
peak at m/z = 238 and the HRMS of the molecular ion confirmed its formula as 
C13H10N4O (M). The IR spectrum of 2.24 showed an absorption band at ν = 3248 cm
–1
 
due to NH2 and NH groups. It also showed a strong band at ν = 1666 cm
–1
 due to the 
C=O. The NMR spectra of 2.24 were in agreement with the assigned structure (See 
Section 6.9). 
 The same method was used for the synthesis of 1,3-dimethyl-7-
phenylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione. Reaction of dimethyluracil 
derivative 2.21 with an equimolar quantity of 1-phenyl-2-propyn-1-one (2.23) in acetic 
acid under microwave conditions gave 1,3-dimethyl-7-phenylpyrido[2,3-d]pyrimidine-
2,4(1H,3H)-dione (2.25) in 97% yield (Scheme 2.16). 
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2.21 2.23 2.25 (97%)
N
N
O
O NH2
Me
Me
N
N N
O
O
Me
Me
O
AcOH
30 min, 120 °C
+
 
Scheme 2.16 Synthesis of 1,3-dimethyl-7-phenylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-
dione (2.25) 
 
 The structure of 2.25 was confirmed by spectroscopic and spectrometric data 
obtained from IR, NMR and MS. The EI–mass spectrum of 2.25 showed a pseudo 
molecular ion peak at m/z = 267 ([M – Me]+) and the HRMS of the pseudo molecular 
ion confirmed its formula as C14H10N3O2. The IR spectrum of 2.25 showed absorption 
bands at ν = 3248 cm-1, due to the NH2 and NH, ν = 1666 cm
–1
, due to the C=O, and 
ν = 1581 cm–1, characteristic of these motifs. The NMR spectra of 2.25 were in 
agreement with the assigned structure (See Section 6.10). 
 As a further example, the reaction of 2,4-diamino-6-hydroxypyridine (2.19) with 
an equimolar quantity of 4-phenyl-1-butyn-2-one (2.26) in acetic acid under microwave 
conditions produced 2-amino-7-phenylpyrido[2,3-d]pyrimidin-4(3H)-one (2.27) in 95% 
yield (Scheme 2.17). 
 
2.21 2.26
HN
N
O
H2N NH2
AcOH
30 min, 120 °C
HN
N N
O
H2N Me
+
O
2.27 (95%)
 
Scheme 2.17: Synthesis of 2-amino-7-phenylpyrido[2,3-d]pyrimidin-4(3H)-one (2.27) 
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 The structure of 2.27 was confirmed by spectroscopic and spectrometric data 
obtained from NMR and MS. The EI–mass spectrum of 2.27 showed a molecular ion 
peak at m/z = 252 (M) and the HRMS of the molecular ion confirmed its formula as 
C14H12N4O. The IR spectrum of 2.27 showed absorption bands at ν = 3233, 1669 and 
1590 cm
–1
 due to the NH2 and NH, C=O and C=C, respectively. The NMR spectra of 
2.27 were in agreement with the proposed structure (See Section 6.11). 
 Finally, the synthesis of 2-amino-7-phenylpyrido[2,3-d]pyrimidin-4(3H)-one 
(2.28) was attempted under similar conditions (Scheme 2.18). Reaction of uracil 
derivative 2.21 with an equimolar quantity of 4-phenyl-1-butyn-2-one (2.26) in acetic 
acid under microwave conditions gave a mixture products, from which the desired 
deazapterin 2.28 could not be isolated, although the signals for the desired product 2.28 
could be identified in the 
1
H NMR spectrum.  
 
N
N
O
O NH2
Me
Me
N
N N
O
O Me
Me
Me
AcOH
30 min, 120 °C
+
MeO
2.282.262.21
 
Scheme 2.18: Synthesis of 2-amino-7-phenylpyrido[2,3-d]pyrimidin-4(3H)-one (2.28) 
 
2.5 Conclusions 
 Recently Bohlmann–Rahtz pyridine synthesis has provided a convenient route 
for the synthesis of various substituted pyridine products. The process has been 
modified in this work to be rapid, simple, operate under mild conditions and high 
yielding. We have shown that substituted pyridines could be synthesized efficiently and 
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in high yields under microwave conditions from readily-available precursors in what is 
essentially a relatively short reaction time. The process has been applied successfully to the 
production of substituted pyrido[2,3-d]pyrimidinone derivatives that represent the core of the 
deazapterins in high yields. Reaction times for these more complex fused targets have been 
reduce from 72 h to 30 min in what is a remarkably efficient and general process. Given the 
great success of this methodology, it is anticipated that the microwave-assisted Brønsted acid 
catalyzed Bohlmann-Rahtz reaction could find further application in the future in the synthesis 
of pyridine-containing targets. 
 
2.6 References 
1) Roth, H. J.; Kleemann, A. Drug synthesis In Pharmaceutical chemistry, vol.1, 
John Wiely and Sons, New York, 1988. 
2) Henkel, T.; Brunne, R. M.; Muller, H.; Reichel, F. Angew. Chem. Int. Ed., 1999, 
38, 643–647. 
3) Bohlmann, F.; Rahtz, D. Chem. Ber., 1957, 90, 2265–2272. 
4) Hantzsch, A. Ber. Dtsch. Chem. Ges., 1881, 14, 1637–1638. 
5) Hantzsch, A. Justus Liebigs Ann. Chem., 1882, 215, 1–82. 
6) Stout, D. M.; Meyers, A. I. Chem. Rev., 1982, 82, 223–224. 
7) Eisner, U.; Kutham, J. Chem. Rev., 1972, 72, 1–42. 
8) Bagley, M. C.; Glover, C.; Merritt, E. A. Synlett, 2007, 2459–2472. 
9) Vanden Eynde, J. J.; Mayence, A. Molecules, 2003, 8, 381–391. 
10) Bagley, M. C.; Lubinu, M. C. Synthesis, 2006, 1283–1288. 
11) Bagley. M. C.; Brace, C.; Dale, J. W.; Ohnesorge, M.; Phillips, N. G.; Xiong, 
X.; Bower, J. J. Chem. Soc., Perkin Trans. 1, 2002, 1663–1671. 
12) Bagley. M. C.; Dale, J. W.; Hughes, D. D.; Ohnesorge, M.; Phillips, N. G.; 
Bower, J. Synlett, 2001, 152–1526. 
Chapter Two: Synthesis of Pyridine Derivatives 
79 
13) Bagley, M. C.; Dale, J. W.; Bower, J. Chem. Commun., 2002, 1682–1683. 
14) Bagley, M. C.; Glover, C.; Merritt, E. A.; Xiong, X. Synlett, 2004, 811–814. 
15) Agami, C.; Dechoux, L.; Hamon, L.; Hebbe, S.; Moulians, J. Synthesis, 2003, 
859–862. 
16) Agami, C.; Dechoux, L.; Hebbe, S. Synlett, 2001, 1440–1442. 
17) Bagley, M. C.; Glover, C.; Chevis, D. Synlett, 2005, 649–651. 
18) Bagley, M. C; Hughes, D. D.; Sabo, H. M.; Taylor, P. H.; Xiong, X. Synlett, 
2003, 1443–1446. 
19) Bagley, M. C.; Lunn, R.; Xiong, X. Tetrahedron Lett., 2002, 43, 8331–8334. 
20) Bagley, M. C.; Jenkins, R. L.; Lubinu, M. C.; Mason, C.; Wood, R. J. Org. 
Chem.; 2005, 70, 7003–7006. 
21) Bagley, M. C.; Hughes, D. D.; Lloyds, R.; Powers, V. E. C. Tetrahedron Lett., 
2001, 42, 6585–6588. 
22) Hughes, D. D.; Bagley, M. C. Synlett, 2002, 1332– 334. 
23) Bagley, M. C.; Lin, Z.; Pope, S. J. A. Chem. Commun., 2009, 5165–5167. 
24) Bagley, M. C.; Fusillo, V.; Jenkins, R. L.; Lubinu, M. C.; Mason, C. Org. 
Biomol. Chem., 2010, 8, 2245–2251. 
25) Adlington, R. M.; Baldwin, J. E.; Catterick, D.; Pritchard, G. J.; Tang, L. T. J. 
Chem. Soc., Perkim Trans.1, 2000, 2311–2316. 
26) Adlington, R. M.; Baldwin, J. E.; Catterick, D.; Pritchard, G. J.; Tang, L. T. J. 
Chem. Soc. Perkin Trans. 1, 2000, 303–305. 
27) Adamo, M. F.; Adlington, R. M.; Baldwin, J. E.; Prichard, G. J.; Rathmell, R. E. 
Tetrahedron, 2003, 59, 2197–2200. 
28) Aoki, M.; Ohtsuka, T.; Itezono, Y.; Yokose, K.; Furihata, K.; Seto, H. 
Tetrahedron Lett., 1999, 32, 221–224. 
Chapter Two: Synthesis of Pyridine Derivatives 
80 
29) Aoki, M.; Ohtsuka, T.; Itezomo, Y.; Yokose, K.; Furihata, K.; Seto, H. 
Tetrahedron Lett., 1991, 32, 217–220. 
30) Kumar, A.; Maurya, R. A. Synlett, 2008, 883–885. 
31) Sharma, G. V. M.; Reddy, K. L.; Lakshmi, P. S.; Krishna, P. R. Synthesis, 2006, 
55–58. 
32) De Paolis, O.; Baffoe, J.; Landge, S. M.; Török, B. Synthesis, 2008, 3423–3428. 
33) Gupta, R.; Paul, S.; Loupy, A. Synthesis, 2007, 2835–2838. 
34) Wang, L.–M.; Shong, J; Zhang, L.; Han, J.–W.; Fan, Z.–Y.; Tian, H.; Aian, C.–
T. Tetrahedron, 2005, 61, 1539–1543. 
35) Evans, C. G.; Gestwicki, J. E. Org. Lett., 2009, 11, 2957–2959. 
36) Simon, L.; Goodman, J. M. J. Am. Chem. Soc., 2008, 130, 8741–8747. 
37) Debache, A.; Ghalem, W.; Boulcina, R.; Belfaitah, A.; Rhouati, S.; Carboni, B. 
Tetrahedron Lett., 2009, 50, 5248–5250. 
38) Guernon, J. M.; Wu, Y. – J. Tetrahedron Lett., 2011, 52, 3633–3635. 
39) Mass, T. A.; Nowak, T. Tetrahedron Lett., 2012, 53, 3056–3060. 
40) Lavilla, R. J. Chem Soc. Perkin Trans. 1, 2002, 1141–1156. 
41) Katritzky, A. R.; Ostercamp, D., L.; Yousaf, T. I. Tetsahedron, 1987, 43, 5171–
5186. 
42) Kashyap, S.; Hotha, S. Tetrahedron Lett., 2006, 47, 2021–2023. 
43) Bagley, M. C.; Dale, J. W.; Bower, J.Synlett, 2001, 7, 1149–1151. 
44) (a) Majumdar, K. C.; Bhattacharyya, T. Synthesis, 2001, 15681572. (b) 
Bhuyan, P.; Boruah, R. C.; Sandhu, J. S. J. Org. Chem,. 1990, 55, 568571. (c) 
Broom, A. D.; Shim, J. L.; Anderson, G. L. J. Org. Chem,. 1976, 41, 
10951099. (d) Kajino, M.; Meguro, K. Heterocycles, 1990, 31, 21532161. (e) 
Chapter Two: Synthesis of Pyridine Derivatives 
81 
Rosas, N.; Sharma, P.; Alvarez, C.; Cabrera, A.; Ramírez, R.; Delgado, A.; 
Arzoumanian, H. J. Chem. Soc., Perkin Trans., 1 2001, 23412343. 
45) Lunt, E.; Newton, C. C. In Comprehensive Heterocyclic Chemistry, 3; Katritzky, 
A. R.; Rees, C. W.; Boulton, A. J.; McKillop, A., Eds.; Pergamon Press: Oxford, 
1984, 199. (b) Lunt, E.; Newton, C. C. In Comprehensive Heterocyclic 
Chemistry, 3; Katritzky, A. R.; Rees, C. W.; Boulton, A. J.; McKillop, A., Eds.; 
Pergamon Press: Oxford, 1984, 232. (c) Lunt, E.; Newton, C. C. In 
Comprehensive Heterocyclic Chemistry, 3; Katritzky, A. R.; Rees, C. W.; 
Boulton, A. J.; McKillop, A., Eds.; Pergamon Press: Oxford, 1984, 260–261. (d) 
Brown, J. D. In Comprehensive Heterocyclic Chemistry, 3; Katritzky, A. R.; 
Rees, C. W.; Boulton, A. J.; McKillop, A., Eds.; Pergamon Press: Oxford, 1984, 
57. (e) Bradshaw, T. K.; Hutchinson, D. W. Chem. Soc. Rev., 1977, 6, 43–62. 
46) (a) Quiroga, J.; Cruz, S.; Insuasty, B.; Abonía, R. Heterocyclic Commun., 2000, 
6, 275–282. (b) Quiroga, J.; Cruz, S.; Insuasty, B.; Abonía, R.; Nogueras, M.; 
Sánchez, A.; Cobo, J.; Low, J. N. J. Heterocyclic Chem., 2001, 38, 53–60. 
47) Thakur, A. J.; Saikia, P.; Prajapati, D.; Sandhu, J. S. Synlett, 2001, 1299–1301. 
48) Bhuyan, P.; Boruah, R. C.; Sandhu, J. S. J. Org. Chem., 1990, 55, 568–571. 
49) Pérez-Pérez, M.-J.; Priego, E.-M.; Jimeno, M.-L.; Camarasa, M.-J. Synlett, 2002, 
155–157. 
50) (a) Hutzenlaub, W.; Pfleiderer, W. Liebigs Ann. Chem., 1979, 1847–1854. (b) 
Müller, C. E.; Geis, U.; Hipp, J.; Schobert, U.; Frobenius, W.; Pawloski, M.; 
Suzuki, F.; Sandoval-Ramírez, J. J. Med. Chem., 1997, 40, 4396–4405. 
Chapter Three: Synthesis of aminopyrazoles, pyrazolopyrimidines, pyrazolopyridines and 
the p38 MAPK inhibitor UR-13756 
81 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
SYNTHESIS OF AMINOPYRAZOLES, PYRAZOLOPYRIMIDINES, 
PYRAZOLOPYRIDINES AND THE P38 MAPK INHIBITOR  
UR-13756 
 
 
 
Chapter Three: Synthesis of aminopyrazoles, pyrazolopyrimidines, pyrazolopyridines 
and the p38 MAPK inhibitor UR-13756 
82 
 
CHAPTER THREE 
SYNTHESIS OF AMINOPYRAZOLES, 
PYRAZOLOPYRIMIDINES, PYRAZOLOPYRIDINES AND THE 
P38 MAPK INHIBITOR UR-13756 
3.1. Introduction 
The p38 mitogen-activated protein kinases (MAPKs) are involved in cell 
differentiation with a highly recognised role in cell cycle regulation, senescence, 
inflammation, tumorigenesis and cell death.
1-3
 P38 is also responsive to heat shock, 
ultraviolet radiation and the action of cytokines. 
Four isoforms of p38 are known which are p38α, p38β, p38γ and p38δ, which 
are also known as MAPK14, MAPK11, MAPK12 and MAPK13, respectively.
4
  The 
p38α isoform is the most studied member of this family which participates in cell-
signalling cascades, upregulated in many inflammatory diseases in humans, and is 
involved in the biosynthesis of pro-inflammatory cytokines.
5
  When activated, p38α 
MAPK is phosphorylated in an activation loop by dual specificity kinase MKK3 and 6 
in response to extracellular stimuli and phosphorylates other kinases, leading to the 
regulation of target genes.  The reduction of pro-inflammatory cytokine levels offers a 
means for the treatment of inflammatory disorders such as rheumatoid arthritis and so 
the design of safe and efficacious p38α inhibitors suitable for clinical investigation 
remains a compelling therapeutic target. 
A range of pyridylimidazoles were originally synthesised as dual 
cyclooxygenase 15-lipoxygenase inhibitors.
6
  As a result SB203580 (3.1; Figure 3.1) 
was discovered and was found to be an ATP-competitive inhibitor of p38 MAPK, 
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reducing the activation of the phosphorylation of the small heat-shock protein 27 
(HSP27) and of MAPK-activated protein kinase 2 (MK2).
7
 
 
 
Figure 3.1: Structure of p38 MAPK inhibitor (3.1) 
 
The SB203580 p38α inhibitor mediates multiple cellular responses, including 
the production of inflammatory cytokines. Following this discovery, a wide variety of 
structurally-distinct chemotypes have been uncovered which inhibit this target enzyme 
with notable differences in their binding motif.  
Of similar structure, CAY10571 (3.2; Figure 3.2) is an anti-inflammatory 
pyridinylimidazole derivative that inhibits the production of eicosanoids and suppresses 
the synthesis of cytokines in human monocytes.
5
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N
H
N
N
S
O
F
CAY10571 (3.2)
O
Me
4-(4-(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)-1H-imidazol-5-yl)pyridine
 
Figure 3.2: Structure of the p38 MAPK inhibitor CAY10571 (3.2) 
 
A wide range of other structurally distinct chemotypes were developed to target 
p38.
8-11
  Recently, our research group developed a synthetic route for the production of 
BIRB796 (3.3; Figure 3.3), which is a urea-based p38 inhibitor.
12
 BIRB796 is similar to 
SB203580 in terms of its inhibition of the JNKs and C-Raf1.
13-15
  Urea-based inhibitors, 
including Boehringer Ingelheim’s p38 MAPK candidate BIRB796, which was advanced 
to clinical trials, are one such chemotype, adopting a unique binding mode that is 
distinct from adenosine 5-triphosphate competitive binders. 
 
N
N N
H
N
H
O
Me
O
N
O
1-(3-ter t-Butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(2-morpholinoethoxy)naphthalen-1-yl)urea
BIRB796 (3.3)
 
Figure 3.3: Structure of the p38 MAPK inhibitor BIRB796 (3.3) 
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Biological evaluation of target inhibitors is illustrated by the behaviour of 
RO3201195 (3.4; Figure 3.4) in a cellular assay.
16
  The ability of RO3201195 to inhibit 
p38α and JNK was tested in human hTERT-immortalized HCA2 cells.16  Kinase 
activity was detected using antibodies specific for phosphorylated (S73) HSP27 and 
antibodies that detect total levels of HSP27, the degree of activation being measured as 
the ratio of phospho-protein/total protein.  In this system p38 activation by anisomycin 
subsequently activates MK2 that then phosphorylates HSP27. For JNK the 
phosphorylation status of the JNK substrate c-jun was monitored. RO3201195 (3.4) 
displays excellent kinase selectivity for p38α MAPK over the related stress-activated 
kinase JNK. 
 
N
N
O
NH2
F
O
HO
HO
RO3201195 (3.4)
(S)-(5-Amino-1-(4-fluorophenyl)-1H-pyrazol-3-yl)(3-(2,3-dihydroxypropoxy)phenyl)methanone
 
Figure 3.4: Structure of RO3201195 p38 MAPK inhibitor (3.4) 
 
A structurally-related p38 inhibitor pyrazolopyridine chemotype (3.5; Figure 
3.5) has been developed.
17
  This heterocyclic motif provided the potential for structure-
activity relationship (SAR) exploration.  The nature of R
1
 provided a degree of 
solubility, with potential interactions between R
2
, R
3
, R
4
 and R
5
 groups and regions of 
the kinase.
17
 
Chapter Three: Synthesis of aminopyrazoles, pyrazolopyrimidines, pyrazolopyridines 
and the p38 MAPK inhibitor UR-13756 
86 
N
N
NR5
R4
R3 R2
R1 = solubilising group
R2 and R3 = front pocket
R4 = hinge region
R5 = back pocket
Pyrazolopyridine chemotype (3.5)
R1
 
Figure 3.5: Structure-activity relationship of pyrazolopyridine chemotypes (3.5) 
 
VX-745 (3.6; Figure 3.6) and its congeners are another particularly interesting 
inhibitor chemotype, in light of the unprecedented levels of selectivity they exhibit for 
p38α over a variety of other closely related kinases.  This exquisite selectivity shown by 
the Vertex class of inhibitors was the inspiration behind their use in WS cells.
18,19
  
VX-745 (3.6; Figure 3.6) is derived from a pyrimido-pyridazinone core and is 
characterized by the presence of an extended vinylogous amide system that is critical 
for functional potency.  An isomeric core based upon a pyrido-pyrimidone was 
envisioned to be a suitable alternative for the development of potential new inhibitors. 
Scaffolds such as 3.6 were reasoned to be stable in biological systems and hence 
desirable as substrates for drug design and development.
18,19
 
 
ClCl
N N
O
N S
F
F
VX-745 (3.6)
5-(2,6-Dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyridazino[1,6-c]pyrimidin-6-one
 
Figure 3.6: Structure of the p38 MAPK inhibitor VX-745 (3.6) 
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UR-13756 (3.7; Figure 3.7) is a potent and selective p38 mitogen-activated 
protein kinase (MAPK) inhibitor that is based on a pyrazolopyridine core.  UR-13756 
showed a better kinase selectivity profile than both BIRB796 and SB203580 with 
regard to the JNKs and C-Raf1 using a kinase panel of 115 kinases.
20,21
 Furthermore, 
UR-13756 showed good selectivity for the p38α isoform, compared with BIRB796 and 
SB203580 which showed equal selectivities for both p38α and p38β.22 
 
N
N
N
N
F
F
Me
UR-13756 (3.7)
4,6-bis(4-Fluorophenyl)-2-methyl-5-(pyridin-4-yl)-2H-pyrazolo[3,4-b]pyridine
 
Figure 3.7: Structure of UR-13756 (3.7) 
 
UR-13756 was synthesised within our research group and its activity in Werner 
syndrome cells was investigated.
23
  Therefore, the work described in this chapter aimed 
to improve the synthesis of UR-13756 (3.7), delivering the target inhibitor in high yield 
and greater quantities using a convenient and rapid method in order to carry out more 
extensive studies on the effect of this inhibitor on cell proliferation in primary Werner 
syndrome cells. 
The route for the synthesis of UR-13756 (3.7) is represented in Scheme 3.1 that 
involves a three-component cyclocondensation reaction related to Hantzsch 
Chapter Three: Synthesis of aminopyrazoles, pyrazolopyrimidines, pyrazolopyridines 
and the p38 MAPK inhibitor UR-13756 
88 
dihydropyridine synthesis.  The method involves condensation of 1-methyl-3-
aminopyrazole (3.8), a ketone 3.9 and 4-fluorobenzaldhyde (3.10), based on literature 
precedent (Scheme 3.1).
21,23
  The first task was therefore the synthesis of 3.8 and 3.9. 
 
N
N
N
N
F
F
Me
N
N
H2N
Me
O
N
F
CHO
F
Hatzsch - type
cyclocondensation
UR-14756 (3.7)
3.8 3.9 3.10
 
Scheme 3.1: Towards the synthesis of UR-13756 (3.7) 
 
3.2. New developments in aminopyrazole synthesis 
3.2.1. Synthesis of 3-amino-1-methylpyrazole hydrochloride (3.8) 
3-Amino-1-methylpyrazole hydrochloride (3.8) was previously prepared within our 
research group in 81% yield from the reaction of chloroacrylonitrile (3.11) and 
methylhydrazine hydrochloride (3.12) in ethanol under microwave conditions (Scheme 
3.2).
23
 
 
Cl
CN
HCl.H2NNHMe N
N
Me
NH2.HCl
3.11 3.12 3.8
MW
EtOH
+
 
Scheme 3.2: Synthesis of 3.8 under microwave conditions 
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The reaction represented in Scheme 3.2 was attempted under microwave 
irradiation at 100 °C for 2 minutes, followed by precipitation of the hydrochloride salt 
of the product, to give 3.8 in 78% yield after purification by recrystallization (Table 1; 
Entry 2).  In an effort to increase the yield of 3.8 by increasing the time, it was found 
that prolonged irradiation of a mixture of 3.11 and 3.12 caused an increase in the yield 
of 3.8 (Table 1; Entries 2 and 3).  After irradiation for 6 min, a yield of 81% was 
obtained, whereas the yield of 3.8 could be improved further to 95% following 
irradiation of 2 minutes at 120 °C. 
 
Table 3.1: Microwave-assisted synthesis of 3-amino-1-methylpyrazole hydrochloride 
(3.6)
a
 
Cl
CN
HCl.H2NNHMe N
N
Me
NH2.HCl
3.11 3.12 3.8
MW
EtOH
+
 
Entry 
Reaction conditions
a 
Yield (%) of 3.8
b 
Temp (°C) Time (min) 
1 100 6 81
 
2 100 2 78 
3 120 2 95
 
 
a
 A solution of 3.11 (0.10 mL; 1.25 mmol) and methylhydrazine hydrochloride (3.12; 
0.21 g; 2.50 mmol) in EtOH (2 mL) was irradiated at the given temperature. 
b
 Yield (%) for isolated pure product. 
 
The structure of compound 3.8 was confirmed by various spectroscopic 
techniques including NMR and infrared spectroscopy, and submitted to mass 
Chapter Three: Synthesis of aminopyrazoles, pyrazolopyrimidines, pyrazolopyridines 
and the p38 MAPK inhibitor UR-13756 
90 
spectrometric analysis.  The electron-impact (EI) mass spectrum showed a very high 
intensity (relative intensity 100%) pseudo molecular ion [M – HCl]+ at m/z = 97.  The 
accurate mass of the pseudo molecular ion confirmed the formula as C4H7N3 [M  
HCl]
+
, indicating the formation of the target pyrazole ring system 3.8.  
The IR spectrum of compound 3.8 showed no absorption band corresponding to 
the vibration of the C≡N group. It showed absorption bands at max 3376 and 3018 cm
-1
 
due to the stretching vibrations of the NH2 group.  
The 
1
H NMR spectrum showed characteristic doublets (J = 2.3 Hz) at δ 7.60 and 
6.02 ppm due to vicinal coupling of H-5 and H-4 of the pyrazole ring, respectively.  It 
also showed an exchangeable singlet at δ 9.30 ppm due to H3NCl protons and a singlet 
at δ 3.77 ppm corresponding to the methyl protons.  The structure of 3.8 was confirmed 
further by the 
13
C NMR spectroscopic data, which showed characteristic resonances at δ 
134.5 and 96.2 ppm due to C-5 and C-4, respectively. 
Our attention next turned to the synthesis of 1-(4-fluorophenyl)-2-(pyridine-4-
yl)ethanone (3.9).  Synthesis of ketone 3.9
25
 was attempted under various basic reaction 
conditions which involved Claisen condensation (Scheme 3.3).  Reaction of 4-picoline 
(3.13) and ethyl 4-fluorobenzoate (3.14) in the presence of lithium 
bis-timethylsilylamide (LHMDS; Scheme 3.3) at room temperature for 1 hour gave 3.9 
in 41% yield after purification.  
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lithium bis-trimethylsilylamide is commonly known as
lithium hexamethyldidilazide (LHMDS)
N
Li
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Me3Si
SiMe3
Me3Si
 
Scheme 3.3: Synthesis of 1-(4-fluorophenyl)-2-(pyridine-4-yl)ethanone (3.9) 
 
Various attempts were made in order to find conditions to improve the yield of 
3.9. Indeed, irradiation of a mixture of 3.13 and 3.14 in the presence of LHMDS at 80 
°C for 10 min gave 3.9 in 50% yield after purification.  However, it was not possible to 
increase the yield of 3.9 further by increasing the reaction time due to formation of side-
products and/or decomposition of the material. 
The structure of compound 3.9 was confirmed by various spectroscopic and 
spectrometric techniques (See experimental section for details).  The electron impact 
(EI) mass spectrum showed a molecular ion peak (M
+
) at m/z = 215.  Moreover, the 
positive elecrospray (ES
+
) mass spectrum showed a pseudo molecular ion [MH]
+
 peak 
at m/z = 216.  The accurate mass of the molecular ion confirmed the formula as 
C13H10NOF.  The IR spectrum of 3.9 showed a strong absorption band at max = 1670 
cm
-1
 due to the stretching vibration of the C=O group. 
The 
1
H NMR spectrum showed all the expected protons and showed a 
characteristic singlet at δ 4.49 ppm corresponding to the CH2 protons.  The structure of 
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3.9 was confirmed further by its 
13
C NMR proton-decoupled spectroscopic data, which 
showed two doublets in the aromatic region at 131.5 and 128.3 ppm due to the C-2/C-6 
and C-3/C-5 of 4-fluorophenyl group.  The carbonyl carbon resonated as a singlet at δ 
191.3 ppm, whereas the CH2 carbon resonated at δ 43.5 ppm. 
Having successfully produced both 3-amino-1-methylpyrazole hydrochloride 
(3.8) and 1-(4-fluorophenyl)-2-(pyridin-4yl)ethanone (3.9) our attention next turned to 
the synthesis of UR-13756 (3.7) using these precursors. 
 
3.3. Synthesis of 4,6-bis(4-fluorophenyl)-2-methyl-5-(pyridine-4-yl)-2H-
pyrazolo[3,4-b]pyridine (UR-13756; 3.7) 
3.3.1. Use of p38 MAPK inhibitors for the treatment of Werner syndrome (WS) 
Oho Werner, a German scientist, investigated Werner syndrome (WS), as part of 
his PhD study.  Werner syndrome is defined as a genetic disorder which can be used as 
a model disease for the investigation of human ageing.  This genetic disorder is 
extremely rare and results from mutation in the WRN gene.
26,27
 
People suffering from Werner syndrome display many clinical features of old 
age such as early susceptibility to several major age related diseases and as a result their 
median life expectancy is reduced to 47 years.
28
  Consequently, WS is widely used as a 
model disease to investigate the mechanisms underlying normal human ageing.  There 
are several signs of Werner syndrome such as premature greying of hair, cataracts, 
retarded growth, osteoporosis, and skin sclerosis.
28 
 For humans suffering with Werner 
syndrome death often occurs as a result of myocardial infarction (20%) or malignancy 
(80%).
28
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Several compounds have been synthesised in the group and were found to 
inhibit the p38 signalling pathway in Werner syndrome cells such as SB203580 (3.1; 
Figure 3.1),
7
 CAY10571 (3.2; Figure 3.20),
5
 BIRB796 (3.3; Figure 3.3),
12
 RO3201195 
(3.4; Figure 3.4),
16
 VX-745 (3.6; Figure 3.6)
18,19
 and UR-13756 (3.7; Figure 3.7).
20-23
 in 
these studies, the effect of RO3201195 (3.4; Figure 3.4) on the p38 signalling pathway 
in WS cells was assessed by immunoblot assay.
29,30
  RO3201195 (3.4) can inhibit 
p38αsignalling as shown in Figure 3.8. In control cells, low p38α activity is indicated 
by low p-HSP27 levels and a low p-HSP27/HSP27 ratio (DMSO columns). Anisomycin 
treatment activates p38α that increases p-HSP27 levels and the p-HSP27/HSP27 ratio 
(columns). RO3201195 pre-treatment increasingly inhibits the anisomycin-induced 
activity of p38α, as indicated by the decreasing p-HSP27 levels and the 
p-HSP27/HSP27 ratio.  Maximal inhibition was achieved between 2.5 and 10.0 µM 
RO3201195. The IC50 in this system is approximately 180–200 nM, similar to the 
reported IC50 for RO3201195 inhibition of p38α induced TNFα, or IL-1β production in 
peripheral blood mononucleocytes that have IC50 values of 500 nM and 400 nM, 
resectively.
29,30
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Figure 3.8: Results for the effect of RO3201195 (3.4) on p38α activity (a and c) and on 
JNK activity (b and d). For the upper panels, total protein is indicated by the white bars, 
and the phosphorylated protein by the dark grey bars. In the lower panel the ratio of 
phosphorylated protein to total protein is indicated by the black bars. DMSO are cells 
with only DMSO treatment, An refers to cells treated with anisomycin, and 0.010–
50.000 are cells pre-treated with increasing concentrations of RO3201195 followed by 
treatment with anisomycin. p-HSP27 and p-c-jun are the phosphorylated forms of 
HSP27 and c-jun, respectively. 
 
Very recently, vitamin C supplementation was found to reverse the premature 
ageing and appeared to normalise several age-related molecular markers.
31
  It was found 
that vitamin C decreases activities in human Werner syndrome and instead increases 
tissue repair gene activities.
31
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3.3.2. Synthesis of the highly selective P38 MAPK inhibitor UR-13756 (3.7) 
Given that an effective route to aminopyrazole 3.8 and ketone 3.9 was secured, 
our efforts turned to the synthesis of UR-13756 (3.7), as represented in Scheme 3.4, 
based on literature precedent.
21,23
 
 
N
N
N
N
F
F
MeN
N
HCl.H2N
Me
O
N
F
CHOF
UR-14756 (3.7)3.8
3.9 3.10
+
 
Scheme 3.4: Synthesis of UR-13756 (3.7) 
 
The process involved a three-component cyclocondensation reaction related to 
the Hantzsch synthesis of dihydropyridine (Scheme 3.4).  The synthesis of UR-13756 
(3.7) involves use of 3-amino-1-methylpyrazole hydrochloride (3.8), as the enamine 
component, which in reaction with 4-fluorobenzaldhyde (3.10) and ketone (3.9) would 
give the pseudo [6.5] bicyclic core of target compound 3.7. 
The Hantzsch-type multicomponent cyclocondensation of 3.8, 3.9 and 3.10 was 
reported to produce the UR-13756 (3.7) in 80% yield after purification by column 
chromatography when the reaction was carried out under reflux conditions for 2 days in 
methoxyethanol as a solvent and hydrochloride acid as the catalyst.
23
  Under these 
reaction conditions, 3.7 was produced in 79% yield as a pure compound (Table 3.2; 
Entry 1). 
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Our aim was to accelerate the process of producing 3.7 by carrying the reaction 
under microwave conditions at a higher temperature.  First, the reaction was attempted 
in 2-methoxyethanol in the presence of HCl at 120 °C under microwave irradiation for 1 
h (Table 3.2; Entry 2).  Following work-up, TLC analysis showed the formation of 3.7 
along with unreacted components 3.8, 3.9 and 3.10. Signals for 3.7 were also seen in the 
1
H NMR spectrum of the crude reaction mixture. 
Various attempts were made to synthesis 3.7 in high yield by irradiation of a 
mixture of 3.8, 3.9 and 3.10 (equimolar preparations) at various temperatures in 
2-methoxyethanonl as the solvent and in presence of hydrochloric acid as a catalyst. 
The results obtained are summarised in Table 3.2. Several variations were attempted to 
improve yield of 3.7 in which reaction time and reaction temperatures were varied but 
none were successful.  Also, a reaction was attempted in which a mixture of ethyl 
acetate and ethanol (1:4 or 5) was irradiated at elevated temperatures (150–170 °C) but 
this failed to give more than a trace of product. Similar observations were made when 
ethanol was used as a solvent and acetic acid was used as a catalyst. 
Our attention next turned to the use of ethanol as solvent and HCl as the catalyst: 
the reaction mixture was irradiated at 140 °C for 2 hours. Following this procedure, 
UR–13756 (3.7) was produced in 27% yield after purification by column 
chromatography on silica (Table 3.3; Entry 1). 
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Table 3.2: Synthesis of UR–13756 (3.7) under various reaction conditions in 
2-methoxyethanol in the presence of HCl 
N
N
N
N
F
F
MeN
N
HCl.H2N
Me
O
N
F
CHOF
UR-14756 (3.7)3.8
3.9 3.10
+
 
Entry 
Reaction conditions 
Yield (%) of 3.7
a 
Temp (°C) Time (h) 
1 reflux 48 79 (80)
b 
2 120 MW 1 ____
c 
3 140 MW 1 ____
c 
4 140 MW 2 ____
c
 
5 140 MW 3 ____
c
 
6 160 MW 1 ____
c
 
7 170 MW 1 ____
c
 
 
a
 Yield reported for pure product. 
b
 Reported yield for a similar reaction.
23
 
c
 The TLC and 
1
H NMR spectrum of the reaction mixture indicated formation of 
UR-13756 (3.7) along with starting materials. No pure product was isolated. 
 
We next attempted to improve the yield of 3.7 under microwave irradiation in 
ethanol in which reaction parameters such as temperature, time and catalyst were 
varied. The results obtained are recorded in Table 3.3. 
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Table 3.3 Synthesis of UR–13756 (3.5) under microwave condition in ethanol 
N
N
N
N
F
F
MeN
N
HCl.H2N
Me
O
N
F
CHOF
UR-14756 (3.7)3.8
3.9 3.10
+
EtOH
 
Entry 
Reaction conditions
 
Yield (%) of 3.7
a 
MW Temp (°C) Time (h) Catalyst 
1 140 48 HCl 27
 
2 150 1 HCl 40
 
3 150 1 H2SO4 33
 
4
b 
130 2 HCl 23 
5 150 3 HCl 45 
6 155 1 HCl 25 
7 150 4 HCl 71 
 
a
 Yield reported for pure product. 
b
 BaMnO4 was added to the reaction mixture. 
 
The results reported in Table 3.3 clearly indicate that ethanol is a much better 
solvent than 2-methoxyethanol and the yield of 3.7 was improved by increasing the 
reaction time. The optimum conditions involved irradiation of equimolar quantities of 
3.8, 3.9 and 3.10 in ethanol in the presence of HCl at 150 °C for 4 hours to give 
UR-13756 (3.7) in 71% yield after purification.  Such a route to UR–13756 is much 
more rapid compared to the reported method involving 48 hours reaction time under 
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reflux conditions.  Also, the new process is convenient and simple to produce 
UR-13756 in high yield. 
Clearly, the results revealed that HCl is a much better catalyst than H2SO4 and 
acetic acid and that the reaction temperature and time play an important role in the 
process (Scheme 3.4). 
The structure of compound 3.7 was confirmed by various spectroscopic 
techniques including IR, NMR and mass spectrometric analysis (See experimental 
section for details).  The electron-impact mass spectrum of 3.7 showed a molecular ion 
peak at m/z = 398.  The accurate mass of the molecular ion confirmed the formula as 
C24H17N4F2. Also, the positive electrospray (ES
+
) mass spectrum showed very high 
intensity (100%) pseudo molecular ion (MH)
+
 at m/z = 399. The IR spectrum of 
compound 3.7 showed strong absorption bands at max = 1610 and 1530 cm
-1
 due to the 
aromatic groups. 
The NMR spectra of 3.7 showed all the expected proton and carbon resonances 
and were in agreement with its structure.  The 
1
H NMR spectrum showed two doublets 
(J = 8.1 Hz) corresponding with H-2/H-6 of two 4-fluorophenyl groups and two 
apparent triplets due to the corresponding H-3/H-5 4-fluorophenyl groups.  It also 
showed a singlet resonance arising from the three methyl protons, whereas H-3 
resonated as a singlet at δ = 7.43 ppm.  The 13C NMR spectrum showed two doublets (J 
= 250 Hz) at δ = 163.2 and 162.3 ppm corresponding to C-4 of two 4-fluorophenyl 
groups, due to coupling of carbons with the fluorine atoms.  C-2 and C-6 of two 
4-fluorophenyl groups resonated as doublets (J = 8.8 Hz) at δ = 130.2 and 128.9 ppm.  
All other carbon signals were observed and are agreement with expected values. 
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This work demonstrated that the use of microwave irradiation can accelerate the 
synthesis of a known p38 inhibitor for testing in Werner syndrome cells. Our attention 
next turned to the synthesis of pyrazolopyridine derivatives such as pyrazolopyridine 
3.15 under microwave conditions. The use of a different inhibitor would allow us to 
explore the behaviour of a panel of p38 inhibitors, with different selectivity profiles, to 
establish the role of p38 inhibition on the WS cell phenotype. 
3.4. Towards the synthesis of pyrazolopyrimidine 3.15 
In studies towards UR-13756, methods for the rapid synthesis of aminopyrazoles 
have been established. The aim of this body of work was to utilize these improvements 
in the synthesis of an alternative p38 inhibitor 3.15
32
 (scheme 3.5). The aminopyrazole 
motif is present in a number of inhibitor chemotypes and this would enable us to test the 
use of this new methodology. Compound 3.15 was identified as a potent and selective 
p38α inhibitorthat was found to be highly efficacious in vivo in an acute 
pharmacodynamic model of TNFα production in mice.32  The literature route for the 
production of 3.15 is represented in Scheme 3.5.
32
 Such synthetic pathway involves 7 
steps, including a cyclocondensation reaction to give an aminopyrazole intermediate 
3.18, and provided 3.15 in 1428% overall yield. It was hoped that, as a first point of 
study, the efficiency and facility of this route could be quickly improved using the 
microwave-mediated pyrazole synthesis to access another chemotype for study of 
accelerated ageing in WS cells. 
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3.19 (90%)3.18 (60%)3.173.16a
 
Scheme 3.5 Synthetic pathway for the production of pyrazolopyrimidine 3.15
32 
 
Focussing upon the initial cyclocondensation reaction, the synthesis of 3.18 was 
attempted under various reaction conditions, including the reported procedures.
19,33
  The 
yields obtained of the pyrazole product 3.18 are recorded in Table 3.4. 
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Table 3.4 Synthesis of 5-amino-4-cyano-1-phenyl pyrazole (3.18) 
NHNH2
OEt
NC
NC EtOH
N
N
CN
NH2
3.183.173.16a
+
 
Entry Temperature (°C) Time Yield (%) 
1 60 1 h 9
a
 (23)
b
 
2 60, MW 1 h 55
c
 
3 60, MW 2 h 38
d 
(60)
c 
4 60, MW 3 h 95
c 
5 70, MW 2 h 35
e 
6 80, MW 1 h 29
e 
7 120, MW 5 min 45
c 
8 120, MW 30 min 63
c 
9 120, MW 45 min 95
c 
 
a
 After crystallization from a mixture of EtOH and H2O (1:10 by volume). 
b 
After crystallization from H2O. 
c
 After column chromatography (petroleum etherethyl acetate in 5:1 by volume). 
d
 After extraction with diethyl ether. 
e
 After filtration of solid obtained followed by washing with diethyl ether. 
 
The results in Table 3.4 showed that use of conductive heating at 60 °C for 1 
hour provided low yields of the pyrazole product (9–23%), although the limits of this 
procedure could in part be attributed to purification. Use of microwave conditions and 
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purification by column chromatography, for the same reaction time and temperature, 
provided an improved yield (55%) of the product 3.18 (Table 3.4; Entry 2). However, 
when the reaction time or temperature were increased (Table 3.4; Entries 4 and 9, 
respectively) an excellent yield of the aminopyrazole product 3.18 was obtained.  
The structure of 3.18 was confirmed by various spectroscopic techniques 
including NMR, and IR spectroscopy, and low and high resolution mass spectrometric 
data (See experimental section for details). 
Having successfully produced 3.18 in excellent yield, our attention next turned 
to the synthesis of 5-amino-4-aminocarbonyl-1-phenyl-1H-pyrazole (3.19). The 
synthesis of 3.19 started by following the literature route
19,33
 but this gave the desired 
product in only 3% yield (Table 3.5; Entry 1).  Increasing the reaction temperature 
(0-50 °C) provided a better yield of 3.19 (64%) after a prolonged reaction time. 
Carrying out the reaction under microwave irradiation provided high yields of 3.19 (60–
85%: Table 3.5; Entries 47) in very short time.  The results obtained are recorded in 
Table 3.5. 
The results reported in Table 3.5 clearly indicated that the use of microwave heating 
improved the yield of 3.19 significantly without the need for column chromatography 
for the purification of the product. This was successful under microwave irradiation on 
a 0.5 g scale. The structure of 3.19 was confirmed by NMR and IR spectroscopic and 
mass spectrometric data. 
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Table 3.5 Synthesis of 5-amino-4-aminocarbonyl-1-phenyl-1H-pyrazole (3.19) 
N
N
CN
NH2
N
N NH2
O
NH2
H2SO4
3.193.18  
Entry Temperature (°C) Time (h) Yield (%) 
1 0 16 3
a
 
2 0 to rt 5 12
a 
3 0 to 50 5 64
b 
4 0 to 50, MW 1 74 
5 0 to 50, MW 3 60
b 
6 0 to 60, MW 3 80
c 
7 0 to 80, MW 1 84
c 
 
a
 Product was extracted by diethyl ether and purified by column chromatography. 
b
 Product was extracted with diethyl ether. 
c
 Product was extracted with chloroform. 
 
Having successfully produced aminopyrazole 3.18 and the hydrolysis product 
3.19 in high yield under microwave-assisted conditions, comparing with the 
literature,
19,33
 we therefore attempted the synthesis of 4-hydroxy-1-phenyl-1H-
pyrazolo[3,4-d]pyrimidine (3.20). 
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A series of experiments was conducted to convert 3.19 to 3.20 under various 
reaction conditions. The reaction was also carried out under the reported procedure to 
for comparison.
19,33
 The yields of 3.20 obtained are recorded in Table 3.6. 
 
Table 3.6 Synthesis of 4-hydroxy-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine (3.20) under 
microwave-assisted conditions 
N
N NH2
O
NH2
3.19
HCONH2
N
N
N
N
HO
3.20  
Entry Temperature (°C) Time (min) Yield (%)
a 
1 100 60 75 
2 150 30 75 
3 150 45 97 
4 160 45 96 
5 190 20 60 
6 190 30 82 
7 190 40 88 
8 180 60 56
a 
 
a
 Yield obtained followed filtration of product and washing with H2O. 
b
 Yield obtained under the reported conditions.
19,33
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The results showed that the yield of 3.20 has been improved by the use of 
microwave irradiation compared to the yield obtained using the literature procedure
19,33
 
(Table 3.5; Entry 8). 
It was found that the yield of 3.20 was dependent on both the reaction 
temperature and time. For example, the yield of 3.20 was 75% when the temperature 
was 100 or 150 °C and the reaction time was 60 or 30 minutes, respectively (Table 3.6; 
Entries 1 and 2).  The optimum conditions gave an improved yield of 97% when the 
temperature was increased to 150 °C and the reaction time was 45 minutes (Table 3.6; 
Entry 3).   
At higher temperatures (190 °C) the yields of 3.20 were reduced somewhat 
(60-88%) indicating that these conditions may not be as suitable, possibly due to partial 
decomposition of product. 
The positive electrospray (ES
+
) mass spectrum of 3.20 showed the presence of a 
very intense (100%) molecular ion peak at m/z = 212 and high resolution mass 
spectrometric analysis confirmed the formula of the molecular ion peak as C11H9N4O. 
The 
1
H NMR spectrum of 3.20 showed a characteristic exchangeable singlet at δ = 9.71 
ppm due to the OH proton and two singlets that resonated at δ = 8.23 and 7.94 ppm due 
to H-5 and H-2, respectively. Also, the 
13
C NMR spectrum showed all of the expected 
signals and was consistent with the given structure. 
Our attention next turned to the conversion of hydroxypyrazolopyrimidine 3.20 
to the corresponding chloride 3.21. 
Various attempts were made to synthesise and improve the conditions for the 
preparation of 3.21. However, all attempts failed to produce a pure sample of 3.21 and 
the purification step turned out to be problematic and so no further attempts were made.  
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These studies had shown that it was possible to adapt our new method of 
aminopyrazole synthesis to prepare the 4-cyanopyrazole intermediate 3.18, using a 
malononitrile derivative, and convert this to pyrazolopyrimidine 3.20, all under 
microwave-assisted conditions. The pyrazole-forming cyclocondensation using an 
alternative, ethoxyacrylonitrile, substrate had caused a change in the regiochemical 
outcome, from the 3-aminopyrazole motif to a 5-aminopyrazole. Thus, it was 
considered whether similar alkoxyacrylonitrile substrates could be used to access a 
range of 5-aminopyrazoles in a microwave-assisted cyclocondensation reaction. 
 
3.5 Towards the synthesis of pyrazolopyridines from aminopyrazoles 
In order to test the cyclocondensation reaction, synthesis of 5-amino-1-methyl-
1H-pyrazole (3.24) was attempted (Scheme 3.6). 
 
N
N
Me
NH2
3.24
MeO
CN
Me NHNH2
3.263.25
solvent
acid,120°C
MW
+
 
Scheme 3.6 Synthesis of 5-amino-1-methyl-1H-pyrazole (3.24) 
 
Reactions of acrylonitrile 3.25 with methyl hydrazine (3.26) in a chosen solvent 
(ethanol or toluene) under various reaction conditions were attempted. The yields 
obtained of 3.24 are recorded in Table 3.7. 
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Table 3.7 Synthesis of 5-amino-1-methyl-1H-pyrazole (3.24) under various reaction 
conditions (at 120 C, MW) according to Scheme 3.6. 
Entry Solvent Acid Time (min) Yield (%) 
1 EtOH ___ 5 ___
a
 
2 EtOH ___ 10 ___
a
 
3 EtOH HCl 5 ___
a
 
4 EtOH HCl 45 ___
a
 
5 EtOH AcOH 15 ___
b 
6 PhMe HCl 15 ___
b
 
7 PhMe AcOH 15 40
c 
8 PhMe AcOH 60 97
c 
9 PhMe ___ 60 32
c 
 
a
 No product was isolated. 
b
 A mixture of two isomeric products was obtained which were difficult to separate by 
column chromatography. 
c
 Yields reported were for pure product after purification by crystallisation from 
hexaneethyl acetate (3:1 by volume). 
 
The results recorded in table 3.7 showed clearly that 5-aminopyrazole 3.24 was 
produced as a single regioisomer (to the limits of detection) in 97% yield (Table 3.7; 
Entry 8) when the reaction was carried out under microwave conditions at 120 °C in 
toluene in the presence of acetic acid for 1 hour. This regiochemical outcome was in 
line with our previous studies in the synthesis of pyrazole 3.18. Also, it was clear that 
acetic acid was much better as a catalyst compared with HCl under similar reaction 
conditions. 
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In order to further explore the scope of the process, a similar target, 5-amino-1-
phenyl-1H-pyrazole (3.27) was synthesised (Scheme 3.7) under various conditions and 
the yields obtained were compared (Table 3.8). 
N
N NH2
NHNH2
MeO
CN
slovent
acid, MW
3.16a 3.26 3.27
+
 
Scheme 3.7 Synthesis of 5-amino-1-phenyl-1H-pyrazole (3.27) 
 
Table 3.8 Synthesis of 5-amino-1-phenyl-1H-pyrazole (3.27) according to Scheme 3.7 
under microwave conditions. 
Entry Solvent Acid Temp (°C) Time (min) Yield (%) 
1 EtOH HCl 120 5 ___
a
 
2 EtOH HCl 120 10 ___
a
 
3 EtOH ___ 120 45 ___
a
 
4 EtOH AcOH 120 15 ___
a
 
5 EtOH AcOH 150 30 ___
a
 
6 PhMe HCl 120 15 ___
a 
7 PhMe AcOH 150 30 75 
8 PhMe AcOH 150 45 82
b 
9 PhMe AcOH 150 60 92
c 
a
 No pure product was obtained. 
b
 Yield reported was for pure product after crystallization from a mixture of toluene and 
acetone (2:1 by volume). 
c
 Product was recrystallized from hexaneethyl acetate mixture (in 3:1 by volume). 
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Again the results in Table 3.8 showed that compound 3.27 can be produced in 
92% yield (Entry 9) under microwave conditions at 150 °C for 1 hour in toluene in the 
presence of acetic acid as a catalyst and isolated as a single regioisomer.   
The structures 3.24 and 3.27 were confirmed by the data collected from IR and 
NMR spectroscopy, and low and high resolution mass spectrometry and agreed with 
literature values.
34
 
Having successfully produced 3.24 and 3.27 in high yields, our attention next 
turned to attempt their conversion to the corresponding pyrazolopyridines 3.28 and 
3.29, respectively (Scheme 3.8). This reaction would employ the 5-aminopyrazole 
substrate as a new enamine component in a Bohlmann-Rahtz reaction, a hitherto 
unreported transformation of 5-aminopyrazoles. If successful this would establish a new 
route to this fused core which could establish an analogue of UR-13756 for biological 
study. 
 
N
N
R
NH2
O Me
SiMe3
PhMe, AcOH
150°C, 1 h, MW N
N
N
R
Me
3.28 R = Me
3.29 R = Ph
3.24 R = Me
3.27 R = Ph 3.30
+
 
Scheme 3.8 Attempted synthesis of pyrazolopyridines 3.28 and 3.29 
 
It was found that reaction of aminopyrazole 3.24 with ethynyl ketone 3.30 in 
toluene in the presence of acetic acid under microwave irradiation at 150 °C for 1 hour 
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gave no product at all and only starting materials were recovered quantitatively, 
indicating that no reaction had taken place. 
On the other hand, reaction of phenylpyrazole 3.27 with the same ethynyl ketone 
3.30 under similar reaction conditions produced the corresponding imine 3.31 (Figure 
3.8) in 35% yield. Clearly, the aminopyrazole under these conditions had demonstrated 
behaviour as an amine nucleophile, rather than an enamine nucleophile in a Bohlmann-
Rahtz cyclocondensation. 
N
N
N
MeN
N N
3.31 (35%)
Me
3.32
 
Figure 3.8 Structures of compounds 3.31 and 3.32 
 
Next, we attempted to convert the imine product of condensation 3.31 to the 
corresponding pyrazolopyridine 3.32 (Figure 3.8) using a mixture of toluene and acetic 
acid in the presence of HAuCl4.H2O as catalyst under microwave irradiation at 150 °C 
for 1 hour. However, no product was obtained and 3.31 were quantitatively recovered. 
No further attempts were made to find conditions to effect the conversions of 3.31 to 
3.32 or 3.24 and 3.27 to the corresponding pyrazolopyridines 3.28 and 3.29, 
respectively. 
Although the 5-aminopyrazoles had failed to behave as enamine components in 
this reaction, it was considered that changing the position of the amino group in 
compound 3.24 or 3.27 might have an effect on this process and could give rise to an 
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alternative pyrazolopyridine motif. Therefore, the synthesis of 3-amino-1-phenyl-1H-
pyrazole (3.33; Scheme 3.9) was attempted.  
N
N
3.33 (85%)
H2N
NHNH2.HCl
MeO
CN NaOEt
EtOH
3.16b 3.26
+
 
Scheme 3.9 Synthesis of 3-amino-1-phenyl-1H-pyrazole (3.33) 
 In order to switch the regiochemical oucome of the pyrazole formation, the 
conditions were altered: instead of carrying the process out in acidic media, reaction of 
phenylhydrazine hydrochloride (3.16b) with 3-methoxyacrylonitrile (3.26) in ethanol 
was studied in the presence of an excess of sodium ethoxide base under microwave 
heating at 150 °C for two hours. Gratifyingly, this caused a complete switch in the 
regiochemistry of the product, giving 3-aminopyrazole 3.33 in 85% yield (Scheme 3.9) 
after purification by column chromatography. 
 With a route to the alternative regioisomer to hand, next, we attempted the 
Bohlmann-Rahtz reaction described in Scheme 3.10 in an attempt to convert 3.33 to its 
corresponding pyrazolopyridine 3.34. However, no product was obtained under these 
conditions, confirming again that the aminopyrazoles are not enamine equivalents in 
this cyclocondensation reaction. No further attempts were made to try to find alternative 
conditions under which this reaction would proceed. 
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N
N
3.33
H2N
O Me
SiMe3
120 °C, MW, 2 h
EtOH, AcOH
N
N
N
3.30 3.34
+
Me
 
Scheme 3.10 Attempt synthesis of pyrazolopyridine (3.34) 
 
 Finally, a one pot synthesis of 3.34 was attempted from the reaction of 
phenylhydrazine hydrochloride 3.16b, acrylonitrile 3.26 and the ethynyl ketone 3.30 
under microwave conditions at 150 °C for two hours in the presence of HAuCl4.H2O. 
However, no pyrazolopyridine 3.34 was produced and instead the 
1
H NMR spectrum of 
the crude reaction mixture showed the presence of imine 3.31 (Figure 3.8), which was 
separated and purified by column chromatography and isolated in 67% yield. 
 
3.6. Conclusions 
The p38 MAPK inhibitor UR-13756 can be prepared rapidly and efficiently 
using Hantzsch-type three component cyclocondensation. Microwave irradiation of a 
mixture of 3-amino-1-methylpyrazole hydrochloride, 1-(4-fluorophenyl)-2-(pyridine-4-
yl)ethanone and 4-fluorobenzaldhyde for 4 hours in ethanol under acidic catalytic 
conditions provided UR-13756 in 71% yield after purification by column 
chromatography. The method is simple and high yielding but still there is room for 
modification. 
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We have also attempted the synthesis of several pyrazolopyrimidines and 
pyrazolopyridine derivatives under microwave conditions. However, no pure products 
were obtained under the conditions investigated. 
However, of greatest interest, it has been demonstrated that using a single 
substrate, methoxyacrylonitrile 3.26, it is possible to isolate a single aminopyrazole 
regioisomer using a microwave-assisted cyclocondensation reaction. Furthermore, by 
choice of conditions, selecting either acidic or basic media, it is possible to switch the 
regiochemical outcome to produce 5-aminopyrazoles or 3-aminopyrazoles, respectively, 
in excellent yield. 
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SYNTHESIS OF PYRAZOLE DERIVATIVES AS INHIBITORS OF 
PROTEIN KINASE MK2 
 
4.1 Introduction 
Tumour necrosis factor-α (TNF-α) is a key cytokine in cutaneous inflammation 
which is mainly produced by macrophages.
13
 The biosynthesis of TNF-α is initiated on 
extracellular activation of signalling pathways that signals via mitogen-activated protein 
kinases (MAPKs) as has been shown for p38 MAPK.
4
 
Modification of the function of TNF-α was found to be very successful for the 
treatment of skin inflammation in several diseases.
2
 However, although there are many 
biological drugs that are known to down regulate TNF-α in the inflammation of skin, their 
clinical use has been hindered by their severe side effects. Also, the use of TNF-α 
inhibitory biological drugs has been restricted by their large molecular weight and size. 
Thus it is desirable to have small molecular weight molecules that elicit a similar response.
2
 
The kinase MK2, which is a direct downstream substrate of p38 involved in the 
production of TNF-α, is a promising inflammatory disease drug target that could be 
inhibited using small molecular weight chemical tools.
5,6
 
Several MK2 inhibitors have been synthesized and used in animal models. The 
coming section will highlight the development in the area of specific MK2inhibitors for 
treatment of inflammatory diseases and in particular the most recent ones that show 
improved selectivity and efficacy profiles. 
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4.2. Development of specific MK2 inhibitors for the treatment of inflammatory 
diseases 
A series of 3-aminopyrazole based MK2 inhibitors have been synthesized by 
Velcicky’s research group3 and have been proven to be selective inhibitors for intracellular 
phosphorylation of hsp27 and Lps-induced TNF-α release in cells. For example, the 
pyrazole derivatives 4.14.5 (Figure 4.1) were revealed by a scaffold hopping strategy and 
have been developed to be selective MK2 kinase inhibitors.
3
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Figure 4.1. Structures of 3-aminopyrazole MK2 inhibitors 4.14.5 developed by 
Velcicky’s research group3 
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4-[1-(4-Methoxyphenyl)-1H-pyrazole-4-yl]benzamide (4.1) was synthesized in 32% 
overall yield in four steps as shown in Scheme 4.1.
3
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Scheme 4.1. Synthesis of 1H-pyrazole 4.1
3 
The first step in their route involved the reaction of 4-(methoxyphenyl)hydrazine 
hydrochloride (4.6) with 1,1,3,3-tetramethoxypropane in ethanol (EtOH) under reflux 
conditions to produce 1-(4-methoxyphenyl)-1H-pyrazole (4.7) in 95% yield (Scheme 4.1).
3
 
This was followed by bromination of the pyrazole (4.7) using N-bromosuccinimide (NBS) 
in tetrahydrofuran (THF) at room temperature to give 4-bromo-1-(4-methoxyphenyl)-1H-
pyrazole (4.8) in 95% yield (Scheme 4.1).
3
 The bromopyrazole (4.8) was an ideal substrate 
for Suzukicoupling711 with 4-cyanophenylboronic acid (4.9) in aqueous propanol in the 
presence of bis-(triphenylphosphine)palladium(II) chloride (PdCl2(PPh3)2) and sodium 
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carbonate at 160 °C for 15 min under microwave conditions to give 
4-[1-(4-methoxyphenyl)-1H-pyrazole-4-yl)benzonitrile (4.10) in 50% yield (Scheme 4.1).
3
 
Finally on hydrolysis amide 4.1 was produced in 70% yield (Scheme 4.1).
3
 
As an alternative, more densely functionalized inhibitor, 4-[3-amino-1-
(4-methoxyphenyl)-1H-pyrazole-4-yl]benzamide (4.2) was synthesized, as represented in 
Scheme 4.2, in ca. 2% overall yield in three steps.
3
 Reaction of 
4-(cyanomethyl)benzonitrile (4.11) with ethyl formate in the presence of sodium hydride 
gave 4-(1-cyano-2-hydroxyvinyl)benzamide (4.12) in 96 % yield (Scheme 4.2).
3
 Treatment 
of 4.12 with (4-methoxyphenyl)hydrazine hydrochloride (4.6) in ethanol in the presence of 
acetic acid under reflux conditions for 3 hours gave 4-[3-amino-1-(4-methoxyphenyl)-1H-
pyrazol-4-yl)benzamide (4.13), but in only 3% yield (Scheme 4.2).
3
  Finally, hydrolysis of 
4.13 gave the desired product, the aminopyrazole 4.2, in 56% yield (Scheme 4.2).
3
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Scheme 4.2. Synthesis of 3-amino-1H-pyrazole 4.2 
The overall yield of 4.2 was improved to 45% by a modification of the synthetic 
procedure represented in scheme 4.2.
3
 It was found that treatment of 4.11 with ethyl 
formate produced 4.12 in-situ which on treatment with iodomethane in dimethylformamide 
(DMF) at 40 °C gave the analogue 4-(1-cyano-2-methoxyvinyl)benzamide (4.14; Figure 
4.2) in 86% yield.
3
 Reaction of acrylonitrile 4.14 with hydrazine 4.6 in ethanol under basic 
conditions improved the yield of the pyrazole synthesis and gave the same nitrile 
intermediate 4.13 in improved yield (93%) that was hydrolysed (56% yield) to give the 
target inhibitor 4.2 in an improved route.
3
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Figure 4.2. Structure of 4-(1-cyano-2-methoxyvinyl)benzamide (4.41) 
In order to probe the SAR of this chemotype, a number of analogues needed to be 
prepared. 4-[3-Amino-1-(4-methoxyphenyl-1H-pyrazole-4-yl]benzamide (4.3) was 
synthesised in 18% overall yield in three steps as represented in Scheme 4.3.
3
 The first step 
involved reaction of the methoxyphenylhydrazine (4.6) with 3-methoxyacrylonitrile in 
ethanol in the presence of a base under reflux conditions for 20 hours to give 3-amino-1-
(4-methoxyphenyl)-1H-pyrazole (4.15) in 73% yield (Scheme 4.3).
3
  
The second step involved bromination of the pyrazole 4.15 with 
N-bromosuccinimide in THF at room temperature for 16 hours to give 3-amino-4-bromo-1-
(4–methoxyphenyl)-1-H-pyrazole (4.16) in 87% yield (Scheme 4.3).3 Finally 
Suzukicoupling711 of 4.16 with 4-bromobenzenesulfonamide pinacol ester (4.17) in the 
presence of bis-(triphenylphosphine)palladium(II) chloride and sodium carbonate in 
aqueous n-propanol at 150 °C under microwave conditions for 15 min gave 4.3 in 29% 
yield (Scheme 4.3).
3
 It is noteworthy that the yield for this Suzuki coupling is somewhat 
low, but it is assumed that this is an unoptimized procedure. 
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Scheme 4.3. Synthesis of 3-amino-1H-pyrazole 4.3 
A series of additional 4-substituted 3-amino-1-(4-methoxyphenyl)-1H-pyrazoles 4.4 
were also prepared by a similar sequence (Scheme 4.4).
3
 Reaction of 4.18 with 
bis(pinacolato)diboron (4.19) in dioxane at 80 °C for 16 hours in the presence of 
[1,1-bis(diphenylphosphino)ferrocene]palladium(II) dichloride and potassium acetate gave 
the corresponding analogues 4.20 in 87-97% yields (Scheme 4.4).
3
 Suzuki-coupling of 4.20 
and 4.16, previously synthesised in Scheme 4.3, in aqueous propanol in the presence of a 
catalyst gave the target inhibitors 4.4 in 17-63% yields (Scheme 4.4).
3
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Scheme 4.4. Synthesis of 3-amino-1H-pyrazoles 4.4 
The authors also varied the substitution pattern of the N-aryl ring (Scheme 4.5). In 
the synthesis of 6-[3-amino-1-aryl-1H-pyrazole-4-yl-3,4-dihydroisoquinolin-1(2H)-ones 
4.5
3
 it was found that the reaction of (3-bromophenyl)hydrazine hydrochloride (4.21) with 
3-methoxyacronitrile in ethanol in the presence of a base under reflux condition for 20 
hours gave 3-amino-1-(3-bromophenyl)-1H-pyrazole (4.22) in 91% yield (Scheme 4.5).
3
  
Suzuki-couplings
711
 of bromobenzene 4.22 and a number of arylboronic acids in the 
presence of a palladium catalyst gave the corresponding 3-amino-1-aryl-1H-pyrazoles, 
which were brominated subsequently using N-bromosuccinimide at room temperature to 
give a subset of 3-amino-1-aryl-4-bromo-1H-pyrazoles 4.23 in 51-96% yields over the two 
steps (Scheme 4.5).
3
  Finally, Suzuki-couplings of 4.23 with 6-[4,4,5,5-tetramethyl-1,3,2-
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dioxaborolan-2-yl)-1(2H)-one (4.20a) gave the corresponding 6-[3-amino-1-aryl-1H-
pyrazol-4-yl-3,4-dihydroisoquinolin-1(2H)-ones 4.5, but in only 9-36% yield (Scheme 
4.5).
3
 Again it is assumed that these yields were not optimized. 
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Scheme 4.5. Synthesis of 3-amino-1H-pyrazoles 4.5 
The work represented in this chapter aimed at improving the synthetic procedure for 
the synthesis of 4-[3-amino-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]benzamide (4.2; 
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Scheme 4.2) and 4-[1(3-(1H-indol-6-yl)phenyl)-3-amino-1H-pyrazol-4-yl] benzamide 
(4.24; Figure 4.3) as simple targets to investigate their MK2 inhibition. 
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N
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Figure 4.3. Structure of 3-amino-1H-pyrazole 4.24 
4.3 Synthesis of 4-[3-amino-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]benzamide (4.2) 
In order to test the role of MK2 in accelerated ageing in Werner syndrome, the 
aminopyrazole chemotype, exemplified by the simple carboxamide derivative 4.2, prepared 
by Velcicky’s research group,3 was chosen as having suitable selectivity profile and ready 
availability based upon these earlier reports. There also seemed interesting regioselectivity 
issues to explore regarding the regiochemistry of aminopyrazole formation (3-amino- vs. 
5-aminopyrazole formation) and the efficiency of many of the Suzuki couplings in the 
reported routes. Retrosynthetic analysis of 4.2 revealed a boronic acid derivative 4.25 and 
3-amino-4-bromo-1-(4-methoxyphenyl)-1H-pyrazole (4.16), available via bromination of 
3-amino-1H-pyrazole (4.15) as shown in Scheme 4.6. It was reported that the 
3-aminopyrazole 4.15 could be prepared from reaction of (4-methoxyphenyl)hydrazine 
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hydrochloride (4.6) and 3-methoxyacronitrile (Scheme 4.6) with the regiochemistry 
determined by carrying out the reaction under strongly basic conditions. Based upon 
previous studies, this heterocyclization appeared suitable for investigation under 
microwave irradiation as it should be effective as a rapid and high yielding route to 
pyrazole targets, providing that the regiochemical outcome could be controlled under the 
alternative conditions. 
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Scheme 4.6. Retrosynthesis of 3-aminopyrazole 4.2 
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The synthesis of 3-aminopyrazole 4.2 was carried out in three steps. The first step 
involved reaction of (4-methoxyphenyl)hydrazine hydrochloride (4.6; 1 molar equivalent) 
and 3-methoxyacrylonitrile (two molar equivalents) in ethanol in the presence of sodium 
ethoxide (4 molar equivalents) under microwave heating (Scheme 4.7). 
The optimized conditions were found to involve 2 hours reaction at 150 °C (150 
W). The reaction mixture was worked-up by passing compressed air through the 
microwave cavity followed by the addition of water. The reaction mixture was extracted 
with ethyl acetate and the organic layer was dried and evaporated under reduce pressure to 
give the crude product. TLC analysis clearly showed the formation of a new product and 
the disappearance of the starting material 4.6. Purification by column chromatography on 
silica gave 3-amino-1-(4-methoxyphenyl)-1H-pyrazole (4.15) in 85% yield as a yellow 
solid. 
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MeO
CN
EtOH, EtONa
MW
N
N
H2N
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4.6 4.15 (85%)
 
Scheme 4.7. Synthesis of 3-amino-1-(4-methoxyphenol)-1H-pyrazole (4.15) 
The structure of 4.15 was confirmed by various spectroscopic techniques including 
IR and 
1
H and 
13
C-NMR spectroscopic analysis and low and high resolution mass 
spectrometry. The electron impact mass spectrum of 4.15 showed the base molecular ion 
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peak at m/z = 189. The accurate mass for the molecular ion confirmed the molecular 
formula of 4.15 as C10H11N3O. The 
1
H-NMR spectrum of 4.15 showed two doublets at δ = 
8.00 and 5.67 ppm (J = 2.5 Hz) corresponding to H-5 and H-4 of the pyrazole ring, 
respectively. It also showed two doublets (J 9.0 Hz) at δ = 7.55 and 6.95 ppm due to 
H
-
2/H-6 and H-3/H-5 of 4-methoxyphenyl ring, respectively.  The two singlets resonating 
at δ = 4.96 (exchanged on addition of D2O) and 3.76 ppm were also observed and 
correspond to the amino and methoxy protons, respectively. The 
13
C-NMR spectrum of 
4.15 showed all of the expected signals and was consistent with the given structure. 
The second step in the synthesis of 4.2 involved bromination of 4.15 to produce 
3-amino-4-bromo-1-(4-methoxyphenyl)-1H-pyrazole (4.16; Scheme 4.8). It was found that 
this process could also be accelerated under microwave irradiation. Reaction of equimolar 
equivalents of 4.15 and N-bromosuccinimide in THF for 2 hours at 150 °C under 
microwave irradiation gave 4.16 in 77% yield (Scheme 4.8) after purification by column 
chromatography. 
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Scheme 4.8. Synthesis of 3-amino-4-bromo-1-(4-methoxyphenyl)-1H-pyrazole (4.16) 
Chapter Four: Synthesis of pyrazole derivatives as inhibitors of MK2 inhibitors 
132 
The electron impact mass spectrum of 4.16 showed two molecular ions at m/z = 269 
and 267 (base peak) for the different Br isotopes. High resolution analysis of the two 
molecular ions confirmed the molecular formula, C10H10N3O
81
Br and C10H10N3O
79
Br, 
respectively.  The 
1
H-NMR spectrum of bromide 4.15 showed a characteristic singlet that 
resonated at δ = 8.34 ppm due to H-5 of the pyrazole ring. Also, 13C-NMR spectroscopic 
analysis showed a characteristic singlet carbon that resonated at δ = 95.3 ppm 
corresponding to C-4 of the pyrazole ring. 
Several attempts were made to improve the yield of 4.16. It was found that reaction 
of 4.15 with N-bromosuccinimide in THF at room temperature for 16 hours gave 4.16 in 
86% yield after purification by column chromatography, but the microwave-mediated route 
was used in preference on account of its short reaction time. 
The third step involved a Suzuki-coupling
711
 reaction of 4.16 with 
4-carbamoylphenylboronic acid 4.25 (Scheme 4.9). Reaction of 4.16 and boronic acid 4.25 
was attempted in aqueous iso-propyl alcohol in the presence of potassium carbonate and 
bis-(triphenylphosphine)palladium(II) chloride under microwave heating (Scheme 4.9). 
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Scheme 4.9. Synthesis of target 4.2 
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It was found that reaction of equimolar quantities of 4.16 and 4.25 under microwave 
conditions gave the target product 4.2 in 54% yield (Scheme 4.9) after purification by 
column chromatography. 
The structure of compound 4.2 was confirmed by IR and NMR spectroscopic and 
mass spectrometric analysis. The IR spectrum of 4.2 showed a strong absorption band at ν 
= 1653 cm
-1
 corresponding to the amide carbonyl stretch.  
The 
1
H-NMR spectrum of 4.2 showed three exchangeable singlet resonances at 
δ 7.96 (1 H), 7.31 (1 H) and 5.18 (2 H) ppm due to the two NH2 groups, respectively. It 
also showed all of the expected resonances and their chemical shifts were consistent with 
the given structure. The 
13
C NMR spectrum of 4.2 showed a singlet that resonated at very 
low field at δ 168.2 ppm due to the carbonyl carbon of the amide group. It also showed all 
of the other expected carbon resonances. 
The electron impact mass spectrum of 4.2 showed a very intense molecular ion base 
peak at m/z 308. The molecular formula of the molecular ion was confirmed as C17H16N4O2 
by high resolution mass spectrometry.  
4.4 Biological behaviour of MK2 inhibitor 4.2 on Werner syndrome cells 
MK2 inhibitor 4.2 was considered as a potential inhibitor of the ‘stress signal’ in 
Werner syndrome (WS). In collaboration with our project partners in the School of 
Medicine at Cardiff University, the ability of MK2 inhibitor 4.2 was examined in 
telomerase-immortalized HCA2 dermal cells to establish our premise for restoring the 
effects of rapid ageing. Using an enzyme linked immune-sorbant assay (ELISA) it was 
possible to detect the behaviour of target 4.2 at different concentrations and establish its 
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inhibition of a downstream target, HSP27. ELISA is a method to determine the extent of 
phosphorylation of specific proteins, and thus to understand the alteration of pathway 
signalling events. The procedure utilizes antibodies to reveal only the interested 
phosphorylated proteins, in a protein mixture with high specificity. In particular, in our 
analysis, the antibody used identifies the total HSP27 (blue columns), heat shock proteins, 
downstream of activated p38, and pHSP27, phosphorylated heat shock proteins (orange 
columns), which acts as a good marker of p38 activity as it is not activated by other 
substrates (Figure 4.4). 
 
Figure 4.4. MK2 inhibitor 4.2 and its effect on p38 signalling activity 
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Each level of protein is examined and compared in HCA2 cells in 
dimethylsulfoxide (DMSO) in the presence of increasing concentrations of 4.2, from 10 nM 
to 50 M, following treatment with anisomycin (A), which stimulates the phosphorylation 
of p38. Initially the DMSO, as carrier control, shows a low level of pHSP27 with respect to 
the total HSP27 protein (DMSO), as expected. The use of anisomycin (A) is an important 
reference because stimulating the phosphorylation of p38, enables the qualitative effects to 
be observed with dosage. WS cells treated with anisomycin to up-regulate p38 confirmed 
an increase of p38 activity with high level of pHSP27, as expected, while the level of 
HSP27 was unchanged. The same experiment was repeated but the cells were cultured with 
the inhibitor 4.2 at different concentrations from 10 nM to 50 M. The level of HSP27 was 
about the same in all samples, visible by the similar heights of the blue columns, contrary 
to the levels of pHSP27 which changed (orange columns) (Figure 4.4). The initial 
concentration of the inhibitor 4.2 was 10 nM (not shown) and processed until 500 nM when 
this last concentration led to a decrease in the level of pHSP27, showing the inhibition of 
p38 signalling. The ratio of pHSP27/HSP27 is shown in Figure 4.5. 
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Figure 4.5. The ratio of pHSP27/HSP27 for MK2 inhibitor 4.2 
 
These experiments show that anisomycin treatment increased the level of pHSP27 
by up-regulation of p38, while an increase in the concentration of 4.2 inhibits the process of 
activation, presumably of MK2, and thus maintains low levels of pHSP27 (Figure 4.5).  
 
4.5 Attempted synthesis of 3-amino-4-[1-(3-1H-pyrazol-4-yl)]benzamide (4.24) 
In an effort to prepare a more efficacious inhibitor, an alternative and more 
structurally-complex MK2 inhibitor 4.24 was selected.  
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Scheme 4.10. Restorsynthesis of 3-amino-4-[1-(3-1H-pyrazol-4-yl)]benzamide (4.24) 
 
Retrosynthetic analysis (Scheme 4.10) of 4.24 revealed a boronic acid derivative 
4.25 and 3-amino-4-bromo-1-[3-(1H-indol-6-yl]-1H-pyrazole (4.30) as shown. Indole 
derivative 4.30 could be prepared from bromination of 3-amino-1-[3-(1H-indol-6-
yl)phenyl]-1H-pyrazole (4.29; Scheme 4.10), which in turn itself could be prepared by 
Suzuki-coupling of boronic acid derivative 4.27 and 3-amino-1-(3-bromophenyl)-1H-
pyrazole (4.28) generated from the reaction of (3-bromophenyl)hydrazine hydrochloride 
(4.26) with 3-methoxyacrylonitrile (Scheme 4.10) using a similar strategy to before. 
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The synthesis of 4.24 could thus take place in four steps. The first step involving the 
synthesis of 3-amino-1-(3-bromophenyl)-1H-pyrazole (4.28; Scheme 4.11) under 
conditions similar to that used in Scheme 4.7, will be discussed first. 
4.5.1 Synthesis of 3-amino-1-(3-bromophenyl)-1H-pyrazole (4.28) 
Reaction of (3-bromophenyl)hydrazine hydrochloride (4.26; one molar equivalent) 
with 3-methoxyacrylonitrile (two molar equivalents) in tert-butyl alcohol in the presence of 
potassium tert-butoxide as a base under microwave heating for 2 hours at 150 °C gave 3-
amino-1-(3-bromophenyl)-1H-pyrazole (4.28) in 68% yield (Scheme 4.11) after 
purification by column chromatography. 
NHNH2.HCl
MeO
CN
MW
N
N
H2N
4.26 4.28 (68-90%)
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Br
Br
+
 
Scheme 4.11. Synthesis of 3-amino-1-(3-bromophenyl)-1H-pyrazole (4.28) 
 
The structure of 4.28 was confirmed by IR and NMR spectroscopic and mass 
spectrometric analysis. The electron impact mass spectrum of 4.28 showed two very 
intense molecular ion base peaks at m/z 239 and 237 for the different Br isotopes. The high 
resolution mass spectrum of the molecular ion at m/z 237 confirmed the molecular formula 
of 4.28 as C9H8N3
79
Br. 
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The NMR spectra of 4.28 showed all the expected proton and carbon resonances 
and their chemical shifts were consistent in all respects with the given structure. The 
1
H-NMR spectrum of 4.28 showed two characteristic doublets (J = 2.5 Hz) at δ = 8.21 and 
5.77 ppm due to H-5 and H-4 of the pyrazole ring, respectively. It also showed an 
exchangeable singlet at δ = 5.17 ppm due to the NH2 protons. The 
13
C-NMR spectrum of 
4.28 showed a characteristic methine signal at δ = 97.6 ppm corresponding to C-4 of the 
pyrazole ring. 
Several experiments were conducted in order to find the optimum conditions under 
which the yield of 4.28 could be improved. It was found that by reducing the microwave 
irradiation hold time, reaction of 4.26 and 3-methoxyacrylonitrile, again used in a molar 
ratio of 1:2, in dry ethanol in the presence of sodium ethoxide under microwave irradiation 
for 1 hour at 150 °C gave 4.28 in 89% yield after purification. The yield of 4.28 was similar 
(90%) when the reaction was carried out in ethanol under reflux conditions for 20 hours. 
Under these conditions, chromatographic purification was not employed since the crude 
product was essentially pure by NMR spectroscopic analysis.  
Having successfully produced 4.28 in high yield, our attention next turned to the 
synthesis of 3-amino-1-[3-(1H-indol-6-yl)phenyl]-1H-pyrazole (4.29). 
4.5.2 Synthesis of 3-amino-1-[3-(1H-indol-6-yl)phenyl]-1H-pyrazole (4.29) 
Suzuki-coupling
710
 of arylbromide 4.28 with 1H-indol-6-ylboronic acid (4.27) was 
attempted (Scheme 4.12). Reaction of 3-amino-1-(3-bromophenyl)-1H-pyrazole (4.28; 3.3 
molar equivalents) and the boronic acid derivative 4.27 (one molar equivalent) in 
N,N-dimethylformamide (DMF) was attempted in the presence of cesium carbonate (6.7 
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molar equivalents) and a catalytic amount of bis-(triphenylphosphine)palladium(II) 
chloride under microwave irradiation for 2 hours at 150 °C (Scheme 4.12). The crude 
product obtained was analyzed by TLC and this confirmed the formation of a new product. 
Purification by column chromatography gave pure indole 4.29 in 84% yield. 
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Scheme 4.12. Synthesis of 3-amino-1-[3-(1H-indol-6-yl)phenyl]-1H-pyrazole (4.29) 
The structure of 4.29 was confirmed by several spectroscopic techniques including 
IR and NMR spectroscopy and mass spectrometry (See Chapter six for details). The 
electron impact mass spectrum of 4.29 showed a very intense molecular ion base peak at 
m/z 274 and the high resolution mass spectrum confirmed its molecular formula as 
C17H14N2. The NMR spectra of 4.29 showed all the expected signals for both pyrazole, 
indole and aryl groups and were consistent with the given structure. 
Our attention next turned to the third step in the synthetic pathway for the 
production of 4.24 - the bromination of 4.29 to produce the corresponding bromo derivative 
4.30. 
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4.5.3 Synthesis 3-amino-1-(3-(1H-indol-6-yl)phenyl)-4-bromo-1H-pyrazole (4.30) 
Bromination of 4.29 with N-bromosuccinimide (NBS) was attempted under various 
reaction conditions in an attempt to synthesize 3-amino-1-(3-(1H-indol-6-yl)phenyl)-4-
bromo-1H-pyrazole (4.30; Scheme 4.13). However, NMR spectroscopic analysis of the 
product was complex and showed the formation of a mixture of products in which 
bromination had occurred at various positions of the pyrazole and indole rings. Attempts 
were made to purify the product but these were not successful. Therefore it was decided to 
attempt the synthesis of the target inhibitor 4.24 by another route. 
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Scheme 4.13. Attempted synthesis of 4.30 by bromination of 4.29 
 
4.5.4 Alternative attempt at the synthesis of 3-amino-4-[1-(3-1H-pyrazol-4-
yl)]benzamide (4.24) 
Retrosynthetic analysis of target 4.24 revealed a boronic acid derivative 4.25 and 
bromide 4.30, available via a selective Suzuki-coupling
710
 of boronic acid derivative 4.27 
and 3-amino-4-bromo-1-(3-bromophenyl)-1H-pyrazole 4.31 (Scheme 4.14). The dibromide 
substrate for this process, 4.31, could be produced via bromination of bromide 4.28 
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(Scheme 4.14). This approach would rely upon the chemoselective reaction of the aryl 
bromide in preference to the heteroarylbromide group. 
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Scheme 4.14. Retrosynthetic pathway for 4.24 
The synthetic pathway represented in Scheme 4.14 involved three steps. The first 
step involved bromination of 3-amino-1-(3-bromophenyl)-1H-pyrazole (4.28) using 
N-bromosuccinimide which was previously prepared as shown in Scheme 4.11. It was 
found that bromination of 4.28 with NBS in THF at room temperature for 16 hours gave 
dibromide 4.31 in 83% yield after purification by column chromatography (Scheme 4.15). 
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Scheme 4.15. Synthesis of 3-amino-4-bromo-1H-pyrazole (4.31) 
The structure of 4.31 was confirmed by IR and NMR spectroscopic and mass 
spectrometric data (see experimental chapter for details). The electron-impact mass 
spectrum showed three different Br isotope peaks for the molecular ion and confirmed the 
molecular formula of 4.31 as C9H7Br2N3. The 
1
H-NMR spectrum of 4.31 showed an 
exchangeable singlet that resonated at δ = 5.38 ppm due to the NH2 protons and a 
characteristic singlet that resonated at δ = 8.55 ppm due to H-5 of the pyrazole ring. The 
13
C-NMR spectrum of 4.31 showed a characteristic singlet at δ = 85.2 ppm and a doublet at 
δ = 127.5 ppm due to C-4 and C-5 of the pyrazole ring, respectively. 
Having successfully synthesised dibromide 4.31, our attention turned to the 
synthesis of 3-amino-4-bromo-1-(3-(1H-indol-6-yl)phenyl)-1H-pyrazole (4.30) via 
chemoselective Suzuki-coupling of 4.31 and boronic acid 4.27 (Scheme 4.16). 
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Scheme 4.16. Attempt synthesis of 4.30 
The reaction was attempted under various conditions and unfortunately starting 
material 4.31 was mostly recovered unreacted along with a complex mixture of products. 
No conditions were found to produce 4.30 cleanly and in high yield. No further attempts 
were made to find conditions under which 4.30 could be prepared and so production of a 
more selective or efficacious MK2 inhibitor were halted in favour of alternative inhibitors 
of study. 
 
4.6 Conclusions 
The synthesis of 4-(3-amino-1-(4-methoxyphenyl)-1H-pyrazol-4-yl)benzamide 
(4.2) has been achieved in three steps. Rigorous experimental procedures have been 
investigated using microwave dielectric heating. This technique led to faster reaction times 
and allowed the rapid optimization of yields. These advantages were employed in all steps 
and allowed the rapid formation of the desired targets in high yield. Biological study of one 
inhibitor 4-(3-amino-1-(4-methoxyphenyl)-1H-pyrazol-4-yl)benzamide (4.2) showed, by 
ELISA analysis, that p38 signalling was inhibited in control dermal cells. Experiments 
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can now be carried out, given its inhibitory profile, to explore the role of MK2 signalling in 
accelerated ageing and these studies are underway in the Kipling laboratories. 
Some progress was made towards the synthesis of 3-amino-4-[1-(3-1H-pyrazol-4-
yl)]benzamide (4.24) but the final product was not obtained and so the synthesis of 
additional inhibitors based upon this chemotype was not pursued further. 
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5.1 Introduction 
The development of p38 inhibitors for the treatment of inflammatory diseases has 
attracted considerable attention from the pharmaceutical industry. P38 MAP kinase plays 
an important role in the regulation of production of pro-inflammatory cytokines and soan 
effective therapy for the treatment of many inflammatory diseases could be achieved by 
blocking p38 MAP kinase.
1,2
 The central role of pro-inflammatory cytokines such as IL-1B 
and TNFα and their validation as a target has been proven by successful therapeutic 
treatment.
1.2
 Various chemotypes have been identified as small molecule p38 mitogen–
activated protein kinase inhibitors.
3,4
 
 In 1994, SB203580 (5.1; Figure 5.1) was discovered as the parent of a class of 
cytokine suppressive inhibitors.
1
 SB203580 (5.1) was found to be an inhibitor for the 
catalytic action of p38 MAP kinase by competitive binding in the ATP pocket. 
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Figure 5.1: The structure of inhibitor SB203580 (5.1) 
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 Further developments in the field of protein kinase targeted drug discovery has led 
to the identification of many inhibitors. Such inhibitors were designed to take advantages of 
specific interactions that are located within or close to the ATP binding site of p38. The 
ability of the inhibitor to imitate ATP (5.2; Figure 5.1) and occupy regions within the ATP 
binding cleft and therefore to mimic specific key H–bond interactions was found to be the 
most important feature in p38 inhibitor and kinase inhibitor design.
1,2
 X–Ray 
crystallography of other kinases complexed with ATP (5.2) shows that this natural ligand 
interacts directly with the p38 hinge region residue His107 and Met109 to form a pair of 
hydrogen bonds with the adenine ring of ATP (Figure 5.2).
5,6
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Figure 5.2: ATP binding mode with p38α 
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The orientation of the triphosphate group in such a way provides efficient catalysis 
for the γ–phosphorylation transfer to the substrate protein upon p38 MAP kinase 
activation.
7
 
 SB203580 (5.1) and related pyridin-4-yl imidazoles bind in the ATP binding site of 
p38 as proven by crystallographic studies. The nitrogen of the pyridine group in 5.1 forms a 
hydrogen bond with the NH of the backbone of Met109 in the linker region.
810
 The 
4-fluorophenyl ring in 5.1 binds to hydrophobic region which in p38 is represented by a 
spacious pocket, a second hydrophobic area below the linker region is left unoccupied by 
simple pyridin-4-yl imidazole inhibitors (Figure 5.3).
8,10
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Figure 5.3: SB 203580 (5.1) binding modes with p38α 
 Efforts have been made to develop various structurally-related p38 inhibitors that 
could improve potency and minimize liabilities, in particular in selectivity, that have been 
identified in the pyridine–imidazole series. 
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5.2 Use of p38 inhibitors for the treatment of Werner syndrome cells 
 The research group of Kipling from Cardiff University has investigated the role of 
p38-transduced stress signalling in Werner syndrome cells using SB203580 (5.1; Figure 
5.1), the cytokine-suppressive anti-inflammatory drug, whose major inhibitory target is 
p38.
1
 
 The study of genome instability observed in WS, along with frequent replication 
fork stalling, provides a plausible trigger for replication stress in WS cells and a possible 
involvement for p38 signalling in inducing the shortened replicative life span.
1
 
 The research groups of Bagley and Kipling, along with others, have investigated the 
use of BIRB796 (5.3; Figure 5.4) as a potent and selective inhibitor of p38α mitogen–
activated protein kinase for the study of accelerated ageing in Werner syndrome cells.
1114
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Figure 5.4: Structure of BIRB 796 (5.3) 
 The 5-aminopyrazol-4-yl ketone p38 inhibitor RO3201195 (5.4; Figure 5.5) was 
discovered by Hoffmann-La Roche. RO3201195 (5.4) is an orally bioavailable and highly 
selective inhibitor of both α and β-isoforms of p38 MAP kinase which binds to both the 
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phosphorylated and unphosphorylated forms of the enzyme, as is common for ATP 
competitive inhibitors.
15
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Figure 5.5: The structure of RO3201195 (5.4) 
 X-Ray crystallographic studies showed that RO3201195 (5.4) was able to form a 
hydrogen bond between the benzoyl oxygen and the NH of Met109 of the main chain. 
Also, it showed an interaction in the ATP binding site.
15
 RO3201195 (5.4) forms two 
hydrogen bonds, one with the backbone His107 and one with the side chain hydroxyl group 
of Thr106.
15,16
 The binding interactions of RO3201195 (5.4) with p38α are shown in Figure 
5.6. 
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Figure 5.6: Binding interactions of RO3201195 (5.4) 
 The kinase selectivity profile of 5.4 in vitro indicated that only 6 kinases were 
inhibited out of a panel of 105 kinases with inhibition 50% at 10 M concentration and 
only two of those were inhibited at comparable concentrations to its p38 activity, PDGFRβ 
and GAK.
15
 The synthesis of RO3201195 (5.4) and its ability to inhibit p38α and JNK was 
investigated in hTERT–immortalized HCA2 and WS dermal fibroblasts at 200 nM 
concentration, both by enzyme linked immumo-sorbent assay (ELISA) and immunoblot 
assay, and displays excellent kinase selectivity for p38α MAPK over the related stress-
activated kinase JNK.
17
 
 
5.3 Synthesis of the highly selective RO3201195 (5.4) 
 RO3201195 (5.4) was previously synthesised
15,17
 in seven steps as shown in 
Scheme 5.1. The first step involves esterification of 3-methoxybenzoic acid (5.5) with 
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methanol to give the corresponding methyl ester 5.6 in 80% yield (Scheme 5.1).
15,17
 The 
second step involves reaction of 5.6 with acetonitrile, in the presence of a base, to give the 
corresponding nitrile 5.7 in low yields (6–18%) depending upon the type of base used.18 
The third step involves reaction of nitrile 5.7 with N,N
’
-diphenylformamidine under reflux 
conditions in dry xylene for 1.5 h to give 3-(phenylamino)acrylonitrile (5.8) in 85% 
yield.
17,18
 This yield was improved to 90% when the reaction was carried out under 
microwave-assisted conditions for 20 minutes at 180 °C (Scheme 5.1).
15,17,18
 
Cyclocondensation of 5.8 with 4-fluorophenylhydrazine hydrochloride in ethanol under 
reflux conditions for 5 hours gave 5-aminopyrazole (5.9) in 37% yield (Scheme 5.1).
15,18
 
The yield of pyrazole 5.9 formation was improved to 86% when the reaction was carried 
out under microwave heating for 1 h at 140 C.15,18 Reaction of 5.9 with boron tribromide 
in dichloromethane 0 C for 20 minutes followed by room temperature for 2.5 h gave 
phenol derivative 5.10 in 59% yield (Scheme 5.1). Reaction of 5.10 with 
(S)-O-iso-propyldipheneglycerol tosylate under basic conditions gave ketal 5.11 in low 
yield (9%).
18
 The final target RO3201195 (5.4) was obtained in 48% yield upon hydrolysis 
of 5.11 under acidic conditions (Scheme 5.1).
18
 Thus, although this route was successful in 
delivering the target inhibitor, many of these steps were poorly efficient and this precluded 
the production of the inhibitor in any appreciable quantities, thus preventing further 
biological study. 
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Scheme 5.1: Synthesis of RO3201195 (5.4) 
 The goals of the work reported in this chapter aimed to improve the synthesis of 
RO3201195 (5.4) and obtain the product in sufficient yield for further study. We now 
report our successful attempts to deliver 5.4 predominantly using microwave heating.
15,17,18
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5.3.1. Synthesis of methyl 3-methoxybenzoate (5.6) 
 The synthesis of RO3201195 (5.4) was first attempted based on literature 
procedures.
15,18
 The esterification of the commercially available 3-methoxybenzoic acid 
(5.5) with methanol in the presence of a catalytic amount of concentrated sulphuric acid 
under reflux condition was attempted. Following work-up and extraction with diethyl ether, 
methyl 3-methoxybenzoate was produced in 80% yield (Scheme 5.2) as a colourless oil.
19
 
This was in good agreement with the literature route. 
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Scheme 5.2: Synthesis of 3–methoxybenzoic acid methyl ester (5.6) 
 The structure of ester 5.6 was confirmed by IR and NMR spectroscopic analysis and 
mass spectrometric data. The 
1
H NMR spectrum of 5.6 showed two singlets at δ = 3.85 and 
3.91 ppm corresponding to two methoxy groups. The 
13
C–NMR spectrum showed a singlet 
signal that resonated at δ = 167.0 ppm corresponding to the carbonyl carbon. Moreover, the 
APCI mass spectrum of 5.6 showed a very intense signal at m/z = 167 corresponding to the 
pseudo molecular ion (MH
+
). 
5.3.2. Synthesis of 3-methoxybenzoylacetonitrile (5.7) 
 Having successfully produced methyl ester 5.6, our attention turned to the 
conversion of 5.6 to the corresponding nitrile 5.7. 3-Methoxybenoylacetonitrile (5.7) was 
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previously synthesised in very low yield (6–18%) within our research group.18 The reaction 
of 5.6 with acetonitrile in the presence of a base was carried out (Scheme 5.3). 
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Scheme 5.3: Synthesis of 3-methoxybenzoylacetonitrile (5.7) 
 First, the literature procedure for the production of 5.7 was followed in which 
sodium ethoxide was used as a base.
20
 A mixture of ester 5.6 and sodium ethoxide was 
stirred at room temperature and at 80 °C for 5 minutes after which a gelatinous mass was 
formed which was slowly added to dry acetonitrile. The mixture was heated under reflux 
conditions for 24 hours and submitted to an aqueous work-up. The residue obtained was 
purified by column chromatography to give acetonitrile 5.7 in only 9% yield, along with a 
significant quantity of starting material 5.6 (Table 5.1; Entry 1). Use of sodium methoxide
21
 
did not improve the yield of 5.7 under similar conditions to the sodium ethoxide reaction 
(Table 5.1; Entry 2). 
 In another experiment, a mixture of 5.6 and sodium hydride in anhydrous 
tetrahydrofuran (THF) was stirred at room temperature for 10 minutes. The mixture was 
added in a dropwise manner to anhydrous acetonitrile under a N2 atmosphere and the 
resulting mixture was heated under reflux for 1.5 hours. Following aqueous work-up and 
purification of the crude product, 5.7 was obtained in a slightly better yield (15 %) but this 
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was still considered low (Table 5.1; Entry 3). The reasons for the low yield of 5.7 obtained 
in this reaction were not clear although the gelatinous state of the reaction medium no 
doubt played a part. In an attempt to improve the yield of 5.7 we decided to carry out the 
reaction under microwave conditions using sodium hydride as the base. 
 A mixture of 5.6 and sodium hydride in THF was stirred at room temperature for 10 
minutes and then added to acetonitrile. The resulting mixture was heated at 150 °C for 1 
hour under microwave heating. The reaction mixture was submitted to aqueous work-up 
and the product was extracted with ethyl acetate to give pure acetonitrile product 5.7 as a 
colourless solid in 35% yield (Table 5.1; Entry 4). The improvement in yield was 
significant but still was not satisfactory; therefore, the reaction was attempted under reflux 
but for a long period of time (24 hours) in an attempt to improve the yield further. 
Table 5.1 Synthesis of 3-methoxybenzoylacetonitrile (5.7) according to Scheme 5.3 
Entry Base Condition Time (h) Yield (%)
a 
1 NaOEt Reflux 24 9 
2 NaOMe Reflux 24 9 
3 NaH Reflux 1.5 15 
4 NaH MW, 150 °C 1 35 
5 NaH Reflux 24 75 
 
a
 Yield obtained of 5.7 either after purification by column chromatography or solvent 
extraction using ethyl acetate. 
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 Indeed, stirring a mixture of 5.6 and NaH in THF at room temperature for 20 
minutes followed by the addition of acetonitrile then heating the whole mixture at reflux for 
24 hours gave the product 5.7 in 75% yield after purification simply by extraction (Table 
5.1; Entry 5). 
 Given the difficulties associated with this transformation and the prolonged reaction 
time required, efforts were made to access benzoylacetonitrile 5.7 by a different route. To 
that end, reaction of 3-iodoanisole (5.12) with 3-methoxyacrylonitrile, used to good effect 
in aminopyrazole synthesis, in the presence of potassium(II) acetate as catalyst under 
microwave heating at 150 °C for 1.5 hours was attempted (Scheme 5.4). Gratifyingly, 
product 5.7 was isolated in 76% yield after purification by colomn chromatography. This 
material 5.7 produced by this route was identical in all respects (melting point, appearance 
and spectroscopic data) to the previously obtained sample. 
I
OMe
O
OMe
CN
5.7 (76%)
MeO
CN
K2CO3, Xantphos
palladium(II) acetate
150 °C, 1.5 h, MW
5.12
 
Scheme 5.4: Synthesis of 3-methoxybenzoyl acetonitrile (5.7) 
 The structure of 5.7 was confirmed by various spectroscopic techniques (See 
Chapter Six for details). The IR spectrum of 5.7 showed absorption bands at νmax = 2343 
and 1650 cm
-1
 due to C≡N and C=O vibrations, respectively. The 1H NMR spectrum 
showed a singlet resonance at δ = 3.89 ppm due to the CH2 protons. The 
13
C NMR 
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spectrum of 5.7 showed a signal that resonated at δ = 29.5 ppm corresponding to CH2 
carbon. The electrospray mass spectrum showed a molecular ion peak at m/z = 175. The 
high resolution mass spectrum of 5.7 confirmed the formula of the molecular ion as 
C10H9NO2. 
 Having successfully synthesised compound 5.7 in high yield (76%), we therefore, 
proceeded with the subsequent steps towards the synthesis of the target inhibitor 5.4. 
5.3.3 Synthesis of 2-(3-methoxybenzoyl)-3-phenylaminoacrylonitrile (5.8) 
 In previous studies, Knoevenagel condensation of 3-methoxybenzoylacetonitrile 
(5.7) and N,N
’
-diphenylformamidine was attempted in dry xylene under reflux conditions 
for 1.5 hours (Scheme 5.5).
18
 However, we chose to heat the reaction mixture under 
microwave irradiation at 180 °C for 20 minutes and then allowed the mixture to cool to 
room temperature and remove the solvent under reduced pressure. The residue obtained 
was treated with diethyl ether to give pure 2-(3-methoxybenzoyl)-3-
phenylaminoacrylonitrile (5.8) in 90% yield. 
HN
N
180 °C, 20 min, MW
O
OMe
CN
NH
5.8 (90%)
Xylene
O
OMe
CN
5.7
 
Scheme 5.5: Synthesis of 2-(3-methoxybenzoyl)-3-phenylaminoacrylonitrile (5.8) 
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 The electron-impact mass spectrum of 5.8 showed a molecular ion peak at m/z = 
278 and high resolution mass spectrometric analysis confirmed the formula of the 
molecular ion as C17H14N2O2 (M
•+
). The 
1
H NMR spectrum of 5.8 showed a doublet (J = 
13 Hz) at δ = 8.06 ppm corresponding to the CH proton and an exchangeable doublet (J = 
13 Hz) at δ = 4.10 ppm corresponding to the NH proton. The 13C NMR spectrum showed 
all of the expected signals and was consistent with the structure of 5.8. 
 
5.3.4 Synthesis of 5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl)-3-methoxyphenyl 
ketone (5.9) 
 Following the successful synthesis of aminoacrylonitrile 5.8, the next step was its 
cyclocondensation with 4-fluorophenylhydrazine hydrochloride (Scheme 5.6). The reaction 
was carried out under microwave heating in ethanol and in the presence of triethylamine 
(TEA) for one hour at 140 °C to give 5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl)-3-
methoxyphenyl ketone (5.9) in 87% yield (Scheme 5.6), after purification by column 
chromatography, as a colourless solid. 
O
OMe
CN
NH
NHNH2.HCl
F
140 °C, 1 h, MW
O
OMe
N
N
F5.9 (87%)5.8
TEA, EtOH
H2N
 
Scheme 5.6: Synthesis of 5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl)-3-methoxyphenyl 
ketone (5.9) 
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 The spectroscopic data collected confirmed the structure of 5.9. The APCI mass 
spectrum of 5.9 showed a pseudo molecular ion (MH
+
) peak at m/z = 312 and the formula 
of MH
+
 was confirmed as C17H15N3O2F by high resolution mass spectrometric analysis. 
The 
1
H NMR spectrum of 5.9 showed a singlet that resonated at δ = 7.83 ppm due to H-3 of 
the pyrazole ring. It also showed an exchangeable singlet at δ = 6.07 ppm due to the NH2 
protons. The 
13
C NMR spectrum showed that the C-4 of the 4-fluorophenyl moiety 
resonated at δ 162.1 ppm (J = 280 Hz) and showed all of the characteristic signals for the 
pyrazole ring as well as all other expected resonances. 
 
5.3.5 Synthesis of 5-amino-1H-(pyrazol-4-yl)-3-hydroxyphenyl ketone (5.10) 
Transformation of the methyl ether of 5.9 to 5-amino-1H-(pyrazol-4-yl)-3-
hydroxyphenyl ketone (5.11) was based on literature precedent.
15,18
 Reaction of 
5-aminopyrazole 5.10 with boron triboromide (BBr3) in dichloromethane was carried out at 
0 °C for 10 minutes and at room temperature overnight (Scheme 5.7). 
BBr3, DCM,
10 min at 0 °C
O
OH
N
N
F
5.10 (77%)
O
OMe
N
N
F
5.9
and overnight at RT
H2N H2N
 
Scheme 5.7: Synthesis of 5-amino-1H-(pyrazol-4-yl)-3-hydroxyphenyl ketone 
(5.10) 
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 The reaction mixture was submitted to aqueous work-up and the product was 
extracted with dichloromethane to give the desired phenol 5.10 in 77% yield as a colourless 
solid. This was an improvement over the reported yield for 5.10 under similar reaction 
conditions (59%).
18
 
 The EI mass spectrum of 5.10 showed a molecular ion peak at m/z = 298 and the 
formula of the molecular ion was confirmed as C16H12N3O2F (M) by high resolution mass 
spectrometric analysis. The NMR spectra were in agreement with the suggested structure of 
5.10. 
 
5.3.6 Synthesis of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-{[(R)-2,2-
dimethyl-1,3–dioxolan-4-yl]methoxy}phenyl ketone (5.11) 
 The next step in the synthesis of RO3201195 (5.4) was the formation of ketal 5.11 
via alkylation of 5.10. Reaction of phenolic compound 5.10 with 
(S)-O-iso-propyldieneglycerol tosylate in anhydrous dimethylsulphoxide (DMSO) in the 
presence of anhydrous potassium carbonate under a N2 atmosphere for 24 hours at 100 °C 
was investigated (Scheme 5.8). Following aqueous work-up, the crude product was 
extracted with ethyl acetate and was purified by crystallization from a hexane–ethyl acetate 
mixture (3:1 by volume) to give ether 5.11 in 68% yield (Scheme 5.8). This was a 
considerable improvement compared to 9% as previously reported and so provided 
substantially more material for study.
18
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O
OH
N
N
F
5.10
O
O
TsO
K2CO3, DMF
100 °C, 24 h
H2N
O
O
N
N
FO
O
5.11 (86%)
H2N
 
Scheme 5.8: Synthesis of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-{[(R)-2,2-
dimethyl-1,3-dioxolan-4-yl]methoxy}phenyl ketone (5.11) 
 
 The structure of 5.11 was confirmed by the use of various spectroscopic techniques 
including IR and NMR and low and high resolution mass spectrometric data. The APCI 
mass spectrum of 5.11 showed a very intense pseudo molecular ion peak (MH
+
) at m/z = 
412 and the formula of the molecular ion was confirmed as C22H23N3O4F by high 
resolution mass spectrometric analysis. The NMR spectra of 5.11 showed all of the 
expected signals and were in agreement with the structure of 5.11. 
 
5.3.7 Synthesis of 5-amino-1-(4-fluorophenyl)-4-{3-[2(S),3-dihydroxypropoxy]-
benzoyl}pyrazole (5.4) 
 The final step in the synthesis of RO3201195 (5.4) was the deprotection of ketal 
5.11 to diol 5.4. A mixture of 5.11 and p–toluenesulfonic acid monohydrate in aqueous 
methanol was stirred overnight at 50 °C under a N2 atmosphere (Scheme 5.9). Following 
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aqueous work-up, the crude product was purified by column chromatography to give 
RO3201195 (5.4) in 56% yield (Scheme 5.9), compared to 48% as previously reported.
18
 
O
O
N
N
FO
O
5.11
O
O
N
N
FHO
HO
5.4 (56%)
MeOH/H2O
p-toluenesulfonic acid monohydrate
50 °C, overnight
H2N H2N
 
Scheme 5.9: Synthesis of RO3201195 (5.4) 
 The APCI mass spectrum of 5.4 showed a very intense pseudo molecular ion peak 
(MH
+
) at m/z = 372. The high resolution mass spectrum confirmed the formula of the 
pseudo molecular ion as C19H19N3O4F. The NMR spectra of 5.4 showed all of the expected 
signals and were in agreement with the given structure. 
 
5.4 Conclusions 
The synthesis of the chemotherapeutic agent RO3201195 (5.4), which is a highly 
selective inhibitor of p38α, has been achieved in seven steps. The procedure has been 
modified and now provides a high yield of the desired product, using in many steps 
microwave heating. The intermediates, 3-methoxybenzoylacetonitrile (5.7), 5-amino-1H-
(pyrazol-4-yl)-3-hydroxyphenyl ketone (5.10) and [5-amino-1-(4-fluorophenyl)-1H-
pyrazol-4-yl]-3-{[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}phenyl ketone (5.11) were 
Chapter Five: Synthesis of the p38 inhibitor RO3201195 
166 
produced in much improved yield (76, 77 and 68%, respectively) compared to earlier 
reports (18, 59 and 9%, respectively).
18
 Also, the final step in the synthetic process 
provided the target product RO3201195 (5.4) in higher yield (56%) compared to the 
reported one (48%).
18
 Prior to this work, RO3201195 was produced in a seven step 
sequence in an overall yield equal to or less-than 0.2%, with the lowest yielding step of the 
sequence the protodemethylation (9%). This severely impeded its use as an inhibitor of 
study in WS cells. Now, in a seven step sequence, RO3201195 can be formed in an overall 
yield of 18%, with the lowest yielding step the final deprotection/purification sequence. 
Furthermore, many of the steps now are rapid and promoted by microwave heating, 
providing expedient access to the inhibitor for biological study. 
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CHAPTER SIX 
 
EXPERIMENTAL 
 
6.1 Experimental Techniques 
Commercially available reagents were used without further purification; solvents were 
dried by standard procedures. Light petroleum refers to the fraction with bp 40–60 °C, 
ether (Et2O) refers to diethyl ether and EtOAc refers to ethyl acetate. Column 
chromatography was carried out using Merck Kieselgel 60 H silica or Matrex silica 60. 
Analytical thin layer chromatography was carried out using aluminium–backed plates 
coated with Merck Kieselgel 60 GF254 that were visualised under UV light (at 254 
and/or 360 nm). Melting points (mp) were determined on a Kofler hot stage apparatus 
and are uncorrected. Infra–red (IR) spectra were recorded in the range 4000–600 cm–1 
on a Jasco FT/IR-660 plus instrument by dissolving the product in chloroform, applying 
droplets on a NaCl plate and allowing evaporation of the solvent or as KBr disks and 
are reported in cm
–1
. Nuclear magnetic resonance (NMR) spectra were recorded in 
CDCl3, DMSO-d6 or TFA-d at 25 °C using a Bruker AV400 or Bruker AV500 
spectrometer operating at 400 or 500 MHz for 
1
H and 100 or 125 MHz for 
13
C 
measurements, respectively. Chemical shifts were reported in ppm relative to TMS; J 
values were recorded in Hz and multiplicities were expressed by the usual conventions 
(s = singlet, d = doublet, t = triplet, app = apparent, m = multiplet). Assignments of 
signals are based on integration values, coupling patterns and expected chemical shift 
values and have not been rigorously confirmed. 
13
C multiplicities were revealed by 
DEPT signals and are reported as s (C), d (CH), t (CH2) and q (CH3). Low-resolution 
mass spectra (MS) were determined on a Waters GCT Premier Spectrometer using 
atmospheric pressure chemical ionization (APCI) unless otherwise stated. ES refers to 
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electrospray ionization, CI refers to chemical ionization (ammonia) and EI refers to 
electron impact. High-resolution mass spectra were recorded on a Waters LCT Premier 
XE instrument using the ionisation methods specified. In vacuo refers to evaporation at 
reduced pressure using a rotary evaporator and diaphragm pump, followed by the 
removal of trace volatiles using a vacuum (oil) pump. Microwave experiments were 
carried out in a CEM Discover microwave synthesizer at the temperature and initial 
power stated, with modulation of power to maintain constant reaction temperature as 
measured by the in-built IR sensor. 
 
6.2 Synthesis of 2-amino-3-ethoxycarbonylhepta-2,4-dien-6-one (2.3a) 
EtO
O
MeH2N
Me
O
2.3a
 
A mixture of ethyl β-aminocrotonate (2.1a; 0.20 mL, 1.6 mmol) and 
4-(trimethylsilyl)but-3-yn-2-one (2.2a; 0.52 mL, 3.2 mmol) in dry ethanol (4 mL) was 
irradiated at 60 °C (initial power 100 W) for 60 min in a sealed pressure-rated reaction 
tube (10 mL), using a CEM Discover Microwave Synthesizer, cooled and then 
evaporated in vacuo. Purification by recrystallization from hexaneacetone mixture 
gave the title compound as a yellow solid (2.3a; 0.31 g, 100%). 
mp 123124 °C (lit.1 125.5–126.4 °C) (Found: M+, 197.1053. C10H15NO3 [M] requires 
197.1052). 
FTIR (KBr)/cm–1 max: 3332, 1740 (C=O), 1554, 1489, 1443, 1352, 1310, 1277, 1200, 
1183, 1111 and 1023. 
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1
H NMR (400 MHz; DMSOd6): 9.20 (br s, exch. D2O, 1 H, 1 H of NH2), 8.50 (br s, 
exch. D2O, 1 H, 1 H of NH2), 7.45 (d, J = 15 Hz, 1 H, CH=CHCOCH3), 6.38 (d, J = 15 
Hz, 1 H, CH=CHCOCH3), 4.15 (q, J = 7.1 Hz, 2 H, CH2CH3), 2.45 (s, 3 H, CH3), 2.10 
(s, 3 H, CH3) and 1.22 (t, J = 7.1 Hz, CH2CH3). 
13
C NMR (100 MHz; DMSOd6):  199.7 (s, CH3C=O), 170.5 (s, C=O), 166.5 (s, 
C-NH2), 140.4 (d, CH=CHCOCH3), 122.0 (d, CH=CHCOCH3), 95.3 (s, 
C=CCOCH2CH3), 59.9 (t, CH2CH3), 29.2 (q, COCH3), 23.5 (q, CH3C=C) and 15.3 (q, 
CH3CH2). 
APCIMS: m/z (%) 197 (M+·, 35), 179 (50), 151 (100) and 108 (85). 
 
6.3 Synthesis of ethyl 2,6-dimethylpyridine-3-carboxylate (2.4a) 
N MeMe
O
EtO
1
2
3
4
5
6
2.4a
 
6.3.1 Method A: 
A mixture of 2-amino-3-ethoxycarbonylhepta-2,4-diene-6-one (2.3a; 0.70 g, 3.55 
mmol) and a solution of gold hydrochloride (HAuCl4.H2O) as (8900 ppm, 0.50 mL) as a 
catalyst in tolueneacetic acid mixture (15 mL; 5:1 by volume) was stirred at room 
temperature for 5 hours. The solution was neutralised with saturated aqueous NaHCO3 
solution and then extracted with ethyl acetate (3 × 25 mL). The combined organic layers 
were washed successively with water and brine, dried (MgSO4) and evaporated in 
vacuo. Purification of the crude product was carried out by column chromatography 
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(silica gel; petroleum etherethyl acetate; 3:1 by volume) to give the title compound 
(2.4a; 0.61 g, 99%) as a light brown oil. 
mp 6163 °C (lit.2 60 oC)  (Found: MH+, 180.1024. C10H14NO2 [MH] requires 
180.1021). 
FTIR (KBr)/cm–1 max: 1760 (C=O), 1640, 1320, 1280, 1191, 1105, 897 and 788. 
1
H NMR (400 MHz; DMSOd6):  8.05 (d, J = 8 Hz, 1 H, H-4), 7.22 (d, J = 8 Hz, 1 H, 
H-5), 4.22 (q, J = 7.1 Hz, 2 H, CH2), 2.62 (s, 3 H, CH3), 2.38 (s, 3 H, CH3) and 1.25 (t, 
J = 7.1 Hz, 3 H, CH2CH3). 
13
C NMR (100 MHz; DMSOd6):  166.1 (s, C=O), 161.9 (s, C-2), 159.5 (s, C-6), 
136.5 (CH, C-4), 122.1 (s, C-3), 121.5 (d, C-5), 60.8 (t, CH2), 25.1 (q, CH3), 25.1 (q, 
CH3) and 14.2 (q, CH2CH3). 
APCIMS: m/z 180 (MH+, 100). 
 
6.3.2 Method B: 
A mixture of ethyl β-aminocrotonate (2.1a; 0.10 mL, 0.81 mmol), 4-(trimethylsilyl)but-
3-yn-2-one (2.2a; 0.25 mL, 1.7 mmol) and a solution of gold hydrochloride (8900 ppm, 
0.10 mL) as a catalyst in tolueneacetic acid mixture (5 mL; 5:1 by volume) was 
irradiated at 120 °C (initial power 100 W) for 60 min in a sealed pressure-rated reaction 
tube (10 mL), using a CEM Discover Microwave Synthesizer. The solution was 
neutralised with saturated aqueous NaHCO3 solution and then extracted with ethyl 
acetate (3 × 20 mL). The combined organic layers were washed successively with water 
and brine, dried (MgSO4) and evaporated in vacuo. Purification of the crude product 
was carried out by column chromatography (silica gel; petroleum etherethyl acetate; 
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3:1 by volume) to give the title compound (2.4a; 0.137 g; 97%) as a light brown oil. The 
spectral data of the product were consistent with that produced from Method A (Section 
6.3.1). 
6.3.3 Method C: 
A mixture of ethyl β-aminocrotonate (2.1a; 0.10 mL, 0.81 mmol), 4-(trimethylsilyl)but-
3-yn-2-one (2.2a; 0.25 mL, 1.7 mmol) and a hydrochloride (0.10 mL) as a catalyst in 
tolueneacetic acid mixture (5 mL; 5:1 by volume) was irradiated at 120 °C (initial 
power 100 W) for 60 min in a sealed pressure-rated reaction tube (10 mL), using a CEM 
Discover Microwave Synthesizer. The solution was neutralised with saturated aqueous 
NaHCO3 solution and then extracted with ethyl acetate (3 × 20 mL). The combined 
organic layers were washed successively with water and brine, dried (MgSO4) and 
evaporated in vacuo. Purification of the crude product was carried out by column 
chromatography (silica gel; petroleum etherethyl acetate; 3:1 by volume) to give the 
title compound (2.4a; 0.103 g; 72%) as a light brown oil. The spectral data of the 
product were consistent with that produced from Method A (Section 6.3.1). 
 
6.4 Synthesis of 2,6-dimethyl-3-pyridinecarbonitrile (2.16) 
N MeMe
NC
1
2
3
4
5
6
2.16
 
A solution of ethyl 3-aminocrotononitrile (2.15; 0.07 g, 0.80 mmol) and 
4-(trimethylsilyl)but-3-yn-2-one (2.2a; 0.25 mL, 1.7 mmol) in dry ethanol (2 mL) was 
irradiated at 150 °C (initial power 200 W) for 60 min in a sealed pressure-rated reaction 
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tube (10 mL), using a CEM Discover Microwave Synthesizer. After cooling in a flow of 
compressed air, the solvent removed under reduced pressure to give the crude product, 
which was purified by column chromatography (petroleum etherethyl acetate; 3:1 by 
volume) to give the title compound (2.16; 0.08 g, 79%) as a light brown solid. 
mp 8385 °C (lit.3 82 °C) (Found: MH+, 132.0687. C8H8N2 requires [M] 132.0687). 
FTIR (KBr)/cm–1 max: 3261, 2190 (CN), 1600, 1560, 1430, 1398, 1267, 1120, 997 
and 873. 
1
H NMR (400 MHz; DMSOd6):  8.05 (d, J = 8 Hz, 1 H, H-4), 7.22 (d, J = 8 Hz, 1 H, 
H-5), 3.32 (s, 3 H, CH3) and 2.61 (s, 3 H, CH3). 
13
C NMR (100 MHz; DMSOd6):  162.6 (s, C-6), 160.2 (s, C-2), 141.1 (d, C-4), 121.3 
(d, C-5), 117.5 (s, CN), 105.61 (s, C-3), 24.9 (q, CH3) and 23.6 (q, CH3). 
EIMS: m/z (%) 132 (M+·, 100). 
APCIMS: m/z (%) 174 ([M + MeCNH]+, 52) and 133 ([MH]+, 100). 
 
6.5 Synthesis of 3–cyano–2-methyl-6–phenylpyridine (2.17) 
N MeMe
NC
1
2
3
4
5
6
Ph
2.17
 
A solution of ethyl 3-aminocrotononitrile (2.15; 0.07 g, 0.80 mmol) and 4-phenyl-3-
butyn-2-one (2.2c; 0.12 mL, 0.80 mmol) in dry ethanol (3 mL) was irradiated at 150 °C 
(initial power 200 W) for 60 min in a sealed pressure-rated reaction tube (10 mL) using 
a CEM Discover Microwave Synthesizer. After cooling in a flow of compressed air, the 
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solvent was removed under reduced pressure to give the crude product. Purification by 
column chromatography (petroleum etherethyl acetate; 3:1 by volume) gave the title 
compound (2.17; 0.08 g, 75%) as a yellow solid. 
mp 107109 °C (lit.4 109110 °C) (Found: MH+, 207.1040. C15H13N [MH] requires 
207.1048). 
FTIR (KBr)/cm–1 max: 2963, 2290, 1601, 1570, 1310, 1250, 1117, 1030, 962 and 803. 
1
H NMR (400 MHz, CDCl3):  7.48 (m, 2 H, H-2´/H-6´), 7.48 (m, 1 H, H-4´), 7.31 (m, 
2 H, H-3´/H5´), 5.98 (s, 1 H, H-5), 2.50 (s, 3 H, CH3) and 2.17 (s, 3 H, CH3). 
13
C NMR (100 MHz, CDCl3):  159.5 (s, C-6), 159.1 (s, C-2), 150.5 (s, C-4), 139.2 (s, 
C-1´), 128.9 (d, C-4´), 128.8 (d, C-3´/C-5´), 128.2 (d, C-2´/C-6´), 126.1 (s, CN), 121.6 
(d, C-5), 117.8 (s, C-3), 24.0 (q, CH3) and 23.2 (q, CH3). 
EIMS: m/z (%) 207 ([MH]+, 100). 
 
6.6 Synthesis of ethyl 2,6-dimethyl-4-phenylpyridine-3-carboxylate (2.18) 
N MeMe
1
2
3
4
5
6
PhO
EtO
2.18
 
A solution of ethyl 3-aminocrotonate (2.1a; 0.07 g, 0.50 mmol), 4-phenyl-3-butyn-2-
one (2.2c; 0.70 mL, 0.50 mmol) and a solution of gold hydrochloride (8900 ppm, 0.050 
mL) as catalyst in tolueneacetic acid (3 mL; 5:1 by volume) was irradiated at 150 °C 
(initial power 200 W) for 60 min in a sealed pressure-rated reaction tube (10 mL), using 
a CEM Discover Microwave Synthesizer. After cooling in a flow of compressed air, the 
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solution was neutralised with saturated aqueous NaHCO3 solution and then extracted 
with ethyl acetate (3 × 10 mL). The organic layers were combined, washed successively 
with water and brine, dried (MgSO4) and evaporated in vacuo, to give the crude 
product. Purification by column chromatography (petroleum etherethyl acetate; 3:1 by 
volume) gave the title compound (2.18; 0.06 g, 49%) as a light brown oil. 
mp 8385 °C (Found: M+, 255.1259. C16H17NO2 [M] requires 255.1261). 
FTIR (KBr)/cm–1: max 3120 (CH), 2980, 1730 (C=O), 1672 (C=O), 1387, 1290, 1178, 
1110, 976, 886 and 723. 
1
H NMR (400 MHz, CDCl3):  7.33 (s, 5 H, Ph), 6.95 (s, 1 H, H-5), 4.02 (q, J = 7.2 Hz, 
2 CH2), 2.55 (s, 3 H, CH3), 2.52 (s, 3 H, CH3) and 0.91 (t, J = 7.2 Hz, CH2CH3). 
13
C NMR (100 MHz, CDCl3):  169.5 (s, C=O), 159.9 (s, C-2), 155.8 (s, C-6), 149.1 (s, 
C-4), 139.3 (s, C-1´), 128.9 (d, C-4´), 128.0 (d, C-3´/C-5´), 126.0 (s, C-3), 121.7 (d, 
C-2´/C-6´), 61.6 (t, CH2), 25.1 (CH3), 22.7 (CH3) and 14.3 (CH2CH3). 
EIMS: m/z (%) 255 (M+·, 73), 237 (12), 226 (14), 210 ([M  EtO]+, 100), 184 (39), 
167 (20), 146 (15) and 129 (22). 
APCIMS: m/z (%) 256 ([MH]+, 100). 
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6.7 Synthesis of 2-amino-7-methylpyrido[2,3-d]pyrimidin-4(3H)-one (2.20) 
HN
N N
O
H2N
1
2
3
4 5
6
7
8
8a
4a
2.20
 
6.7.1 Method A: 
A solution of 2,4-diamino-6-hydroxypyridine (2.19; 0.214 g, 1.70 mmol) and 3-butyn-
2-one (2.2d; 0.133 mL, 1.70 mmol) in acetic acid (4 mL) was irradiated at 120 °C for 30 
min in a pressure-rated glass tube (10 mL) using a CEM Discover microwave 
synthesizer by moderating the initial power (150 W). After cooling in a flow of 
compressed air the mixture was washed with water, filtered and dried in vacuo to give 
the title compound (2.20; 0.263 g, 90%) as a colourless solid, mp > 300 °C (lit.
5
 > 330 
°C) (Found: MH
+
, 177.0773 C8H9N4O requires MH
+
 177.0776). 
FTIR (KBr)/cm–1 max: 3248 (NH2 and NH), 1666 (C=O) and 1581 (C=C). 
1
H NMR (500 MHz; TFA-d):  9.05 (d, J = 8.1 Hz, 1 H, H-5), 7.62 (d, J = 8.1 Hz, 1 H, 
H-6) and 3.04 (s, 3 H, CH3). 
13
C NMR (125 MHz; TFA-d):  161.6 (s, C-4), 156.4 (d, C-5), 154.6 (s, C-2), 147.3 (s, 
C-8a), 127.0 (d, C-5), 121.8 (d, C-6), 113.4 (s, C-4a) and 20.6 (q, CH3). 
APCIMS: m/z 177 (MH+, 91%). 
6.7.2 Method B: 
A solution of 2,4-diamino-6-hydroxypyridine (2.19; 0.214 g, 1.70 mmol), 3-butyn-2-
one (2.2d; 0.133 mL, 1.70 mmol) and a solution of gold hydrochloride (8900 ppm, 0.10 
mL) as catalyst in acetic acid (4 mL) was irradiated at 120 °C for 30 min in a pressure-
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rated glass tube (10 mL) using a CEM Discover microwave synthesizer by moderating 
the initial power (150 W). After cooling in a flow of compressed air the mixture was 
washed with water, filtered and dried in vacuo to give the title compound (2.20; 0.227 g, 
76%) as a light grey solid. 
 
6.8 Synthesis of 1,3,7-trimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2.22) 
1
2
3
4 5
6
7
8
8a
4a
N
N N
O
O
Me
Me
2.22
 
 A solution of 6-amino-1,3-dimethyluracil (2.21; 0.263 g, 1.70 mmol) and 
3-butyn-2-one (2.2d; 0.133 mL, 1.70 mmol) in acetic acid (4 mL) was irradiated at 120 
°C for 30 min in a pressure-rated glass tube (10 mL) using a CEM Discover microwave 
synthesizer by moderating the initial power (150 W). After cooling in a flow of 
compressed air the mixture was neutralised with saturated aqueous NaHCO3 solution. 
The aqueous layer was extracted with EtOAc (3 × 35 mL) and the organic extracts were 
combined, washed successively with water and brine, dried (MgSO4) and evaporated in 
vacuo to give the title compound (2.22; 0.321 g, 99%) as a creamy solid (Found: [M  
Me]
+
, 190.0614. C9H8N3O2 requires [M  Me] 190.0617). 
FTIR (KBr)/cm–1 max: 1660 (C=O), 1577 (C=C) and 1500. 
1
H NMR (500 MHz; CDCl3):  8.32 (d, J = 8.1 Hz, 1 H, H-5), 7.03 (d, J = 8.1 Hz, 1 H, 
H-6), 3.75 (s, 3 H, CH3), 3.45 (s, 3 H, CH3) and 2.82 (s, 3 H, CH3). 
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13
C NMR (125 MHz; CDCl3):  162.1 (s, C-2 and C-4), 159.2 (s, C-8a), 149.5 (s, C-7), 
138.3 (d, C-5), 119.5 (d, C-6), 107.5 (s, C-4a), 30.1 (q, CH3), 29.1 (q, CH3) and 26.3 (q, 
CH3). 
EIMS: m/z (%) 191 ([MH  Me]+, 13), 190 ([M  Me]+, 100), 164 (33), 163 (46), 110 
(7) and 85 (73). 
 
6.9 Synthesis of 2-amino-7-phenylpyrido[2,3-d]pyrimidin-4(3H)-one (2.24) 
HN
N N
O
H2N
2.24
1
2
3
4 5
6
7
8
8a
4a
 
A solution of 2,4-diamino-6-hydroxypyridine (2.19) (0.097 g, 0.77 mmol) and 
1-phenyl-2-propyn-1-one (2.23) (0.10 g, 0.77 mmol) in acetic acid (4 mL) was 
irradiated at 120 °C for 30 min in a pressure-rated glass tube (10 mL) using a CEM 
Discover microwave synthesizer by moderating the initial power (150 W). After cooling 
in a flow of compressed air, water was added to the mixture and the precipitate was 
filtered, washed with saturated aqueous NaHCO3 solution and dried in vacuo to give the 
title compound (2.24; 0.176 g, 96%) as a yellow solid, mp > 300 °C (Found: M
+
, 
238.0852. C13H10N4O requires [M] 238.0855). 
FTIR (KBr)/cm–1 max: 3248 (NH2 and NH), 1666 (C=O) and 1581 (C=C). 
1
H NMR (500 MHz; TFA-d):  9.16 (d, J = 8.3 Hz, 1 H, H-6), 8.078.00 (m, 3 H, H-5 
and H-2/H-6 of Ph), 7.89 (t, J = 7.8 Hz, 1 H, H-4 of Ph) and 7.82 (t, J = 7.5 Hz, 2 H, 
H-3/H-5 of Ph). 
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13
C NMR (125 MHz; TFA-d):  160.5 (s, C-4), 159.3 (s, C-7), 155.0 (s, C-2), 145.8 (s, 
C-8a), 134.5 (s, C-1 of Ph), 130.0 (d, C-5), 127.9 (d, C-6), 117.8 (d, C-4 of Ph), 115.3 
(d, C-3/C-5 of Ph), 113.2 (d, C-2/C-6 of Ph) and 110.8 (s, C-4a). 
EIMS: m/z (%) 239 ([MH]+, 12), 238 (M•+, 100), 212 (22), 170 (33) and 77 (65). 
 
6.10 Synthesis of 1,3-dimethyl-7-phenylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-
dione (2.25) 
2.25
N
N N
O
O
Me
Me
1
2
3
4 5
6
7
8
8a
4a
 
A solution of 6-amino-1,3-dimethyluracil (2.21; 0.120 g, 0.77 mmol) and 1-phenyl-2-
propyn-1-one (2.23; 0.10 g, 0.77 mmol) in acetic acid (4 mL) was irradiated at 120 °C 
for 30 min in a pressure-rated glass tube (10 mL) using a CEM Discover microwave 
synthesizer by moderating the initial power (150 W). After cooling in a flow of 
compressed air, water was added to the mixture and the precipitate was filtered, washed 
with saturated aqueous NaHCO3 solution and dried in vacuo to give the title compound 
(2.25; 0.199 g, 97%) as a colourless solid, mp > 300 °C (Found: [M  Me]+, 267.1008. 
C15H13N3O2 requires [M  Me] 267.1008). 
FTIR (KBr)/cm–1 max: 1668 (C=O), 1592 (C=C) and 1524. 
1
H NMR (500 MHz; DMSO-d6):  8.40 (d, J = 8.1 Hz, 1 H, H-5), 8.21 (d, J = 7.5 Hz, 2 
H, H-2/H-6 of Ph), 7.91 (d, J = 8.1 Hz, 1 H, H-6) and 7.55 (m, 3 H, H-3/H-4/H-5 of Ph). 
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13
C NMR (125 MHz; DMSO-d6):  160.2 (s, C-4), 150.9 (s, C-8a), 150.6 (s, C-2), 145.7 
(s, C-7), 138.3 (d, C-5), 137.8 (s, C-1 of Ph), 131.0 (d, C-4 of Ph), 129.8 (d, C-3/C-5 of 
Ph), 128.0 (d, C-2/C-6 of Ph), 113.7 (d, C-6), 109.5 (s, C-4a), 29.5 (q, CH3) and 28.2 (q, 
CH3). 
EIMS: m/z (%) 268 ([MH  Me]+, 14), 267 ([M  Me]+, 100), 226 (39), 165 (52) and 
77 (80). 
 
6.11 Synthesis of 2-amino-5-methyl-7-phenylpyrido[2,3-d]pyrimidin-4(3H)-one 
(2.27) 
1
2
3
4 5
6
7
8
8a
4a
HN
N N
O
H2N Me
2.27
 
A solution of 2,4-diamino-6-hydroxypyridine (2.19; 0.088 g, 0.70 mmol) and 4-phenyl-
1-butyn-2-one (2.26; 0.10 mL, 0.70 mmol) in acetic acid (4 mL) was irradiated at 120 
°C for 30 min in a pressure-rated glass tube (10 mL) using a CEM Discover microwave 
synthesizer by moderating the initial power (150 W). After cooling in a flow of 
compressed air, water was added to the mixture and the precipitate was filtered, washed 
with saturated aqueous NaHCO3 solution and dried in vacuo to give the title compound 
(2.27; 0.168 g, 95%) as a brown solid, mp > 300 °C (Found: M
+
, 252.2713. C14H12N4O 
requires [M] 252.2713). 
FTIR (KBr)/cm–1 max: 3233 (NH2 and NH), 1669 (C=O), 1590 (C=C) and 1514. 
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1
H NMR (500 MHz; TFA-d):  7.70 (t, J = 7.5 Hz, 1 H, H-4 of Ph), 7.62 (t, J = 7.5 Hz, 
2 H, H-3/H-5 of Ph), 7.51 (d, J = 7.5 Hz, 2 H, H-2/H-6 of Ph), 7.44 (s, 1 H, H-6) and 
2.98 (s, 3 H, CH3). 
13
C NMR (125 MHz; TFA-d):  157.9 (s, C-4), 152.0 (s, C-8a), 149.1 (s, C-7), 148.2 (s, 
C-2), 128.2 (s, C-5), 127.3 (s, C-1 of Ph), 117.8 (d, C-4 of Ph), 115.6 (d, C-3/C-5 of 
Ph), 113.2 (d, C-2/C-6 of Ph), 111.0 (d, C-6), 110.1 (s, C-4a) and 18.6 (q, CH3). 
EIMS: m/z (%) 253 ([MH]+, 13), 252 (M+, 100), 238 (7), 190 (28), 155 (43) and 77 
(78). 
 
6.12 Synthesis of 3-amino-1-methyl-1H-pyrazole hydrochloride (3.8) 
N
N
Me
HCl.H2N
1
2
3 4
5
3.8
 
A solution of 2-chloroacrylonitrile (3.11; 0.10 mL, 1.25 mmol) and methylhydrazine 
hydrochloride (3.12; 0.14 mL, 2.5 mmol) in EtOH (2 mL) was irradiated at 120 °C for 2 
min in a pressure-rated glass tube (10 mL) using a CEM Discover microwave 
synthesizer by moderating the initial power (100 W). After cooling in a flow of 
compressed air, the mixture was kept in refrigerator for overnight. The solid obtained 
was filtered and washed with ethyl acetate to give the title compound (3.8; 0.16 g, 95%) 
as a colourless solid. 
mp 163165 °C (lit.6 161163 °C)  (Found: [M  HCl]+, 97.0640. C4H7N3 [M  HCl] 
requires 97.0637). 
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FTIR (KBr)/cm–1 max: 3376 (NH), 3018 (NH), 2951 (CH), 1570, 1515, 1496, 1458, 
1386, 1226 and 1119. 
1
H NMR (400 MHz; DMSOd6):  9.30 (s, exch. D2O, 3 H, NH2.HCl), 7.68 (d, J = 2.3 
Hz, 1 H, H-4), 6.02 (d, J = 2.3 Hz, 1 H, H-5) and 3.77 (s, 3 H, CH3). 
13
C NMR (100 MHz; DMSOd6):  143.1 (d, C-3), 134.8 (d, C-5), 96.2 (s, C-4) and 
37.5 (q, CH3). 
EIMS: m/z (%) 98 ([M  Cl]+, 5), 97 ([M  HCl]+·, 100) and 96 ([M  HCl  H]+, 55). 
 
6.13 Synthesis of 1-(4-fluorophenyl)-2-(4-pyridyl)ethanone (3.9) 
NO
F
1
2
3
4
5
6
3.9
 
6.13.1  Method A: 
A solution of 4-picoline (3.13; 2.21 mL, 22.73 mmol) and ethyl 4-fluorobenzoate (3.14; 
3.33 mL, 22.71 mmol) in THF (17 mL) was stirred at 0 °C for 15 min. Lithium 
bistrimethylsilyl amide (LHMDS; 20 mL) was added dropwise with stirring over an 
hour at room temperature. The mixture was triturated with light petroleum (20 mL) and 
the solid obtained was dissolved in HCl (3 M). The solution was neutralised with 
saturated aqueous NaHCO3 solution and then extracted with ethyl acetate (3 × 15 mL). 
The organic layers were combined, washed successively with water and brine, dried 
(MgSO4) and evaporated in vacuo to give the title compound (3.9; 1.96 g, 40%) as a 
yellow solid. 
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mp 8284 °C (lit.6 7981 °C) (Found: 215.0740. C13H10FNO [M] requires 215.0746). 
FTIR (KBr)/cm–1 max: 3390, 3015 (CH), 2897, 1670 (C=O), 1610, 1465 and 1305. 
1
H NMR (400 MHz; DMSOd6):  8.50 (m, 2 H, H-2 and H-6), 8.13 (m, 2 H, H-2´/H-
6´), 7.39 (m, 2 H, H-3´/H-5´), 7.28 (m, 2 H, H-3 and H-5) and 4.49 (s, 2 H, CH2). 
13
C NMR (100 MHz; DMSOd6):  191.3 (s, C=O), 166.9 (s, C-4´), 147.8 (d, C-2/C-6), 
147.7 (s, C-4), 133.1 (s, C-1´), 131.5 (d, C-2´/C-6´), 128.3 (d, C-3/C-5), 119.2 (d, C-
3´/C-5´) and 43.5 (t, CH2C=O). 
EIMS: m/z (%) 215 (M+·, 34), 123 ([M  C6H5F]
+·
, 100), 95 ([C6H4F]
+·
, 95) and 75 
(47). 
ES
+MS: m/z (%) 216 ([MH]+, 100), 216 (100) and 217 (20). 
6.13.2  Method B: 
A solution of 4-picoline (3.13; 0.22 mL, 2.27 mmol) and ethyl 4-fluorobenzoate (3.14; 
0.33 mL, 2.27 mmol) in THF (2.5 mL) was stirred at 0 °C for 15 min. Lithium 
bis-trimethylsilyl amide (LHMDS; 2.2 mL) was added dropwise with stirring for 5 
minutes, then irradiated for 10 minutes at 80 °C in a sealed pressure-rated reaction tube 
(10 mL), using a CEM Discover Microwave Synthesizer. The mixture was triturated 
with light petroleum (2.5 mL) and the solid obtained was dissolved in HCl (3 M). The 
solution was neutralised with saturated aqueous NaHCO3 solution and then extracted 
with ethyl acetate (3 × 15 mL). The organic layers were combined, washed successively 
with water and brine, dried (MgSO4) and evaporated in vacuo to give the title compound 
(3.9; 0.235 g, 50%). as a beige solid. 
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6.14 Synthesis of 4,6-bis(4-fluorophenyl)-2-methyl-5-(pyridin-4-yl)-2H-
pyrazolo[3,4-b]pyridine [UR-14756 (3.7)] 
1
2
34
5
N
N
N
Me
N
F
F
6 7a
3a
7
UR-14756 (3.7)
 
6.14.1 Method A: 
A solution of 1-(4-fluorophenyl)-2-(4-pyridyl)ethanone (3.9; 0.21 g, 0.97 mmol), 
3-amino-1-methyl-1H-pyrazole hydrochloride (3.8; 0.13 g, 0.97 mmol), 
4-fluorobenzaldehyde (3.10; 0.10 mL, 0.97 mmol) and hydrochloric acid (0.40 mL, 10 
M) in ethanol (4 mL) was irradiated at 150 °C for 4 hours in a pressure-rated glass tube 
(10 mL) using a CEM Discover microwave synthesizer by moderating the initial power 
(150 W). After cooling in a flow of compressed air the solution was neutralised with 
saturated aqueous NaHCO3 solution and then extracted with ethyl acetate (3 × 20 mL). 
The organic layers were combined, washed successively with water and brine, dried 
(MgSO4) and evaporated in vacuo. Purification of the crude product was carried out by 
column chromatography (silica gel; petroleum etherethyl acetate; 1:1 by volume) to 
give the title compound (3.7; 0.28 g, 71%) as a colourless solid. 
mp 9395 °C (lit.6 9294 °C) (Found: MH+, 399.1429. C24H17N4F2 [MH] requires 
399.1421). 
FTIR (KBr)/cm–1 max: 3557, 1610, 1530, 1402, 1350, 1290, 1245, 1168, 1112 and 
1078. 
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1
H NMR (400 MHz; DMSOd6):  8.34 (d, J = 6.0 Hz, 2 H, H-2´/H-6´), 7.43 (s, 1 H, 
H-3), 7.42 (dd, J = 8.8, 5.4 Hz, 2 H, H-2´´/H-6´´), 7.31 (dd, J = 8.8, 5.4 Hz, 2 H, 
H-2´´´/H-6´´´), 7.12 (app t, J = 8.8 Hz, 2 H, H-3´´/H-5´´), 6.97 (app t, J = 8.8 Hz, 2 H, 
H-3´´´/H-5´´´), 6.95 (d, J = 6.0 Hz, 2 H, H-3´/H-5´) and 3.78 (s, 3 H, CH3). 
13
C NMR (100 MHz; DMSOd6):  163.2 (s [d, J = 250 Hz], C-4´´), 162.3 (s [d, J = 
250 Hz], C-4´´´), 160.1 (s, C-7a), 158.8 (s, C-4), 152.2 (d, C-2´/C-6´), 149.9 (s, C-6), 
143.5 (s, C-1´), 135.6 (s [d, J = 3.3 Hz], C-1´´), 131.7 (d [d, J = 3.4 Hz], C-1´´´), 130.2 
(d [d, J = 8.3 Hz], C-2´´/C-6´´), 128.9 (d [d, J = 8.3 Hz], C-2´´´/C-6´´´), 126.7 (d, C-5), 
125.9 (s, C-3), 123.9 (d, C-3´/C-5´), 116.1 (d [d, J = 21.7 Hz], C-3´´/C-5´´), 113.8 (d [d, 
J = 21.6 Hz], C-3´´´/C-5´´´), 101.9 (s, C-3a) and 41.1 (q, CH3). 
ES
+MS: m/z (%) 399 ([MH]+, 100) 399 (100) and 400 (11). 
EI
+MS: m/z (%) 398 (M+·, 12) 397 ([M  1]+, 25), 347 (78), 304 (23), 275 (12), 230 
(15), 109 (100) and 95 (26). 
6.14.2 Method B: 
A solution of 1-(4-fluorophenyl)-2-(4-pyridyl)ethanone (0.42 g, 1.95 mmol), 3-amino-
1-methyl-1H-pyrazole hydrochloride (0.26 g, 1.95 mmol), 4-fluorobenzaldehyde (0.21 
mL, 1.95 mmol) and hydrochloride acid (0.12 mL, 10 M) in methyl glycol (6 mL) was 
heated under reflux for 48 hours. The solution was neutralised with saturated aqueous 
NaHCO3 solution and then extracted with ethyl acetate (3 × 20 mL). The organic layers 
were combined, washed successively with water and brine, dried (MgSO4) and the 
solvent was evaporated in vacuo to give the crude product. Purification by column 
chromatography (silica gel; petroleum etherethyl acetate; 1:1 by volume) gave the title 
compound (0.61 g, 79%) as a colourless solid. The NMR spectral data of the product 
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obtained via this method was identical in all respects with data produced from using 
Method A (Section 6.14.1). 
 
6.15 Synthesis of 5-amino-4-cyano-1-phenyl-1H-pyrazole (3.18) 
N
N1
2
3
4
5
CN
NH2
3.18
 
6.15.1 Method A: 
A mixture of phenylhydrazine (3.16a; 0.45 mL, 4.2 mmol) and 
ethoxymethylenemalononitrile (3.17; 0.51 g, 4.2 mmol) in ethanol (4 mL) was 
irradiated at 120 °C for 45 min in a pressure-rated glass tube (10 mL) using a CEM 
Discover microwave synthesizer by moderating the initial power (100 W). After cooling 
in a flow of compressed air, the solvent was removed under reduced pressure to give the 
crude product. Purification by column chromatography (petroleum etherethyl acetate; 
5:1 by volume) gave the title compound (3.18; 0.74 g, 95%) as light brown solid. 
mp 137139 °C (lit.7 140 °C) (Found: MH+, 185.0827. C10H9N4 requires [MH]: 
185.0822). 
FTIR (KBr)/cm–1 max: 3302 (NH), 3240 (NH), 2230 (CN), 1577, 1530 and 1368. 
1
H NMR (400 MHz; CDCl3):  7.58 (s, 1 H, H-3), 7.497.37 (m, 5 H, Ph) and 4.52 (s, 
exch. D2O, 2 H, NH2). 
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13
C NMR (100 MHz, CDCl3):  141.9 (d, C-3), 135 (s, C-5), 129.3 (s, C-1´), 125.5 (d, 
C-3´/C-5´), 124.1 (d, C-4´), 121.3 (d, C-2´/C-6´), 115.6 (s, CN) and 86.2 (s, C-4). 
APCIMS: m/z (%) 226 ([M + MeCNH]+, 100) and 185 ([MH]+, 64). 
6.15.2 Method B: 
A solution of phenylhydrazine (3.16a; 0.45 mL, 4.2 mmol) and 
ethoxymethylenemalononitrile (3.17; 0.514 g, 4.2 mmol) in a tolueneacetic acid 
mixture (5:1 by volume; 4 mL) was irradiated at 120 °C for 60 min in a pressure-rated 
glass tube (10 mL) using a CEM Discover microwave synthesizer by moderating the 
initial power (100 W). After cooling in a flow of compressed air, the reaction mixture 
was neutralised with saturated aqueous NaHCO3 solution and then extracted with ethyl 
acetate (3 × 15 mL). The organic layers were combined, washed successively with water 
and brine, dried (MgSO4) and evaporated in vacuo. Purification of the crude product by 
crystallization from hexaneethyl acetate (9:1 by volume) gave the title compound (0.42 
g, 54%) as a light brown solid. The physical properties and the NMR spectral data of 
the product obtained was consistent in all respects with data produced from using 
Method A (Section 6.15.1). 
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6.16 Synthesis of 5-amino-4-aminocarbonyl-1-phenyl-1H-pyrazole (3.19) 
N
N1
2
3 4
5 NH2
O
NH2
3.19
 
A mixture of 5-amino-4-cyano-1-phenyl-1H-pyrazole (3.18; 0.47 g, 2.55 mmol) and 
H2SO4 (4 mL) was irradiated for 60 min at 80 °C in a sealed pressure-rated glass tube 
(10 mL) using a CEM Discover microwave synthesizer by moderating the initial power 
(150 W). After cooling in a flow of compressed air, the mixture was extracted with 
chloroform (2 × 20 mL), washed with brine, dried over MgSO4 and evaporated in vacuo 
to give the title compound (3.19; 0.43 g, 85%) as a colourless solid 
mp 170172 °C (lit.7 172173 °C) (Found: 203.0931. C10H11N4O [MH] requires 
203.0927). 
FTIR (KBr)/cm–1 max: 3420 (NH), 3230 (NH), 1680 (C=O), 1611, 1505 and 1430. 
1
H NMR (400 MHz, CDCl3):  7.53 (s, 1 H, H-3), 7.497.37 (m, 5 H, Ph), 5.48 (br s, 
exch. D2O, 2 H, NH2) and 4.23 (br, s, exch. D2O, 2 H, NH2). 
13
C NMR (100 MHz, CDCl3):  168.0 (s, C=O), 141.9 (s, C-4), 135.5 (s, C-5), 129.3 (s, 
C-1´), 125.5 (d, C-3), 124.0 (d, C-3´/C-5´), 122.9 (d, C-4´) and 121.3 (d, C-2´/C-6´). 
ES
+MS: m/z (%) 244 ([M + MeCNH]+, 7), 203 ([MH]+, 100) and 186 (21). 
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6.17 Synthesis of 4-hydroxy-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine (3.20) 
N
N7
6
5
1
2
34
N
N
HO
7a
4a
3.20
 
A mixture of 5-amino-4-aminocarbonyl-1-phenyl-1H-pyrazole (3.19; 0.15 g, 0.74 
mmol) in formamide (0.50 mL, 5.55 mmol) was irradiated at 150 °C for 45 min in a 
pressure-rated glass tube (10 mL) using a CEM Discover microwave synthesizer by 
moderating the initial power (150 W). After cooling in a flow of compressed air the 
mixture was diluted with water and allowed to stand in a refrigerator overnight. The 
solid obtained was filtered, washed with water and dried to give the title compound 
(3.20; 0.152 g, 97%) as a colourless solid. 
mp 296298 °C (lit.7 299 °C)  (Found: MH+, 213.0678. C11H9N4O requires [MH]: 
213.0771). 
FTIR (KBr)/cm–1 max: 3223 (OH), 2850 (CH), 1560, 1510 and 1170. 
1
H NMR (400 MHz, CDCl3):  9.71 (s, exch. D2O, 1 H, OH), 8.23 (s, 1 H, H-5), 7.96 
(d, J = 8.0 Hz, 2 H, H-2´/H-6´), 7.94 (s, 1 H, H-2), 7.47 (t, J = 8.0 Hz, 2 H, H-3´/H-5´) 
and 7.19 (t, J = 8.0 Hz, 1 H, H-4´). 
13
C NMR (100 MHz, CDCl3):  158.0 (s, C-4), 150.1 (d, C-2), 148.3 (s, C-7a), 137.5 (s, 
C-1´), 130.9 (d, C-5), 127.6 (d, C-3´/C-5´), 124.5 (d, C-4´), 118.9 (d, C-2´/C-6´) and 
103.9 (s, C-4a). 
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ES
+MS: m/z (%) 212 ([M]+·, 100), 184 ([M  N2]
+•
, 69), 157 (75), 142 (20) 130 (32), 
103 (22), 91 (51) and 77 ([Ph]
+
, 83). 
 
6.18 Synthesis of 5-amino-1-methyl-1H-pyrazole (3.24) 
N
N
Me
1
2
3 4
5 NH2
3.24
 
A solution of methylhydrazine (3.26; 0.25 mL, 2.3 mmol) and 3-methoxyacrylonitrile 
(3.25; 0.20 mL, 4.6 mmol) in a tolueneacetic acid mixture (4:1 by volume; 5 mL) was 
irradiated at 120 °C (initial power 100 W) for 60 min in a sealed pressure-rated reaction 
tube (10 mL), using a CEM Discover microwave synthesizer. The solution was 
neutralised with saturated aqueous NaHCO3 solution and then extracted with ethyl 
acetate (3 × 20 mL). The organic layers were combined, washed successively with water 
and brine, dried (MgSO4) and evaporated in vacuo to give the title compound (3.24; 
0.22 g, 97%) as a colourless solid. 
mp 7173°C (lit.8 70 °C) (Found: M+, 97.0640. C4H7N3 [M] requires 97.0611). 
FTIR (KBr)/cm–1 max: 3340 (NH), 3120 (NH), 2965 (CH), 1575, 1560, 1490, 1450, 
1371, and 1099. 
1
H NMR (400 MHz; DMSOd6):  7.60 (d, J = 2 Hz, 1 H, H-3), 5.15 (d, J = 2 Hz, 1 H, 
H-4) 3.85 (br s, exch. D2O, 2 H, NH2) and 3.50 (s, 3 H, CH3). 
13
C NMR (125 MHz; DMSOd6):  145.6 (s, C-5), 138.5 (d, C-3), 90.8 (d, C-4) and 
34.0 (q, CH3). 
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APCIMS: m/z (%) 97 (M•+, 100). 
 
6.19 Synthesis of 5-amino-1-phenyl-1H-pyrazole (3.27) 
N
N1
2
3 4
5 NH2
3.27
 
A solution of phenylhydrazine (3.16a; 0.12 mL, 1.15 mmol) and 3-methoxyacrylonitrile 
(3.26; 0.10 mL, 1.15 mmol) in a tolueneacetic acid mixture (1:1 by volume; 5 mL) was 
irradiated at 120 °C (initial power 100 W) for 60 min in a sealed pressure-rated reaction 
tube (10 mL), using a CEM Discover microwave synthesizer. The solution was 
neutralised with saturated aqueous NaHCO3 solution and then extracted with ethyl 
acetate (3 × 20 mL). The organic layers were combined, washed successively with water 
and brine, dried (MgSO4) and evaporated in vacuo. Purification of the crude product by 
crystallization from a mixture of hexaneethyl acetate (3:1 by volume) gave the title 
compound (3.27; 0.17 g, 92%) as pale yellow crystals. 
mp 4850 °C (lit.8 50 °C) (Found: 159.0796. C9H9N3 requires [M] 159.0780). 
FTIR (KBr)/cm–1 max: 3420 (NH), 3240 (NH), 1540 (C=N), 1510, 1415 and 1137. 
1
H NMR (400 MHz; DMSOd6):  9.60 (br s, exch. D2O, 2 H, NH2), 7.30-6.95 (m, 6 H, 
H-3 and Ph) and 6.18 (d, J = 1.8 Hz, 1 H, H-4). 
13
C NMR (125 MHz; DMSOd6):  148.0 (s, C-5), 140.9 (d, C-3), 139.9 (s, C-1´), 
129.5 (d, C-3´/C-5´), 126.5 (d, C-4´), 120.4 (d, C-2´/C-6´) and 94.1 (d, C-4). 
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APCIMS: m/z (%) 159 (M•+, 100). 
 
6.20 Synthesis of 3-amino-1-phenyl-1H-pyrazole (3.33) 
N
N1
2
3 4
5
H2N
3.33
 
A solution of phenylhydrazine hydrochloride (3.16b; 0.17 g, 1.20 mmol), 
3-methoxyacrylonitrile (3.26; 0.20 mL, 2.40 mmol) and NaOEt (0.41 g, 4.8 mmol) in 
EtOH (4 mL) was irradiated at 150 °C for 2 h in a sealed, pressure-rated glass tube (10 
mL) using a CEM Discover microwave synthesizer by moderating the initial power 
(150 W). The mixture was cooled by passing a stream of compressed air through the 
microwave cavity and water was added (10 mL). The aqueous layer was extracted with 
ethyl acetate (2 × 20 mL) and the organic extracts were combined, washed with brine, 
dried over MgSO4 and evaporated in vacuo. Purification by column chromatography 
[silica gel; hexane–ethyl acetate (1:3 by volume)] gave the title compound (3.33; 0.19 g, 
85%) as a yellow solid. 
mp 9092 °C (lit.9 91 °C) (Found: 159.0796. C9H9N3 [M] requires 159.0796). 
FTIR (KBr)/cm–1 max: 3477 (NH), 3297 (NH), 1490, 1415, 1367 and 1172. 
1
H NMR (400 MHz; DMSOd6):  8.13 (d, J = 2.4 Hz, 1 H, H-5), 7.64 (d, J = 7.7 Hz, 2 
H, H-2´/H-6´), 7.39 (t, J = 7.7 Hz, 2 H, H-3´/H-5´), 7.11 (t, J = 7.7 Hz, 1 H, H-4´), 5.74 
(d, J = 2.4 Hz, 1 H, H-4) and 5.09 (s, exch. D2O, 2 H, NH2). 
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13
C NMR (125 MHz; DMSOd6):  157.5 (s, C-3), 140.4 (s, C-1´), 129.7 (d, C-5), 
128.2 (d, C-3´/C-5´), 124.3 (d, C-4´), 116.8 (d, C-2´/C-6´) and 96.8 (d, C-4). 
EIMS: m/z (%) 160 ([MH]+, 12), 159 (M+·, 100), 158 ([M  1]+, 30), 131 ([M  N2]
+ •
, 
13), 104 (16), 92 (8), 84 (27) and 77 ([Ph]
+
, 29). 
 
6.21 Synthesis of 3-amino-1-(4-methoxyphenyl)-1H-pyrazole (4.15) 
N
N1
2
3 4
5
H2N
OMe
4.15
 
A solution of 4-methoxyphenyl hydrazine hydrochloride (4.6; 0.210 g, 1.2 mmol), 
3-methoxyacrylonitrile (0.20 mL, 2.43 mmol) and NaOEt (0.41 g, 4.8 mmol) in EtOH 
(3 mL) was irradiated at 150 °C for 2 h in a sealed pressure-rated glass tube (10 mL) 
using a CEM Discover microwave synthesizer by moderating the initial power (150 W). 
The mixture was cooled by passing a stream of compressed air through the microwave 
cavity and water was added (10 mL). The aqueous layer was extracted with EtOAc (2 × 
20 mL) and the organic extracts were combined, washed with brine, dried over MgSO4 
and evaporated in vacuo. Purification by column chromatography (silica gel; hexane–
EtOAc in 1:3 by volume) gave the title compound (4.15; 0.19 g, 85%) as a yellow solid. 
mp 146149 °C (Found: M+, 189.0900. C10H11N3O [M] requires 189.0902). 
FTIR (KBr)/cm–1: max 3360 (NH), 1556, 1310, 1299 and 1069. 
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1
H NMR (400 MHz; DMSOd6):  8.00 (d, J = 2.5 Hz, 1 H, H-5), 7.55 (d, J = 9.0 Hz, 2 
H, H-2´/H-6´), 6.95 (d, J = 9.0 Hz, 2 H, H-3´/H-5´), 5.67 (d, J = 2.5 Hz, 1 H, H-4), 4.97 
(s, exch. D2O, 2 H, NH2) and 3.76 (s, 3 H, OCH3). 
13
C NMR (125 MHz; DMSOd6):  157.1 (s, C-4´), 156.5 (s, C-3), 134.5 (s, C-1´), 
127.9 (d, C-5), 118.3 (d, C-3´/C-5´), 114.8 (d, C-2´/C-6´), 95.8 (d, C-4) and 55.8 (q, 
OCH3). 
EIMS: m/z (%) 189 (M+·, 100) and 174 (81). 
 
6.22 Synthesis of 3-amino-4-bromo-1-(4-methoxyphenyl)-1H-pyrazole 
(4.16) 
N
N1
2
3 4
5
H2N
OMe
Br
4.16
 
6.22.1 Method A: 
A mixture of 3-amino-1-(4-methoxyphenyl)-1H-pyrazole (3.15; 0.13 g, 0.68 mmol) and 
NBS (0.12 g, 0.68 mmol) in THF (4 mL) was irradiated at 150 °C for 2 h in a sealed 
pressure-rated glass tube (10 mL) using a CEM Discover microwave synthesizer by 
moderating the initial power (150 W). The mixture was cooled by passing a stream of 
compressed air through the microwave cavity and evaporated in vacuo. The residue 
obtained was dissolved in EtOAc, filtered through Celite and the solvent was 
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evaporated in vacuo. Purification by column chromatography (silica gel; hexane–
EtOAC in 3:1 by volume) gave the title compound (3.16; 0.14 g, 77%) as a brown solid. 
mp 93–96 °C (Found: M+, 267.0015. C10H10N3O
79
Br [M] requires 267.0007). 
FTIR (KBr)/cm–1 max 3353 (NH), 1548, 1516, 1403, 1245, 1084 and 1041. 
1
H NMR (400 MHz; DMSOd6):  8.34 (s, 1 H, H-5), 7.57 (d, J = 9.0 Hz, 2 H, H-2´/H-
6´), 6.98 (d, J = 9.0 Hz, 2 H, H-3´/H-5´), 5.15 (s, exch D2O, 2 H, NH2) and 3.76 (s, 3 H, 
OCH3). 
13
C NMR (125 MHz; DMSOd6):  157.0 (s, C-4´), 155.5 (s, C-3), 134.2 (s, C-1´), 
127.8 (d, C-5), 118.5 (d, C-3´/C-5´), 114.9 (d, C-2´/C-6´), 95.3 (s, C-4) and 55.8 (q, 
OCH3). 
EIMS: m/z (%) 269 (81BrM•+, 97) and 267 (79BrM•+, 100). 
6.22.2 Method B: 
A mixture of 3-amino-1-(4-methoxyphenyl)-1H-pyrazole (3.15; 0.07 g, 0.37 mmol) and 
NBS (0.06 g, 0.37 mmol) in THF (10 mL) was stirred at room temperature for 16 hours. 
The solvent was removed under reduced pressure and the residue obtained was 
dissolved in EtOAc, filtered through Celite and the solvent was evaporated in vacuo. 
Purification by column chromatography (silica gel; hexane–EtOAC in 3:1 by volume) 
gave the title compound (0.08 g, 82%) as a brown solid. The product was identical in all 
respects with data produced via Method A (Section 6.22.1). 
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6.23 Synthesis of 3-amino-4-(4-aminocarbonylphenyl)-1-(4-methoxyphenyl)-1H-
pyrazole (4.2) 
N
N1
2
3
4
5
H2N
OMe
O
NH2
4.2
 
A mixture of 3-amino-4-bromo-1-(4-methoxyphenyl)-1H-pyrazole (4.16; 0.15 g, 0.55 
mmol), 4-carbamoylphenylboronic acid (4.26; 0.090 g, 0.54 mmol), K2CO3 (0.20 g, 
1.44 mmol) and PdCl2(PPh3)2 (0.04 g, 0.05 mmol) in 2-PrOH–H2O (5 mL; 1:1 by 
volume) was irradiated at 150 °C for 2 h in a sealed pressure-rated glass tube (10 mL) 
using a CEM Discover microwave synthesizer by moderating the initial power (150 W). 
The mixture was cooled by passing a stream of compressed air through the microwave 
cavity and water was added (10 mL). The aqueous layer was extracted with EtOAc (2 × 
20 mL) and the organic extracts were combined, washed with brine, dried over MgSO4 
and evaporated in vacuo. Purification by column chromatography (silica gel; hexane–
EtOAc in 1:3 by volume) gave the title compound (4.2; 0.09 g, 54%) as a cream solid. 
mp 251–253 °C (Found: M+, 308.1281. C17H16N4O2 [M] requires 308.1273). 
FT–IR (KBr)/cm–1 max: 3389 (NH), 1653 (C=O), 1554, 1522, 1399 and 1106. 
1
H NMR (400 MHz; DMSO–d6):  8.59 (s, 1 H, H-5), 7.96 (br s, exch. D2O, 1 H, 
NHH), 7.90 (d, J = 8.4 Hz, 2 H, H-2´/H-6´), 7.69 (d, J = 7.6 Hz, 2 H, H-3´´/H-5´´), 7.67 
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(d, J = 7.6 Hz, 2 H, H-2´´/H-6´´), 7.31 (br s, exch. D2O, 1 H, NHH), 7.02 (d, J = 8.4 Hz, 
2 H, H-3´/H-5´), 5.18 (s, exch. D2O, 2 H, NH2) and 3.51 (s, 3H, OCH3). 
13
C NMR (125 MHz; DMSO–d6):  168.2 (s, C=O), 158.3 (s, C-4´), 155.5 (s, C-3), 
135.1 (s, C-1´´), 133.6 (s, C-4´´), 132.1 (s, C-1´), 128.9 (d, C-3´´/C´´-5), 126.5 (d, C-5), 
125.5 (d, C-2´´/C-6´´), 119.5 (d, C-3´/C-5´), 116.7 (d, C-2´/C-6´) and 56.0 (q, OCH3). 
EI–MS: m/z (%) 308 (M•+, 100). 
 
6.24 Synthesis of 3-amino-1-(3-bromophenyl)-1H-pyrazole (4.28) 
N
N1
2
3 4
5
H2N
Br
4.28
 
6.24.1 Method A: 
A solution of 3-bromophenyl hydrazine hydrochloride (4.26; 0.136 g, 0.60mmol), 
3-methoxyacrylonitrile (0.10 mL, 1.20 mmol) and KO
t
Bu (0.30 g, 2.60 mmol) in 
t-BuOH (3 mL) was irradiated at 150 °C for 2 h in a sealed pressure-rated glass tube (10 
mL) using a CEM Discover microwave synthesizer by moderating the initial power 
(150 W). The mixture was cooled by passing a stream of compressed air through the 
microwave cavity and water was added (10 mL). The aqueous layer was extracted with 
EtOAc (3 × 15 mL) and the organic extracts were combined, washed with brine, dried 
over MgSO4 and evaporated in vacuo. Purification by column chromatography (silica 
gel; petroleum ether–EtOAc in 3:1 by volume) gave the title compound (4.28; 0.10 g, 
68%) as a yellow solid. 
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mp 85–88 °C (Found: M+, 236.9902. C9H8N3
79
Br [M] requires 236.9898). 
FT–IR (KBr)/cm–1 max: 3351 (NH), 2921, 2348, 2205, 1627 and 1587. 
1
H NMR (400 MHz; DMSO–d6):  8.21 (d, J = 2.5 Hz, 1 H, H-5), 7.86 (m, 1 H, H-2´), 
7.65 (m, 1 H, H-4´), 7.33 (app t, J = 8.0 Hz, 1 H, H-5´), 7.28 (m, 1 H, H-6´) 5.77 (d, J = 
2.5 Hz, 1 H, H-4) and 5.17 (s, exch. D2O, 2 H, NH2). 
13
C NMR (125 MHz; DMSO–d6):  157.9 (s, C-3), 141.7 (s, C-1´), 131.7 (d, C-5´), 
128.8 (d, C-4´), 126.6 (d, C-5), 122.7(s, C-3´), 119.2 (d, C-6´), 115.4 (d, C-2´) and 97.6 
(d, C-4). 
EI–MS: m/z (%) 239 ([81Br]M+·, 96), 237 ([79Br]M+·, 100), 211 ([{81Br}M – N2]
+•
, 5), 
209 ([{
79
Br}M – N2]
+•
, 6), 170 (7), 155 (12), 131 (21), 109 (15), 93 (18), 84 (24) and 69 
(45). 
6.24.2 Method B: 
A solution of 3-bromophenylhydrazine hydrochloride (4.26; 0.136 g, 0.60 mmol), 
3-methoxyacrylonitrile (0.10 mL, 1.20 mmol) and NaOEt (0.18 g, 2.60 mmol) in dry 
EtOH (3 mL) was irradiated at 150 °C for 1 hour in a sealed pressure-rated glass tube 
(10 mL) using a CEM Discover microwave synthesizer by moderating the initial power 
(150 W). The mixture was cooled by passing a stream of compressed air through the 
microwave cavity and water was added (3 mL). The pH of the mixture was adjusted to 
ca. 2–3 by the addition of HCl (6 M) and the mixture was stirred for 10 min at room 
temperature. The mixture was neutralised with saturated aqueous NaHCO3 solution. 
The aqueous layer was extracted with EtOAc (3 × 15 mL) and the organic extracts were 
combined, washed successively with water and brine, dried (MgSO4) and evaporated in 
vacuo. Purification by crystallization from a mixture of petroleum hexane–EtOAc (3:1 
by volume) gave the title compound (4.28; 0.13 g, 89%) as a yellow solid. The spectral 
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data of the product were consistent in all respects with data obtained via Method A 
(Section 6.24.1). 
6.19.3 Method C: 
A solution of 3-bromophenyl hydrazine hydrochloride (4.26; 1.36 g, 6.00 mmol), 
3-methoxyacrylonitrile (1.00 mL, 12.00 mmol) and NaOEt (1.77 g, 26.0 mmol) in dry 
EtOH (30 mL) was heated at reflux for 20 hours. After cooling the mixture to room 
temperature, water was added and the formed precipitate was filtered, washed with 
water and finally dissolved in CH2Cl2. The residual water was removed in a separating 
funnel and the organic extract was then washed successively with water and brine, dried 
(MgSO4) and evaporated in vacuo to obtain the title compound (4.28; 1.29 g, 90%) as a 
yellow solid after drying under high vacuum. The spectral data of the product were 
consistent in all respects with data obtained via Method A (Section 6.24.1). 
 
6.25 Synthesis of 3-amino-4-bromo-1-(3-bromophenyl)-1H-pyrazole (4.31) 
N
N1
2
3 4
5
H2N
Br
Br
4.31
 
A mixture of 3-amino-4-bromo-1-(3-bromophenyl)-1H-pyrazole (4.28; 0.16 g, 0.68 
mmol) and NBS (0.120 g, 0.68 mmol) in THF (10 mL) was stirred at room temperature 
for 16 hours. The solvent was removed in vacuo.  The crude residue was dissolved in 
EtOAc, filtered through Celite and evaporated in vacuo. Purification by column 
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chromatography on SiO2, eluting with hexane–EtOAC (3:1 by volume), gave the title 
compound (4.31; 0.18 g, 83%) as a brown solid. 
mp 93–95 °C (Found: [79Br2]M
+
, 314.9005. C9H7Br2N3 [{
79
Br2}M] requires 314.9007). 
FT–IR (KBr)/cm–1 max: 3983 (NH), 3415 (C=N), 3312, 3213, 1629, 1594 and 1556. 
1
H NMR (400 MHz; DMSO–d6):  8.55 (s, 1 H, H-5), 7.88 (m, 1 H, H-2´), 7.67 (m, 1 
H, H-5´), 7.37-7.35 (m, 2 H, H-4´/H-6´) and 5.38 (s, exch. D2O, 2 H, NH2). 
13
C NMR (125 MHz; DMSO–d6):  159.9 (s, C-3), 142.5 (s, C-1´), 131.8 (d, C-5´), 
128.6 (d, C-4´), 127.5 (d, C-5), 122.7 (s, C-3´), 119.3 (d, C-6´), 115.1 (d, C-2´) and 85.2 
(s, C-4). 
EI-MS: m/z (%) 319 ([{
81
Br2}M]
+·
, 61) 317 ([{
81
Br
79
Br}M]
+·
, 30), 315 ([{
79
Br2}M]
+·
, 
17, 220 (42), 205 (100), 189 (8) 177 (14), 145 (15) and 105 (12). 
 
6.26 Synthesis of 3-amino-1-(3-(1H-indol-6-yl)phenyl)-1H-pyrazole (4.29) 
N
N1
2
3 4
5
H2N
H
N
4.29
 
A solution of 3-amino-1-(3-bromophenyl)-1H-pyrazole (4.28; 0.20 g, 0.84 mmol), 
6-indolylboronic acid (4.27; 0.13 g, 0.25 mmol), caesium carbonate (0.55 g, 1.68 mmol) 
and Pd(PPh3)4 (0.10 g, 0.08 mmol) in DMF (4 mL) was irradiated at 150 °C for 2 hours 
in a sealed pressure-rated glass tube (10 mL) using a CEM Discover microwave 
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synthesizer by moderating the initial power (150 W). The mixture was cooled by 
passing a stream of compressed air through the microwave cavity and water was added 
(10 mL). The aqueous layer was extracted with EtOAc (3 × 20 mL) and the organic 
extracts were combined, washed with brine, dried over MgSO4 and evaporated in vacuo. 
Purification of the crude product by column chromatography (silica gel; hexane–EtOAc 
in 1:1 by volume) gave the title compound (4.29; 0.19 g, 84%) as a colourless solid. 
mp 97–99 °C (Found: M+, 274.1218. C17H14N2 requires [M] 274.1222). 
FT–IR (KBr)/cm–1 max: 3411 (NH), 2922 (CH), 1626, 1604, 1586 and 1479. 
1
H NMR (400 MHz; DMSO–d6) : 11.18 (s, exch., D2O, 1 H, NH), 8.26 (d, J = 2.6 Hz, 
1 H, H-5), 7.96 (m, 1 H, H-2´), 7.69 (m, 1 H, H-7´´), 7.63 (d, J = 8.3 Hz, 1 H, H-6´), 
7.58 (m, 1 H, H-5´), 7.46-7.41 (m, 3 H, H-4´, H-2´´ and H-4´´),  7.35 (dd, J = 8.3, 1.6 
Hz, 1 H, H-4´´), 6.47 (m, 1 H, H-3´´), 5.76 (d, J = 2.6 Hz, 1 H, H-4) and 5.17 (s, exch., 
D2O, 2 H, NH2). 
13
C NMR (100 MHz; DMSO–d6) : 157.5 (s, C-3), 134.3 (s, C-1´), 141.0 (s, C-6´´), 
137.0 (s, C-3´) 133.5 (s, C-7´´a), 130.2 (s, C-3´´a), 128.5 (d, C-5´), 127.9 (d, C-5), 126.8 
(d, C-4´), 122.7 (d, C-2´´), 120.9 (d, C-4´´), 118.8 (d, C-6´), 115.2 (d, C5´´), 114.9 (d, 
C-2´), 110.0 (d, C7´´), 101.5 (C-3´´) and 96.7 (d, C-4). 
EI–MS: m/z (%) 275 ([MH]+, 17), 274 (M+·, 100), 273 ([M – 1]+, 19), 246 ([M – N2]
+·
, 
7), 205 (6), 191 (9), 133 (14) and 84 (21). 
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6.27 Synthesis of 3-methoxybenzoic acid methyl ester (5.6) 
OMe
O
OMe
5.6
 
A solution of 3-methoxybenzoic acid (5.5) (1.00 g, 6.57 mmol) and concentrated 
sulfuric acid (0.075 mL, 0.165 mmol) in methanol (6 mL, 3.41 mmol) was stirred at 
reflux for 2.5 h.  The residue was evaporated and then the mixture was extracted with 
ether. The ethereal solution was washed with saturated aqueous NaHCO3 solution, dried 
(Na2SO4) and evaporated in vacuo to afford the title compound (5.6; 0.87 g, 80%)
10
 as a 
colourless oil. 
[Rf = 0.64 (petroleum ether–EtOAc, 6:4)] (Found: MNa
+
, 189.0522. C9H10O3Na 
requires [MNa
+
], 189.0522). 
FT–IR (nujol)/cm-1 max 2939, 2902, 2886, 1732, 1725, 1695, 1653, 1453, 1429, 1326, 
1284, 1103, 1048 and 758. 
1
H NMR (400 MHz, CDCl3):  7.63 (1H, d, J = 8.0 Hz, 6-ArH), 7.56 (1H, s, 2-ArH), 
7.35 (1H, t, J = 8.0 Hz, 5-ArH), 7.10 (1H, d, J = 8.0 Hz, 4-ArH), 3.91 (3H, s, COOCH3) 
and 3.85 (3H, s, ArOCH3). 
13
C NMR (100 MHz, CDCl3):  167.0 (s, C), 159.6 (s, C), 131.4 (s, C), 129.4 (d, CH), 
122.0 (d, CH), 119.5 (d, CH), 114.0 (d, CH), 55.4 (q, CH3) and 52.2 (q, CH3).  
APcI–MS: m/z 167 (MH+, 100%). 
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6.28 Synthesis of 3-methoxybenzoylacetonitrile (5.7) 
1
2
3
4
5
O
CN
OMe
6
5.7
 
6.28.1 Method A: 
A mixture of dry tetrahydrofuran (4 mL), sodium hydride (0.50 g, 60 % in mineral oil) 
and 3-methoxybenzoic acid methyl ester (5.6; 0.75 g, 3.93 mmol) was stirred at room 
temperature for 10 min. A dry acetonitrile (0.13 mL, 3.93 mmol) then was added 
dropwise to the mixture and then was irradiated at 150 °C for 1 hour in a pressure–rated 
glass tube (10 mL) using a CEM Discover microwave synthesizer by moderating the 
initial power (100 W). After cooling in a flow of compressed air, the product was 
diluted with ether (15 mL) and the resultant precipitate was washed with ether, 
dissolved in water (15 mL) and diluted with hydrochloric acid. The mixture was 
neutralised with saturated aqueous NaHCO3 solution and the aqueous layer was 
extracted with EtOAc (3 × 20 mL). The organic extracts were combined, washed with 
brine, dried over MgSO4 and evaporated in vacuo to afford the title compound as a 
colourless solid (5.7; 0.23 g, 35%). 
mp 57–58 °C (lit.10 55 ˚C) (Found: M+, 175.0635. C10H9NO2 requires [M] 175.0633). 
FT–IR (KBr)/cm–1 max: 3103 (CH), 2343 (CN), 1945, 1750 (C=O), 1697, 1533, 1487 
and 1435. 
1
H NMR (400 MHz, CDCl3):  7.43–7.35 (m, 2 H, H-4 and H-6), 7.13 (m, 1 H, H-4), 
4.10 (s, 3H, OCH3) and 3.89 (s, 2 H, CH2). 
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13
C NMR (100 MHz, CDCl3):  187.1 (s, C=O), 160.2 (s, C-3), 136.7 (s, C-1), 130.3 (d, 
C-2), 121.3 (d, C-5), 119.5 (d, C-6), 115.9 (s, CN), 113.6 (d, C-4), 55.7 (q, CH3) and 
29.5 (t, CH2). 
ES
+–MS: m/z (%) 175 (M+·, 37), 135 ([M – CH2CN]
+
, 87), 107 ([M – COCH2CN]
+
, 33), 
92 ([M – COCH2CN – OH]
+
, 15), 85 (92), 84 (100) and 77 (23). 
6.28.2 Method B: 
A mixture of dry tetrahydrofuran (50 mL), sodium hydride (2.00 g, 60% in mineral oil) 
and 3-methoxybenzoic acid methyl ester (5.6; 4.20 g, 29.06 mmol) was stirred at room 
temperature for 20 min. Dry acetonitrile (1.20 mL) was then added dropwise and the 
mixture was heated at reflux for 24 h. After cooling, the product was diluted with ether 
(50 mL) and the resultant precipitate was washed with ether, dissolved in water (35 mL) 
and diluted with hydrochloric acid. The solution was neutralised with saturated aqueous 
NaHCO3 solution and the aqueous layer was extracted with EtOAc (3 × 60 mL). The 
organic extracts were combined, washed with brine, dried over MgSO4 and evaporated 
in vacuo to afford the title compound as a colourless solid (5.7; 3.83 g, 75%). The 
spectral data of the product were consistent in all respects with the data obtained via 
Method A (Section 6.28.1). 
6.28.3 Method C: 
A solution of 3-iodoanisole (5.12; 0.25 mL, 1.90 mmol), 3-methoxyacrylonitrile (0.16 
mL, 1.90 mmol), K2CO3 (0.35 g, 1.91 mmol), xantphos (0.11 g, 0.19 mmol) and 
palladium(II) acetate (0.05 g, 0.19 mmol) in a mixture of acetonitrilewater (2:1 by 
volume; 4 mL) was irradiated at 150 °C for 1.5 h in a pressure-rated glass tube (10 mL) 
using a CEM Discover microwave synthesizer by moderating the initial power (150 W). 
After cooling in a flow of compressed air, HCl (3M) was added to the mixture to adjust 
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the pH to ca. 2–3 and the mixture was stirred for 10 min at room temperature. The 
mixture was neutralised with saturated aqueous NaHCO3 solution. The aqueous layer 
was extracted with EtOAc (3 × 25 mL) and the organic extracts were combined, washed 
successively with water and brine, dried (MgSO4) and evaporated in vacuo. Purification 
by column chromatography (silica gel; petroleum ether–ethyl acetate in 3:1 by volume) 
gave the title compound (5.7; 0.25 g, 76%) as a colourless solid. The spectral data of the 
product were consistent in all respects with data obtained via Method A (Section 
6.28.1). 
 
6.29 Synthesis of 2-(3-methoxybenzoyl)-3-phenylaminoacrylonitrile (5.8) 
O
CN
OMe
1
2
3
4
5
6
NH
5.8
 
A solution of 3-methoxybenzoylacetonitrile (5.8; 0.05 g, 0.29 mmol) and 
N,N′-diphenylformamidine (0.06 g, 0.29 mmol) in dry xylenes (2 mL) was irradiated at 
180 °C for 20 min in a pressure-rated glass tube (10 mL) using a CEM Discover 
microwave synthesizer by moderating the initial power (200 W). After cooling in a 
stream of compressed air, the mixture was diluted with ether. The precipitate was 
filtered and washed with ether to afford the title compound (5.8; 0.07 g, 90%) as a 
colourless solid. 
mp 102–104 °C (lit.10 105 °C) (Found: M+, 278.1061. C17H14N2O2 requires [M] 
278.1061). 
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FT–IR (KBr)/cm–1: max 3120 (NH), 3093 (CH), 2971, 2206 (CN), 1638 (C=O) and 
1574. 
1
H NMR (400 MHz, CDCl3):  8.06 (d, J = 13.0 Hz, 1 H, C=CHNH), 7.57 (d, J = 7.4 
Hz, 1 H, H-6), 7.36–7.47 (m, 4 H, H-2, H-5 and H-2´/H-6´), 7.28 (t, J = 7.2 Hz, 1 H, 
H-4), 7.13 (d, J = 8.0 Hz, 2 H, H-3´/H-5´), 7.10 (d, J = 8.0 Hz, 1 H, H-4), 4.10 (d, J = 
13.0 Hz, exch. D2O, 1 H, NH) and 3.89 (s, 3 H, OCH3). 
13
C NMR (100 MHz, CDCl3):  192.3 (s, C=O), 159.5 (s, C-3), 154.1 (d, C=CHNH), 
139.1 (s, C-1), 138.0 (s, C-1´), 130.2 (d, C-3´/C-5´), 129.5 (d, C-4´), 126.7 (d, C-6), 
120.5 (d, C-4), 120.4 (s, CN), 118.9 (d, C-2´/C-6´ of Ph), 117.9 (d, C-5), 112.6 (d, 
C-2), 55.5 (q, OCH3) and 83.4 (s, C=CHNH).  
EI–MS: m/z (%) 278 (M+·, 78), 277 ([M – 1]+, 100), 247 ([M – OMe]+, 10), 209 (30), 
175 (92), 135 (98), 107 (92), 77 ([Ph]
+
, 95) and 64 (47). 
 
6.30 Synthesis of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-
methoxyphenyl ketone (5.9) 
O
OMe
N
N
F
H2N
1
2
3
4
5
5.9
 
A mixture of 2-(3-methoxybenzoyl)-3-phenylaminoacrylonitrile (5.8; 0.11 g, 0.40 
mmol), 4-fluorophenylhydrazine hydrochlororide (0.06 g, 0.40 mmol) and triethylamine 
(0.010 mL, 0.09 mmol) in ethanol (4 mL) was irradiated in a sealed tube at 140 °C for 1 
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h using a CEM Discover single-mode microwave synthesizer, by moderating the initial 
microwave power (150 W). After cooling in a stream of compressed air, the mixture 
was evaporated in vacuo and purified by column chromatography on silica, eluting with 
petroleum ether–EtOAc (3:2; by volume), to afford the title compound (5.9; 0.01 g, 
87%) as a colourless solid. 
mp 116–117 °C (Ref.10 114 °C) (Found: MH+, 312.1143. C17H15N3O2F requires [MH] 
312.1143). 
FT–IR (KBr)/cm–1 max: 3996 (NH), 3312 (NH), 2980 (CH), 1636, 1654 (C=O) and 
1577. 
1
H NMR (400 MHz, CDCl3):  7.83 (s, 1 H, H-3), 7.56–7.58 (m, 2 H, H-2´/H-6´), 
7.447.40 (m, 2 H, H-5´´ and H-6´´), 7.28 (m, 1 H, H-2´), 7.24–7.29 (m, 2 H, H-3´/H-
5´), 7.13 (m, 1 H, H-4´), 6.07 (br s, exch. D2O, 2 H, NH2) and 3.90 (s, 3 H, OCH3). 
13
C NMR (100 MHz, CDCl3):  189.5 (s, C=O), 162.1 (s [d, J = 248.0 Hz], C-4´), 159.7 
(s, C-4´´), 150.5 (s, C-5), 142.0 (d, C-3), 140.9 (s, C-1´´), 133.1 (s [d, J = 3.3 Hz, C-1´), 
129.5 (d, C-5), 126.1 (d [d, J = 8.8 Hz], C-2´/C-6´), 117.8 (d, C-6´´), 120.6 (d, C-4´´), 
116.9 (d [d, J = 23.0 Hz], C-3´/C-5´), 112.9 (d, C-2´´), 104.8 (s, C-4) and 55.4 (q, 
OCH3). 
APcI–MS: m/z (%) 312 (MH+, 100). 
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6.31 Synthesis of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-hydroxyphenyl 
ketone (5.10) 
O
OH
N
N
F
H2N
1
2
3
4
5
5.10
 
A solution of [5-amino-1-(4–fluorophenyl)-1H-pyrazol-4-yl]-3-methoxyphenyl ketone 
(5.9; 0.10 g, 0.32 mmol) in dry CH2Cl2 (15 mL) was added at 0 °C to a solution of 
boron tribromide (BBr3; 0.45 mL, 1.22 mmol) in CH2Cl2 under nitrogen and the mixture 
was stirred overnight at room temperature. Water (10 mL) was added and the mixture 
was extracted with CH2Cl2 (2 x 15 mL). The organic extracts were combined, dried 
(MgSO4) and evaporated in vacuo to afford the title compound (5.10; 0.073 g, 77%) as a 
colourless solid. 
mp 153–154 °C (Ref.10 153 °C) (Found: M+ 297.0914. C16H12N3O2F requires [M] 
297.0909). 
FT–IR (KBr)/cm–1 max: 3520 (NH/OH), 3470 (NH/OH), 3337, 2980 (CH), 1625 
(C=O), 1587, 1513 and 1487. 
1
H NMR (400 MHz, CD3OD):  7.72 (s, 1 H, H-3), 7.51-7.47 (m, 2 H, H-2´/H-6´), 7.22 
(m, 3 H, H-5´´, H-6´´ and OH), 7.07 (m, 1 H, H-2´´), 6.90 (m, 1 H, H-4´´) and 7.02 (d, J 
= 8.1 Hz, 1 H, H-4´´). 
13
C NMR (100 MHz, CD3OD) : 189.9 (s, C=O), 162.3 (s [d, J = 246.6 Hz], C-4´), 
157.5 (s, C-3´´), 151.6 (s, C-5), 141.9 (d, C-3), 141.0 (s, C-1´´), 133.4 (d [d, J = 3.3 Hz], 
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C-1´), 129.3 (d, C-5´´), 126.7 (d [d, J = 8.8 Hz], C-2´/C-6´), 118.9 (d, C-6´´), 118.3 (d, 
C-4´´), 116.3 (d [d, J = 23.4 Hz], C-3´/C-5´), 114.3 (d, C-2´´) and 103.9 (s, C-4). 
EI–MS: m/z (%) 298 ([MH]+, 12), 297 (M+·, 71), 296 ([M – 1]+, 100), 280 ([M – OH]+, 
15), 204 ([M – C6H4OH]
+
, 25), 149 (6), 121 (4) and 95 (12). 
 
6.32 Synthesis of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-{[(R)-2,2-
dimethyl-1,3-dioxolan-4-yl]methoxy}phenyl ketone (5.11) 
O
O
N
N
F
H2N
1
2
3
4
5
O
O
5.11
 
To a solution of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-hydroxyphenyl ketone 
(5.10; 0.05 g, 0.16 mmol) in dry dimethylsulfoxide (DMSO; 5 mL) was added 
(S)-2,2-dimethyl-1,3-dioxolane-4-methanol p-toluenesulfonate (0.06 g, 0.21 mmol) 
followed by anhydrous potassium carbonate (0.07 g, 0.38 mmol). The reaction mixture 
was warmed to 100 °C under nitrogen. After 24 hours, the reaction was cooled to room 
temperature, diluted with water (20 mL) and the product was extracted with EtOAc (2 x 
20 mL). The combined organic layers were washed with brine, dried (MgSO4) and then 
concentrated in vacuo to give the crude product as a brown oil. Purification by 
crystallization using a mixture of hexane–EtOAc (3:1 by volume)] gave the title 
compound (5.11; 0.062 g, 68%) as colourless crystals.
11 
mp 58–61 °C (Found: MH+ 412.1673. C22H23N3O4F requires [MH], 412.1669). 
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FT–IR (KBr)/cm–1 max: 3412 (NH), 3309 (NH), 2986 (CH), 1621 (C=O), 1599, 1578, 
1512 and 1310. 
1
H NMR (400 MHz, CDCl3):  7.66 (s, 1 H, H-3), 7.44–7.48 (m, 2 H, H-2´/H-6´), 7.32 
(app. t, J = 8.0 Hz, 1 H, H-5´´), 7.26-7.81 (m, 4 H, H-2, H-6 and H-3´/H-5´), 7.06 (m, 1 
H, H-4´´), 4.80 (br s, exch. D2O, 2 H, NH2), 4.38 (m, 1 H, CH), 4.14 (m, 1 H, 1 H of 
CH2), 4.12 (m, 1 H, 1 H of CH2), 4.02 (m, 1 H, 1 H of CH2), 3.92 (m, 1 H, 1 H of CH2), 
1.31 (s, 3 H, CH3) and 1.26 (s, 3 H, CH3). 
13
C NMR (100 MHz, CDCl3):  189.2 (s, C=O), 162.2 (s [d, J = 249.6 Hz], C-4´), 158.8 
(s, C-3´´), 150.6 (s, C-5), 142.0 (d, C-3), 141.1 (s, C-1´´), 133.2 (s [d, J = 3.3 Hz], C-1´), 
129.6 (d, C-5´´), 126.2 (d [d, J = 8.8 Hz], C-2´/C-6´), 121.1 (d, C-6´´), 118.4 (d, C-4´´), 
117.0 (d [d, J = 23.4 Hz], C-3´/C-5´), 113.6 (d, C-2´´), 109.9 (s, C-4), 104.8 (s, 
C(CH3)2), 74.0 (d, CH), 70.0 (t, CH2), 66.8 (t, CH2), 26.8 (q, CH3) and 25.4 (q, CH3). 
APcI–MS: m/z (%) 412 ([MH]+, 100), 372 (5), 354 (6) and 312 (4). 
 
6.33 Synthesis of 5-amino-1-(4-fluorophenyl)-4-{3-[2(S)-3-
dihydroxypropoxy]benzoyl}pyrazole (RO3201195) (5.4) 
O
O
N
N
F
H2N
1
2
3
4
5
OH
HO
5.4
 
To a solution of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-{[(R)-2,2-dimethyl-
1,3-dioxolan-4-yl]methoxy}phenyl ketone (5.11; 0.02 g, 0.05 mmol) in dry methanol 
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(2 mL) was added distilled water (0.03 mL) and p-toluenesulfonic acid monohydrate 
(0.60 g, 3.15 mmol). The mixture was warmed to 50 °C under nitrogen and stirred 
overnight. The reaction mixture was cooled to room temperature and concentrated in 
vacuo to give a yellow oil. The oil was dissolved in ethyl acetate and washed with 
aqueous sodium bicarbonate solution (NaHCO3). The organic layer was separated, dried 
(MgSO4) and concentrated in vacuo. Purification by column chromatography (silica gel; 
petroleum ether–EtOAc in 3:2 by volume) afforded the title compound as a colourless 
solid
11
 (5.4; 0.013 g, 56%).
 
mp 77–78 °C (Ref10 75 °C) (Found: MH+, 372.1354. C19H19N3O4F requires [MH] 
372.1352). 
FT–IR (KBr)/cm–1 max: 3520 (OH), 3110 (NH), 2380 (CH), 1970, 1635 (C=O), 1567, 
1515, 1470, 1324 and 1295. 
1
H NMR (400 MHz, DMSO–d6):  7.81 (s, 1 H, H-3), 7.60–7.63 (m, 2 H, H-2´/H-6´), 
7.25–7.43 (m, 3 H, H-5´´ and H-3´/H-5´), 7.26 (m, 1 H, H-6´´), 7.24 (s, 1 H, H-2´´), 
7.13–7.20 (m, 3 H, NH2 and H-4´´), 5.02 (d, J = 4.8 Hz, exch. D2O, 1 H, CHOH), 4.71 
(t, J = 5.7 Hz, exch. D2O, 1 H, CH2OH), 4.09 (m, 1 H, 1 H of CH2O), 3.94 (m, 1 H, 1 H 
of CH2O), 3.83 (m, 1 H, CHOH) and 3.46-3.47 (m, 2 H, CH2OH). 
13
C NMR (125 MHz, DMSO–d6):  188.1 (s, C=O), 161.2 (s [d, J = 245.9 Hz], C-4´), 
159.3 (s, C-3´´), 151.7 (s, C-5), 141.9 (d, C-3), 141.4 (s, C-1´´), 134.3 (s [d, J = 3.0 Hz], 
C-1´), 130.2 (d, C-5´´), 126.9 (d [d, J = 9.1 Hz], C-2´/C-6´), 120.6 (d, C-6´´), 118.4 (d, 
C-4´´), 116.9 (d [d, J = 21.2 Hz], C-3´/C-5´), 113.8 (d, C-2´´), 104.0 (s, C-4), 70.4 (d, 
CH), 70.3 (t, CH2) and 63.1 (t, CH2). 
APcI–MS: m/z (%) 372 (MH+, 100).  
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